<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="pmc-domain-id">1754</journal-id><journal-id journal-id-type="pmc-domain">frontimmu</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8294057</article-id><article-id pub-id-type="pmcid-ver">PMC8294057.1</article-id><article-id pub-id-type="pmcaid">8294057</article-id><article-id pub-id-type="pmcaiid">8294057</article-id><article-id pub-id-type="pmid">34305945</article-id><article-id pub-id-type="doi">10.3389/fimmu.2021.705360</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>
<italic toggle="yes">Staphylococcus aureus</italic> Vaccine Research and Development: The Past, Present and Future, Including Novel Therapeutic Strategies</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Clegg</surname><given-names initials="J">Jonah</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1307212"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Soldaini</surname><given-names initials="E">Elisabetta</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/135319"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>McLoughlin</surname><given-names initials="RM">Rachel M.</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/100744"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rittenhouse</surname><given-names initials="S">Stephen</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bagnoli</surname><given-names initials="F">Fabio</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/40593"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Phogat</surname><given-names initials="S">Sanjay</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/341655"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>GSK</institution>, <addr-line>Siena</addr-line>, <country>Italy</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Host Pathogen Interactions Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin</institution>, <addr-line>Dublin</addr-line>, <country>Ireland</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>GSK</institution>, <addr-line>Collegeville, PA</addr-line>, <country>United States</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Julia Kzhyshkowska, Heidelberg University, Germany</p></fn><fn fn-type="edited-by"><p>Reviewed by: Piergiuseppe De Berardinis, Consiglio Nazionale delle Ricerche (Bologna), Italy; Paulo Bettencourt, Catholic University of Portugal, Portugal</p></fn><corresp id="fn001">*Correspondence: Sanjay Phogat, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:sanjaykumar.x.phogat@gsk.com">sanjaykumar.x.phogat@gsk.com</email></corresp><fn fn-type="other" id="fn002"><p>This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology</p></fn></author-notes><pub-date pub-type="epub"><day>07</day><month>7</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>12</volume><issue-id pub-id-type="pmc-issue-id">375200</issue-id><elocation-id>705360</elocation-id><history><date date-type="received"><day>05</day><month>5</month><year>2021</year></date><date date-type="accepted"><day>22</day><month>6</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>22</day><month>07</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-04-01 21:25:24.367"><day>01</day><month>04</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2021 Clegg, Soldaini, McLoughlin, Rittenhouse, Bagnoli and Phogat</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Clegg, Soldaini, McLoughlin, Rittenhouse, Bagnoli and Phogat</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fimmu-12-705360.pdf"/><abstract><p>
<italic toggle="yes">Staphylococcus aureus</italic> is one of the most important human pathogens worldwide. Its high antibiotic resistance profile reinforces the need for new interventions like vaccines in addition to new antibiotics. Vaccine development efforts against <italic toggle="yes">S. aureus</italic> have failed so far however, the findings from these human clinical and non-clinical studies provide potential insight for such failures. Currently, research is focusing on identifying novel vaccine formulations able to elicit potent humoral and cellular immune responses. Translational science studies are attempting to discover correlates of protection using animal models as well as <italic toggle="yes">in vitro</italic> and <italic toggle="yes">ex vivo</italic> models assessing efficacy of vaccine candidates. Several new vaccine candidates are being tested in human clinical trials in a variety of target populations. In addition to vaccines, bacteriophages, monoclonal antibodies, centyrins and new classes of antibiotics are being developed. Some of these have been tested in humans with encouraging results. The complexity of the diseases and the range of the target populations affected by this pathogen will require a multipronged approach using different interventions, which will be discussed in this review.</p></abstract><kwd-group><kwd><italic toggle="yes">Staphylococcus aureus</italic></kwd><kwd>vaccinology</kwd><kwd>host-pathogen interactions</kwd><kwd>humoral immunity</kwd><kwd>models of infection</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">GlaxoSmithKline foundation<named-content content-type="fundref-id">10.13039/501100002066</named-content></funding-source></award-group><award-group><funding-source id="cn002">Science Foundation Ireland<named-content content-type="fundref-id">10.13039/501100001602</named-content></funding-source></award-group></funding-group><counts><fig-count count="1"/><table-count count="3"/><equation-count count="0"/><ref-count count="205"/><page-count count="19"/><word-count count="10550"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>
<italic toggle="yes">Staphylococcus aureus</italic> is a gram-positive bacterium responsible for significant morbidity and mortality worldwide. In the United States of America, <italic toggle="yes">S. aureus</italic> is estimated to cause 20,000 deaths and amount to a total bill of $15 billion on the health service annually (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). <italic toggle="yes">S. aureus</italic> can be a highly lethal pathogen with a mortality rate during bacteremia of approximately 18% in developed countries (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>). This rate has been seen to increase in developing countries, establishing <italic toggle="yes">S. aureus</italic> as a global pathogen (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>). One of the most striking and challenging aspects of <italic toggle="yes">S. aureus</italic> clinical management is the ability of the bacterium to develop resistance to treatment with antibiotics. This effect was exemplified during the emergence of methicillin resistant <italic toggle="yes">S. aureus</italic> (MRSA) during the 1960&#8217;s and more recently with strains displaying moderate, and in very rare cases, complete resistance to vancomycin, one of the remaining treatment options for MRSA infection (<xref rid="B7" ref-type="bibr">7</xref>). Alternative therapies for <italic toggle="yes">S. aureus</italic> are therefore considered an urgent public need. Immunotherapies represent an attractive option due to the reduced likelihood for the development of resistance due to the multifaceted nature of the human immune system. The last two decades have seen considerable effort by the scientific community to develop a vaccine preventing <italic toggle="yes">S. aureus</italic> infection and yet, no vaccine candidates have proven successful at this objective during clinical testing.</p><p>
<italic toggle="yes">S. aureus</italic> vaccine development has seen laudable innovation. Ever-increasing diversity in vaccine platforms is being observed as viewed through the wide array of antigen selection and the use of novel adjuvants and delivery systems aimed at harnessing specific humoral and cellular immunity. While data explaining the past failure of vaccines continues to emerge, it is imperative that this information is analyzed and reflected upon appropriately to maximize the likelihood of success when developing future vaccines. One of the most important factors that has held back the development of a vaccine is the lack of successful translation of vaccine protectivity that is observed in preclinical models of infection, to protective efficacy seen in human subjects. Here, we propose that the usage of more relevant animal models, more representative <italic toggle="yes">in vitro</italic> models and <italic toggle="yes">ex vivo</italic> human tissues to study the pathogenicity of <italic toggle="yes">S. aureus</italic> will increase the fidelity of data obtained at the preclinical level and therefore increase the likelihood of vaccines entering into clinical trials being efficacious. In addition to ongoing activities related to the development of a vaccine against <italic toggle="yes">S. aureus</italic> at the levels of vaccine design and preclinical testing, we discuss vaccines currently enrolled in clinical trials and alternative therapies for the treatment of <italic toggle="yes">S. aureus</italic> infection. We aim to provide this information while using evidence from past failings regarding <italic toggle="yes">S. aureus</italic> vaccine design, as well as lessons learned from non-<italic toggle="yes">S. aureus</italic> vaccine research, to provide a critical discussion of current research activities in order to pave the way for future research efforts in the field.</p><p>To further understand the challenges involved in creating an efficacious vaccine, we also give consideration to certain complexities of the host pathogen relationship between humans and <italic toggle="yes">S. aureus</italic>. Aside from being a major human pathogen with multiple virulence factors specifically focused on disarming key components of the immune system, <italic toggle="yes">S. aureus</italic> also establishes colonizing interactions which in turn results in most, if not all, individuals harboring pre-existing immunity (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>). A requirement for an efficacious vaccine will therefore be to improve upon natural immunity and so, provide protection from infection. In parallel to vaccine development, the emergence of novel therapeutic and short-term prophylactic treatments for <italic toggle="yes">S. aureus</italic> disease means that there are now numerous different strategies under investigation for the targeting of <italic toggle="yes">S. aureus</italic> (<xref ref-type="fig" rid="f1">
<bold>Figure&#160;1</bold>
</xref>). The revitalization of strategies such as bacteriophage therapy, monoclonal antibody treatment and antibiotics as well as the development of new therapeutic proteins such as centyrins, represent exciting experimental treatments for <italic toggle="yes">S. aureus</italic>.</p><fig id="f1" position="float" orientation="portrait"><label>Figure&#160;1</label><caption><p>Methods of targeting <italic toggle="yes">Staphylococcus aureus</italic>. There are numerous therapies being investigated as treatments for <italic toggle="yes">S. aureus</italic> infections. Antibiotics are currently the only option with clinical approval. Antibiotics act directly on bacteria <italic toggle="yes">via</italic> either bacteriostatic or bactericidal mechanisms. Bacteriophages also act directly on <italic toggle="yes">S. aureus</italic> to kill bacteria. Centyrins are small proteins with the ability to neutralize bacterial exo-toxins and virulence factors. Monoclonal antibodies can act in the same manner as centyrins to neutralize bacterial exo-toxins and virulence factors, with a secondary mechanism of opsonizing the bacteria due the presence of antibody Fc regions. Vaccines generate populations of memory B and T cells. B cells produce antibodies that act in the same manner as described for monoclonal antibodies. Memory T cells can also be induced which, through pro-inflammatory cytokines such as IFN-&#947; and IL-17, aid in the activation and recruitment of innate effector cells such as Macrophage (M&#966;) and Neutrophils (PMN) which in turn kill bacteria. While CD4<sup>+</sup> T cells have a more classical role in adaptive memory responses, there is growing evidence to suggest that &#947;&#948; T cells may be induced by vaccination and play a protective role during <italic toggle="yes">S. aureus</italic> infections (<xref rid="B10" ref-type="bibr">10</xref>&#8211;<xref rid="B13" ref-type="bibr">13</xref>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-12-705360-g001.jpg"/></fig></sec><sec id="s2"><title>Vaccine Development Technologies</title><sec id="s2_1"><title>Recombinant Proteins and Glycoconjugation</title><p>The most common method employed during clinical trials of <italic toggle="yes">S. aureus</italic> vaccines has been the use of recombinant proteins or polysaccharide antigens of the bacterium to evoke a specific immune response in vaccine recipients. The choice of which antigen or combination of antigens to use is a question of paramount importance. Protein antigens typically considered for developing vaccines, are surface antigens or secreted toxins, for the following main reasons: 1) both can be detected by the immune response; 2) antibodies against surface antigens have the potential to induce opsonophagocytosis and block virulence functions (i.e., adhesion and nutrient uptake); 3) antibodies against secreted toxins can block toxicity. <italic toggle="yes">S. aureus</italic> possesses an extracellular polysaccharide coating which has been the target of multiple vaccine formulations entering into clinical trials. Following from the success of licensed vaccines against the bacterial pathogens: <italic toggle="yes">Streptococcus pneumoniae</italic>, <italic toggle="yes">Haemophilus influenzae B</italic> and <italic toggle="yes">Neisseria meningitidis</italic> which used protein glycoconjugation in order to generate strong, long-lived, T cell-dependent B cell immunity towards polysaccharide antigens, this strategy is also being applied to <italic toggle="yes">S. aureus</italic> vaccines (<xref rid="B14" ref-type="bibr">14</xref>). As opposed to the classical approach of chemical conjugation, bioconjugation is a more novel method of linking protein and polysaccharide antigens using genetically engineered bacteria to produce these conjugates (<xref rid="B15" ref-type="bibr">15</xref>). This technique was used to create an experimental vaccine for <italic toggle="yes">S. aureus</italic> in which the two most common capsular serotypes in clinical settings, CP5 and CP8 (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>), were conjugated to exoprotein A of <italic toggle="yes">Pseudomonas aeruginosa</italic> and importantly, a vaccine consisting of CP5 successfully conjugated to the <italic toggle="yes">S. aureus</italic> protein &#945;-toxin (Hla) was also generated (<xref rid="B18" ref-type="bibr">18</xref>). The conjugate containing two staphylococcal antigens proved to be the most immunogenic formulation in murine models of <italic toggle="yes">S. aureus</italic> bacteremia and pneumonia, therefore confirming two important principles for <italic toggle="yes">S. aureus</italic> vaccine development: 1) that &#8220;designer&#8221; glycoconjugates containing antigens from the same microbe are feasible and 2) that including carrier proteins from <italic toggle="yes">S. aureus</italic> increases vaccine immunogenicity. Considering that two of the most high-profile failures of prior <italic toggle="yes">S. aureus</italic> vaccines (Nabi&#8217;s StaphVax and Pfizer&#8217;s SA4Ag) used chemical conjugation to combine capsular polysaccharides to carrier proteins of unrelated bacteria, bioconjugation to native bacterial proteins may represent an area in which vaccine efficacy can be improved upon (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>). This point is further validated by the finding that an abundance of disease-causing <italic toggle="yes">S. aureus</italic> strains do not express a capsular polysaccharide (<xref rid="B21" ref-type="bibr">21</xref>).</p></sec><sec id="s2_2"><title>Extracellular Vesicles</title><p>Gram-negative bacteria naturally secrete outer membrane vesicles (OMVs) composed of membrane-encapsulated periplasmic material. Being native secretions from bacteria, OMVs contain large amounts of pathogen associated molecular patterns (PAMPs) such as bacterial lipopolysaccharide, which activate the innate immune system and display highly effective adjuvant properties (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>). Such inherent immunogenicity combined with a relative ease of production and the ability to incorporate non-native proteins has placed OMVs as an emerging and exciting vaccine delivery platform (<xref rid="B24" ref-type="bibr">24</xref>). This potential is being realized as we see vaccines using OMVs produced by genetically modified bacteria to increase antigenic yield and to reduce the toxic effects of endogenous Lipid A (known as Generalized Modules of Membrane Antigens or GMMAs) enter into clinical testing (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>). While <italic toggle="yes">S. aureus</italic> is a gram-positive bacterium, the applicability of OMV-based vaccination was recently demonstrated using <italic toggle="yes">Escherichia coli</italic> transfected with plasmids encoding five staphylococcal antigens, each fused to the leader sequence of the endogenous lipoprotein LPP, in order to traffic antigens into OMVs. Purified OMVs were used to successfully immunize mice against <italic toggle="yes">S. aureus</italic> sepsis, kidney abscess and skin infection (<xref rid="B27" ref-type="bibr">27</xref>). Interestingly, <italic toggle="yes">E. coli</italic> derived OMVs containing no staphylococcal antigens also provided strong protection against <italic toggle="yes">S. aureus</italic> sepsis and kidney abscess models. Such a finding may be a result of the short time frame between final immunization and infection (10 &#8211; 14 days) whereby residual immune potentiators induced through OMV immunization mediate anti-staphylococcal defense or, suggest that OMVs themselves induce non-specific protective immunity, an effect known as innate immune memory or trained immunity that has previously shown to play a protective role during murine models of <italic toggle="yes">S. aureus</italic> infection (<xref rid="B28" ref-type="bibr">28</xref>&#8211;<xref rid="B31" ref-type="bibr">31</xref>).</p><p>As an alternative to using OMVs which are by definition derived from gram-negative bacteria, the discovery that gram-positive bacteria, including <italic toggle="yes">S. aureus</italic>, secrete extracellular vesicles (EVs) has led to their experimental use as a novel vaccination platform (<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>). Proteomic analysis has revealed the composition of such EVs to be large and functionally heterogenous with cytoplasmic, secreted and cell membrane proteins with roles in cellular homeostasis, immune evasion and antibiotic resistance (<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B34" ref-type="bibr">34</xref>). Similar to OMVs, <italic toggle="yes">S. aureus</italic> EVs display inherent adjuvant qualities, shown to drive the production of innate proinflammatory cytokines such as TNF-&#945;, IL-6 and IL-12 in dendritic cells and dermal fibroblasts (<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B36" ref-type="bibr">36</xref>). As such, EVs are expected to be highly capable of acting as standalone vaccine platforms. Indeed, during murine models of infection, mice immunized three times with <italic toggle="yes">S. aureus</italic> EVs demonstrated protective immunity towards subsequent <italic toggle="yes">S. aureus</italic>-induced pneumonia one week after receiving final vaccination and crucially, immunity was also demonstrated during a lethal model of <italic toggle="yes">S. aureus</italic>-induced sepsis 40 days after final vaccination, confirming the induction of long-term protective immunity (<xref rid="B35" ref-type="bibr">35</xref>). Interestingly, this immunity could be largely transferred <italic toggle="yes">via</italic> T cells and was completely abrogated upon the genetic deletion of IFN-&#947;. This finding echoes previous studies demonstrating T cell-derived IFN-&#947; as a crucial mediator of protection during systemic <italic toggle="yes">S. aureus</italic> infections in humans and mice (<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B38" ref-type="bibr">38</xref>). Interestingly, exosomes released by mammalian cells have recently been shown to exert a protective effect against <italic toggle="yes">S. aureus</italic> and other bacteria acting as decoys against Hla and other bacterial toxins (<xref rid="B39" ref-type="bibr">39</xref>).</p></sec><sec id="s2_3"><title>Whole Cell and Live-Attenuated <italic toggle="yes">S. aureus</italic> Vaccination</title><p>Using chemically or physically inactivated or live-attenuated bacteria as a vaccine platform presents up and down-sides. Using whole cell bacteria ensures that a wide array of antigens are present to which a recipient may induce an immune response however, such vaccine formulations may also be associated with significant adverse events when compared to subunit vaccination, best exemplified in such vaccines against <italic toggle="yes">Bordetella pertussis</italic> (<xref rid="B40" ref-type="bibr">40</xref>). Furthermore, although live-attenuated vaccines possess an extremely low risk of mutating back into a virulent form, there are exceptions as is seen with the current vaccine-derived circulating strains of Poliovirus in Africa (<xref rid="B41" ref-type="bibr">41</xref>). Recently, an attenuated auxotrophic mutant of <italic toggle="yes">S. aureus</italic> MRSA strain 132 was created through genetic disruption of the D-alanine biosynthesis pathway, known to be essential for cell wall structure and viability across different bacterial phyla (<xref rid="B42" ref-type="bibr">42</xref>&#8211;<xref rid="B45" ref-type="bibr">45</xref>). While lethal at high doses (1.1 x 10<sup>9</sup> CFU), the auxotrophic strain of <italic toggle="yes">S. aureus</italic> was shown to be well tolerated by mice when introduced intraperitoneally at doses of 7 x 10<sup>7</sup> CFU and lower (<xref rid="B46" ref-type="bibr">46</xref>). Furthermore, whether introduced intravenously or intraperitoneally, the auxotrophic strain was cleared within two days of administration. Excitingly, vaccination with this strain proved to be highly immunogenic protecting mice from lethal infection with <italic toggle="yes">S. aureus</italic> and further generating cross-reactive antibodies against a variety of <italic toggle="yes">S. aureus</italic> strains.</p><p>Inactivated whole cell vaccines have seen success in preclinical studies using both mouse and bovine models of <italic toggle="yes">S. aureus</italic> infection (<xref rid="B47" ref-type="bibr">47</xref>&#8211;<xref rid="B49" ref-type="bibr">49</xref>). In fact, there are currently two whole cell <italic toggle="yes">S. aureus</italic> vaccines (Lysigin<sup>&#174;</sup> and Startvac<sup>&#174;</sup>) approved for use in preventing and reducing the severity of bovine mastitis. Notably, a study investigating the protective capability of Startvac<sup>&#174;</sup> demonstrated a strong inverse correlation (r = -0.71) between vaccine-specific IgG2 responses directed towards a polysaccharide antigen (known as <italic toggle="yes">slime associated antigenic complex</italic>) and survival of <italic toggle="yes">S. aureus</italic> during an infectious challenge (<xref rid="B50" ref-type="bibr">50</xref>). Considering that here the antigen in question is structural and not a <italic toggle="yes">S. aureus</italic> toxin or immune evasion protein, it is possible to extrapolate that humoral immunity either opsonizing bacteria or reducing bacterial attachment is important for <italic toggle="yes">S. aureus</italic> clearance during bovine mastitis. Aside from acting as an alternate model of infection, an important value of veterinarian vaccines for <italic toggle="yes">S. aureus</italic> such as Lysigin<sup>&#174;</sup> and Startvac<sup>&#174;</sup> is the possibility to examine efficacy of diverse vaccine systems in settings where infections can occur naturally, thereby better mimicking the situation in humans. At this point however, data showcasing prevention of infection or indeed pronounced reductions in severity of disease are lacking (<xref rid="B51" ref-type="bibr">51</xref>). As such, meaningful translatability of protection to human subjects in these vaccine systems is not readily indicated. In humans there has been reported success for whole-cell vaccines during early phase clinical trials of i) SA75 containing chloroform inactivated <italic toggle="yes">S.&#160;aureus</italic> and ii) heat-killed (HK) <italic toggle="yes">S. aureus</italic> of strain ATCC 12598 (<xref rid="B52" ref-type="bibr">52</xref>). While published data for the SA75 trial is lacking, the phase&#160;one trial was reported a success and similarly, within the trial of HK-ATCC 12598, no safety concerns were raised by patients. Nonetheless, these vaccines were not further developed. As mentioned above, development of such vaccines presents several limitations for reaching today&#8217;s quality standards and that is why vaccine manufactures usually prefer newer technologies. Furthermore, both whole cell and live-attenuated vaccines are difficult to characterize as a reproducible product.</p></sec><sec id="s2_4"><title>Nucleic Acid Vaccines</title><p>Nucleic acid vaccines deliver antigens encoded either as DNA or messenger RNA to cells which then transcribe and/or translate vaccine antigens into proteins. While until very recently no nucleic acid vaccines had been approved for human use, extremely promising RNA-based vaccine candidates against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly progressed through clinical testing and, as of the time of writing this review (June 2021), two have been approved for human use (<xref rid="B53" ref-type="bibr">53</xref>, <xref rid="B54" ref-type="bibr">54</xref>). The rapid progress made by both vaccines using an RNA vaccine platform has brought a renewal of interest into this vaccine strategy. To our knowledge, RNA-based vaccination has not yet been directly investigated with <italic toggle="yes">S. aureus</italic> in humans. One reason for this may be that (although there is long-standing evidence demonstrating the cross-presentation of endogenously derived antigens to class II MHC molecules) endogenously derived antigen is typically associated with presentation on class I MHC molecules, therefore favoring the generation of anti-viral immune responses such as CD8<sup>+</sup> T cells (<xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B56" ref-type="bibr">56</xref>). In line with this, when pulsed with mRNAs encoding the <italic toggle="yes">S. aureus</italic> antigens SpA, MecA and SitC, healthy human monocyte-derived dendritic cells appeared to stimulate antigen-specific cytokine production in donor-matched CD8<sup>+</sup> T cells to a greater degree than that of CD4<sup>+</sup> T cells (<xref rid="B57" ref-type="bibr">57</xref>). Considering that intracellular survival of <italic toggle="yes">S. aureus</italic> in various cell types has been widely reported, CD8<sup>+</sup> T cells may represent an understudied component of protective immunity during infection (<xref rid="B58" ref-type="bibr">58</xref>&#8211;<xref rid="B60" ref-type="bibr">60</xref>). mRNA based vaccination against group A and group B Streptococci has been shown to drive protective immune responses in mice, even providing transgenerational, humoral protection (<xref rid="B61" ref-type="bibr">61</xref>). As such, mRNA vaccination may well prove a viable strategy for immunization against gram-positive bacteria such as <italic toggle="yes">S. aureus</italic>. Another point of interest in this study from Maruggi and colleagues, was that the inclusion of a leader sequence targeting the group B Streptococcus protein BP-2a for cell secretion increased vaccine immunogenicity. Specifically, this relocalization of BP-2a led to greater survival rates amongst the pups of immunized mice when challenged with a lethal infection of <italic toggle="yes">Streptococcus agalactiae</italic>, an effect that was most apparent when a combined vaccine regime using priming RNA doses and a booster dose with recombinant protein was employed (<xref rid="B61" ref-type="bibr">61</xref>).</p><p>DNA vaccines consisting of plasmid encoded antigens are another intensely studied nucleic acid-based vaccine platform that has previously shown efficacy against <italic toggle="yes">S. aureus</italic> in preclinical studies during murine models of infection (<xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B63" ref-type="bibr">63</xref>). Like RNA-based vaccination, DNA vaccines carry with them the ability to prime CD8<sup>+</sup> T Cells responses (<xref rid="B62" ref-type="bibr">62</xref>). However, a major obstacle that has obstructed the development of an efficacious DNA-based vaccine to date is the low immunogenicity observed in human subjects (<xref rid="B64" ref-type="bibr">64</xref>).</p></sec><sec id="s2_5"><title>Adjuvants</title><p>Adjuvants are used to boost the immunogenicity of otherwise poorly immunogenic antigens. The majority of previously discussed vaccine platforms are considered self-adjuvanted due to the presence of PAMPs in the case of OMV-based and whole cell vaccines or due to the immunostimulatory nature of exogenously derived nucleic acids [though adjuvants have previously been shown to boost immunogenicity in nucleic acid vaccines (<xref rid="B65" ref-type="bibr">65</xref>)]. Recombinant proteins and glycoconjugates however, are more often combined with adjuvants as they do not contain any outright activators of the innate immune system and are therefore generally less immunogenic. In previous clinical trials for <italic toggle="yes">S. aureus</italic>, recombinant proteins and glycoconjugates have been used both with and without adjuvants. Two separate vaccine candidates, V710 and StaphVAX, which both failed during phase 3 clinical efficacy testing were unadjuvanted. Merck&#8217;s V710 vaccine contained Iron Surface Determinant B (IsdB) while Nabi&#8217;s StaphVAX contained CP5/CP8 capsular polysaccharides conjugated to <italic toggle="yes">P. aeruginosa</italic> exoprotein A (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B66" ref-type="bibr">66</xref>&#8211;<xref rid="B68" ref-type="bibr">68</xref>). In the case of StaphVax, efficacy in reducing <italic toggle="yes">S. aureus</italic> bacteremia was evident at an estimated level of efficacy of 57% 40 weeks post-vaccination, however, by 54 weeks, efficacy drastically dropped to 26% (<xref rid="B19" ref-type="bibr">19</xref>). Vaccination with V710 showed minimal efficacy in reducing the onset of surgical site infection with <italic toggle="yes">S. aureus</italic> and actually increased the rate of mortality in those developing post-operative <italic toggle="yes">S. aureus</italic> infections (<xref rid="B69" ref-type="bibr">69</xref>). Mechanistically, this increased mortality has been previously linked to low endogenous levels of IL-2 and IL-17 in patients prior to receiving the vaccine (<xref rid="B66" ref-type="bibr">66</xref>). More recently, a novel mechanism explaining such worse outcomes was put forward by Nishitani and colleagues whereby at sites of surgical infection with <italic toggle="yes">S. aureus</italic>, antibodies against IsdB were shown to be captured in reverse orientation by the cell surface protein SpA. Here, the exposed Fab region of such antibodies may bind their target protein, IsdB which in turn binds its ligand: Hemoglobin-Haptoglobin complexes (<xref rid="B70" ref-type="bibr">70</xref>). Finally, Hemoglobin-Haptoglobin complexes are recognized and internalized by macrophages through the expression of CD163 which, due to the aforementioned ability of <italic toggle="yes">S. aureus</italic> to survive intracellularly, facilitates a behavior known as the Trojan horse hypothesis, whereby dissemination of <italic toggle="yes">S. aureus</italic> throughout the body occurs <italic toggle="yes">via</italic> macrophage migration within the blood supply (<xref rid="B71" ref-type="bibr">71</xref>, <xref rid="B72" ref-type="bibr">72</xref>).</p><p>One possible explanation for these failures may be the lack of an adjuvant employed in both vaccines. Evidence for this hypothesis comes primarily from preclinical studies using murine models and demonstrating enhanced immunogenicity in <italic toggle="yes">S. aureus</italic> vaccine formulations after the inclusion of an adjuvant or demonstrating differential immune profiles in mice vaccinated with identical antigens using altered adjuvant systems. In fact, antigen-specific antibody titers (<xref rid="B73" ref-type="bibr">73</xref>&#8211;<xref rid="B76" ref-type="bibr">76</xref>), antigen-specific T cell responses (<xref rid="B74" ref-type="bibr">74</xref>, <xref rid="B76" ref-type="bibr">76</xref>) as well as bacterial clearance and survival during subsequent infection (<xref rid="B73" ref-type="bibr">73</xref>&#8211;<xref rid="B77" ref-type="bibr">77</xref>) were all shown to increase with the inclusion of an adjuvant or to be significantly altered when comparing the use of different adjuvants, confirming the important impact an adjuvant may have on <italic toggle="yes">S. aureus</italic> vaccine efficacy. It should be noted however, that a recent study investigating the efficacy of various antigen combinations in murine models of skin and systemic <italic toggle="yes">S. aureus</italic> infections found no demonstrable differences in efficacy between a variety of adjuvants (<xref rid="B78" ref-type="bibr">78</xref>). Considering that in this study, no unadjuvanted control groups were included, and further that skin-infection was essentially attenuated by all vaccine formulations, meaningful conclusions are difficult to draw.</p><p>Although human data supporting a role for adjuvants in <italic toggle="yes">S. aureus</italic> vaccination is sparse, a phase 1 clinical trial for a <italic toggle="yes">S. aureus</italic> vaccine containing recombinant Hla, clumping factor a (ClfA) and CP5/CP8 conjugated to tetanus toxoid, the adjuvant system AS03 was investigated. AS03 is an oil-in-water emulsion shown in previous clinical trials to significantly increase the immunogenicity of influenza vaccination (<xref rid="B79" ref-type="bibr">79</xref>, <xref rid="B80" ref-type="bibr">80</xref>). The non-adjuvanted vaccine induced a rapid and potent antibody response towards the vaccine antigens suggesting that the vaccine induced a memory response, which pre-existed prior to vaccination. This phenomenon can be explained by the fact that humans are virtually all exposed to <italic toggle="yes">S. aureus</italic> and indeed the presence of antibodies against its antigens in healthy subjects has been documented (<xref rid="B81" ref-type="bibr">81</xref>). The effect for AS03 in boosting the <italic toggle="yes">S. aureus</italic> vaccine immunogenicity appeared not statistically superior as compared to the non-adjuvanted vaccine (<xref rid="B82" ref-type="bibr">82</xref>). The reason behind this may rely on the effect of pre-existing immunity, which makes antibody titers increase even without an adjuvant. In those conditions, it is likely that the quality, more than the quantity, of the antibodies can be improved in the presence of a proper adjuvant. However, it is difficult to derive any conclusions from the available clinical data on this hypothesis. Continuing with this idea, these findings open the door for a broader discussion on exactly what type of adjuvant should be considered for <italic toggle="yes">S. aureus</italic> vaccines.</p><p>Aside from the aforementioned use of AS03, all other <italic toggle="yes">S. aureus</italic> vaccines trialed in humans have used aluminum-based adjuvants. While yet to be fully understood, the mechanism through which alum-based adjuvants enhance the immunogenicity of vaccines is believed to be through a combination of antigen retention at the site of injection and local activation of the NLRP3 inflammasome to promote innate cytokine secretion (<xref rid="B83" ref-type="bibr">83</xref>, <xref rid="B84" ref-type="bibr">84</xref>). Alum has been shown to specifically polarize T cells towards Th2 and Tfh subsets, both associated with protection from extracellular parasites and the generation of humoral immunity (<xref rid="B85" ref-type="bibr">85</xref>&#8211;<xref rid="B88" ref-type="bibr">88</xref>). While the correlates of immunity to <italic toggle="yes">S. aureus</italic> infection are not definitively established, a role is appreciated for that of cellular immunity, specifically Th1 and Th17 mediated immunity, as evidenced by genetic, clinical and experimental data (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B89" ref-type="bibr">89</xref>&#8211;<xref rid="B91" ref-type="bibr">91</xref>). Importantly, these findings help to demarcate a second reason as to why adjuvant selection is important in <italic toggle="yes">S. aureus</italic> vaccine design and why alternatives to alum may be required: directionality of the induced immune response. Like AS03, MF59 is an oil-in-water emulsion that is used in licensed influenza vaccines (<xref rid="B92" ref-type="bibr">92</xref>). In a preclinical study investigating the immunogenicity of a multi-component <italic toggle="yes">S. aureus</italic> vaccine containing FhuD2, Csa1A, Hla, EsxA, and EsxB, a direct comparison was conducted between alum and MF59-adjuvanted vaccines (<xref rid="B74" ref-type="bibr">74</xref>). When given the MF59-adjuvanted vaccine, mice developed moderately enhanced antigen-specific memory T cell responses, demonstrated by CD4<sup>+</sup> T cell proliferation and cytokine production, one month post-vaccination compared to that of mice receiving the alum-adjuvanted vaccine, however this effect was not apparent at the four month time-point. Furthermore, evidence of greater protection afforded by the vaccine including MF59 was not wholly apparent when compared to the alum vaccine group. As such, while hinting at greater induction of T cell responses, MF59 does not appear to present itself as a clearly more efficacious adjuvant than alum in generating protective <italic toggle="yes">S. aureus</italic> immunity in a murine model.</p><p>Using the same experimental vaccine, a separate study found that inclusion of a TLR7 activating small molecule immune potentiator adsorbed onto alum could significantly enhance protective immunity in vaccinated mice versus control mice receiving a vaccine adjuvanted with alum alone (<xref rid="B75" ref-type="bibr">75</xref>). T cell responses were also greatly increased when compared to the alum only group, with enhancement of antigen-specific production of IL-2, TNF-&#945;, IFN-&#947; and a trend towards an increase of IL-17 observed. Notably, no increase in Th2 cytokines was observed, suggesting that the directionality of the induced immune response was specifically focused (<xref rid="B75" ref-type="bibr">75</xref>). Indeed, further analysis confirmed the induction of Th17 immunity as well as Th1 immunity, and further found that vaccine-induced protective immunity was highly dependent on both humoral and CD4<sup>+</sup> T cell responses (<xref rid="B76" ref-type="bibr">76</xref>). These encouraging results suggest that adjuvants acting through TLR7 may prove useful for the development of <italic toggle="yes">S. aureus</italic> vaccines.</p><p>Another TLR-activating adjuvant is CpG, composed of unmethylated cytosine and guanine repeats. When used as an adjuvant, CpG has been shown previously to evoke Th1 humoral and cellular responses in both mice and humans (<xref rid="B93" ref-type="bibr">93</xref>, <xref rid="B94" ref-type="bibr">94</xref>). This Th1 biasing effect was harnessed in two separate studies to successfully develop protective vaccination regimes in mice against localized and systemic infections with <italic toggle="yes">S. aureus</italic> (<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B95" ref-type="bibr">95</xref>, <xref rid="B96" ref-type="bibr">96</xref>). It should be noted that, in addition to Th1 responses, CpG-mediated induction of antigen-specific humoral and Th17 immunity was also observed and correlated with protection from infection (<xref rid="B95" ref-type="bibr">95</xref>, <xref rid="B96" ref-type="bibr">96</xref>). As such, the activity of CpG through TLR9 may represent a promising pathway for the induction of humoral and polyfunctional T cell responses associated with protection from <italic toggle="yes">S. aureus</italic> infections.</p><p>To summarize, the diversity observed in preclinical testing relating to vaccination strategies and choice of adjuvant is highly encouraging. While current research aims to elucidate the correlates of protection to <italic toggle="yes">S. aureus</italic> infection and to clinically validate the selection of particular antigens, diversity will be key to ensuring success in <italic toggle="yes">S. aureus</italic> vaccine design.</p></sec></sec><sec id="s3"><title>Models for the Study of <italic toggle="yes">S. aureus</italic> Infections</title><p>The conversation of <italic toggle="yes">S. aureus</italic> vaccine development is framed by past failings of clinical trials that all showed exciting promise during preclinical development. As such, we can conclude that the translation of preclinical data into clinical results is not successfully occurring. It&#8217;s clear that more accurate preclinical models to study <italic toggle="yes">S. aureus</italic> infections and the human immune response to such infections are needed to improve the predictability of laboratory-generated vaccines in protecting human subjects. In addition, determining the correlates of protection of <italic toggle="yes">S. aureus</italic> infections requires faithful recapitulation of human tissues and the human immune system. The most utilized model for studying <italic toggle="yes">S. aureus</italic> infections is the mouse. On one hand, the gene expression profiles of <italic toggle="yes">S. aureus</italic> extracted from natural cutaneous infections of human patients or from the kidneys of mice with experimentally induced systemic infections have been shown to be similar (<xref rid="B97" ref-type="bibr">97</xref>). However, the ability of mice, and in particular laboratory mice, being able to recapitulate the human immune response to infection has been under scrutiny in recent years (<xref rid="B98" ref-type="bibr">98</xref>, <xref rid="B99" ref-type="bibr">99</xref>). While this is undoubtedly true in a generalized immunological sense, <italic toggle="yes">S. aureus</italic>-specific examples of this effect can also be observed through the reduced affinity of staphylococcal toxins for non-human homologs of toxin receptors. For example, the bicomponent toxins: Panton-Valentine leukocidin (PVL), LukAB, HlgCB and HlgAB all display reduced affinity towards murine homologs of each of their human receptors, meaning that virulence mediated by these proteins may be missed through the use of mice&#160;(<xref rid="B100" ref-type="bibr">100</xref>, <xref rid="B101" ref-type="bibr">101</xref>). This effect has been demonstrated through the&#160;infection of immunodeficient mice re-constituted with human hematopoietic stem cells, thereby classified as humanized mice.&#160;Studies exposing humanized mice to a variety of <italic toggle="yes">S. aureus</italic> infections, including pneumonia, skin infection and intraperitoneal infection consistently showed increased susceptibility compared to wild-type or immunodeficient controls (<xref rid="B102" ref-type="bibr">102</xref>&#8211;<xref rid="B104" ref-type="bibr">104</xref>). In one such study, the efficacy of successful humanization as measured by the ratio of human to murine CD45<sup>+</sup> cells was directly correlated with the size of skin abscesses in mice and skin lesions were significantly reduced in humanized mice when a PVL-deficient strain of <italic toggle="yes">S. aureus</italic> was used, an effect not observed in wild-type mice (<xref rid="B102" ref-type="bibr">102</xref>). These findings combine to suggest that <italic toggle="yes">S. aureus</italic> host-specificity is a crucial factor for the outcome of infection and that humanization of mice may be a highly useful tool to increase the translatability of preclinical vaccine data (<xref rid="B105" ref-type="bibr">105</xref>). Notably, rabbits, while still much less than that of humans, are more susceptible to the effect of many <italic toggle="yes">S. aureus</italic> toxins, therefore suggesting rabbits as a more relevant <italic toggle="yes">in vivo</italic> model (<xref rid="B106" ref-type="bibr">106</xref>). <italic toggle="yes">S. aureus</italic> vaccines and monoclonal antibodies have also occasionally been tested in non-human primates, generating highly relevant data (<xref rid="B107" ref-type="bibr">107</xref>, <xref rid="B108" ref-type="bibr">108</xref>).</p><p>An additional caution to be noted when using mouse models for the study of <italic toggle="yes">S. aureus</italic> pathology is that specific pathogen free mice purchased from commercial vendors, as well as laboratory housed mice, may be naturally colonized with mouse-adapted <italic toggle="yes">S. aureus</italic> (<xref rid="B109" ref-type="bibr">109</xref>&#8211;<xref rid="B111" ref-type="bibr">111</xref>). Considering that pre-exposure to <italic toggle="yes">S. aureus</italic> in the contexts of colonization and infection alter the host immune response to subsequent infection, as reported in both mice and humans (<xref rid="B112" ref-type="bibr">112</xref>&#8211;<xref rid="B114" ref-type="bibr">114</xref>), the potentiality that experimental mice may or not be pre-colonized introduces a confounding factor into preclinical research. From an alternative standpoint, the evidence of host adaptation occurring in mice colonized with <italic toggle="yes">S. aureus</italic> may actually give value to the mouse model <italic toggle="yes">via</italic> two mechanisms. Firstly, the opportunity to study previously reported, naturally developing <italic toggle="yes">S. aureus</italic> infections in mice would mirror the process of human infection much more closely than experimentally induced infections (<xref rid="B110" ref-type="bibr">110</xref>). Secondly, though mouse-derived strains of <italic toggle="yes">S. aureus</italic> will be less clinically relevant than human-derived strains, host-adaptation may allow for more accurate comparative immunology approaches to be undertaken when studying the mouse immune response to <italic toggle="yes">S. aureus</italic>.</p><p>An interesting alternative animal model for studying <italic toggle="yes">S. aureus</italic> pathology that has been mobilized in recent years is the Zebrafish. The benefits of using this more distantly related organism include: i) the ability to study innate immune responses before the adaptive immune system has developed (this only occurs four weeks after fertilization), ii) a high degree of evolutionary divergence between human and Zebrafish immune systems allows us to specifically examine the functionality of highly conserved genomic material, thereby reducing the complexity of the system in question and iii)&#160;advanced microscopy techniques are applicable to this model due to its transparent appearance (<xref rid="B115" ref-type="bibr">115</xref>). Indeed, while utilized significantly less than the mouse model, some important basic research findings concerning the pathogenicity of <italic toggle="yes">S. aureus</italic> as well as inferences of protective immunity were made using the Zebrafish model (<xref rid="B116" ref-type="bibr">116</xref>, <xref rid="B117" ref-type="bibr">117</xref>).</p><p>The development of <italic toggle="yes">in vitro</italic> models to study human immunology is crucial towards moving away from the biologically and ethically undesirable use of animal models. Two leading approaches for recapitulating the physiological environment of human organs are: organoids and organs on chips. Organoids are cell culture models containing heterogenous cell types and anatomical organization that mimic a particular organ (<xref rid="B118" ref-type="bibr">118</xref>). In the context of <italic toggle="yes">S. aureus</italic>, the skin, lungs and bones represent some of the most common biological niches of non-systemic infection in humans. Therefore, establishing systems that model these organs <italic toggle="yes">in vitro</italic> could be relevant for the investigation of host immunity during infection. Recently, a human skin organoid was developed from human pluripotent stem cells that displayed complex architecture, hair production and a transcriptome all faithfully recapitulating that of human facial skin (<xref rid="B119" ref-type="bibr">119</xref>). Further still, cultured skin could be xenografted and integrated into a mouse model, therefore adding a significant degree of humanization for <italic toggle="yes">in vivo</italic> analysis of a hypothetical <italic toggle="yes">S. aureus</italic> infection. Similarly, the development of lung and bone organoid cultures has become more refined in recent years (<xref rid="B120" ref-type="bibr">120</xref>&#8211;<xref rid="B122" ref-type="bibr">122</xref>). Drawbacks to using organoids in <italic toggle="yes">S. aureus</italic> vaccinology research include i) the complexity of natural human tissue and the difficulty in fully re-creating such complexity <italic toggle="yes">in vitro</italic> ii) the inability to address the contribution of a tissue&#8217;s microbiome iii)&#160;the lack of potentially important cell types, for example tissue-resident lymphocyte populations which are abundantly present in many organs and finally iv) a lack of interaction with a systemic immune system when used in isolation (<xref rid="B123" ref-type="bibr">123</xref>, <xref rid="B124" ref-type="bibr">124</xref>).</p><p>Organs-on-chips consist of micro-scale organs, derived either from cell culture methods akin to that of an organoid or alternatively from <italic toggle="yes">ex vivo</italic> samples of an organ, often connected to a microfluidics system which mimics that of a physiologically relevant vascular system (<xref rid="B125" ref-type="bibr">125</xref>). The applicability of this model in studying S. <italic toggle="yes">aureus</italic> infections was recently demonstrated by Kim and colleagues. In this study, a micro-biopsy of skin was taken from healthy human subjects, infected with <italic toggle="yes">S. aureus</italic> and then loaded into a chip containing two chambers: one for the skin explant and another for the addition of one drop of whole blood. Importantly, blood and skin were separated by columns selectively allowing for the autonomous migration of neutrophils in response to chemotactic signals secreted by the skin (<xref rid="B126" ref-type="bibr">126</xref>). As such, it may be possible to obtain minimally invasive micro-samples of skin and blood from humans enrolled in clinical trials receiving <italic toggle="yes">S. aureus</italic> vaccines to determine whether skin-derived and/or systemic immunity raised by a vaccine may contribute to physiologically relevant protection from <italic toggle="yes">S. aureus</italic> infection, using this model. A lung organ-on-chip was also recently developed and investigated for its ability to study <italic toggle="yes">S. aureus</italic> infections. Here Deinhardt-Emmer et&#160;al. (<xref rid="B127" ref-type="bibr">127</xref>) used three cell lines to establish an artificial alveolus consisting of endothelial, epithelial and macrophage cells that was then infected with both <italic toggle="yes">S. aureus</italic> and influenza virus (<xref rid="B127" ref-type="bibr">127</xref>). The alveolus-on-chip was connected to a fluidics system consisting of a peristaltic pump ensuring unidirectional flow and a reservoir of cell culture medium, mimicking a circulatory system.</p><p>A highly valuable model to study the infective behavior of <italic toggle="yes">S. aureus</italic> are human <italic toggle="yes">ex vivo</italic> samples. <italic toggle="yes">Ex vivo</italic> samples are derived directly from human subjects and consist of complex tissues influenced by a natural microbiome, containing diverse genetic makeups and fully relevant cell populations. When considering <italic toggle="yes">S. aureus</italic> infections, there are some human tissues/fluids highly relevant to the study of host-pathogen interactions, that are also accessible for <italic toggle="yes">ex vivo</italic> analysis. For example, the transcriptome of <italic toggle="yes">S. aureus</italic> cultured <italic toggle="yes">ex vivo</italic> within human blood is distinct from that of the bacterium cultured in tryptic soy broth <italic toggle="yes">in vitro</italic>, also found with <italic toggle="yes">S. aureus</italic> derived from human sputum in cystic fibrosis patients (<xref rid="B128" ref-type="bibr">128</xref>, <xref rid="B129" ref-type="bibr">129</xref>). The skin is another tissue of great relevance and opportunity for the study of <italic toggle="yes">S. aureus</italic> infectivity [as reviewed recently (<xref rid="B130" ref-type="bibr">130</xref>)]. Skin can be accessed through the donation of surgical waste samples, micro-biopsies and may even be probed <italic toggle="yes">in-situ</italic>, as demonstrated recently through the development of microneedle patches designed to extract interstitial fluid as well as antigen-specific lymphocytes from human skin (<xref rid="B131" ref-type="bibr">131</xref>). The cytokine response to <italic toggle="yes">S. aureus</italic> infection as well as the toxicity of Hla and PVL have previously been investigated using skin explant models, generating physiologically valuable data and a launchpad for future <italic toggle="yes">ex vivo</italic> analysis (<xref rid="B132" ref-type="bibr">132</xref>, <xref rid="B133" ref-type="bibr">133</xref>). Recently, the presence of <italic toggle="yes">S. aureus</italic>-specific tissue-resident CD4<sup>+</sup> T cells in the skin of healthy subjects has been shown using abdominal skin explants (<xref rid="B134" ref-type="bibr">134</xref>). The protective efficacy of this frontline adaptive immune response could be harnessed by future vaccination strategies (<xref rid="B135" ref-type="bibr">135</xref>).</p><p>In summary, prior rates of failure demand alternatives to standard mouse models when investigating the protective capacity of experimental <italic toggle="yes">S. aureus</italic> vaccines and to determine the correlates of immunity to infection. While alternate animal models such as the zebrafish can help to elucidate certain aspects of <italic toggle="yes">S. aureus</italic> behavior, the further development and use of humanized mouse models or novel <italic toggle="yes">in vitro</italic> models such as organoids, organs-on-chips and <italic toggle="yes">ex vivo</italic> tissue culture will be critical in increasing the clinical translatability of laboratory generated data.</p></sec><sec id="s4"><title>An Update Regarding Ongoing and Recently Concluded Clinical Trials for <italic toggle="yes">S. aureus</italic> Vaccines</title><p>There have recently been some key developments in the landscape of <italic toggle="yes">S. aureus</italic> vaccine development (<xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>). The most noteworthy of these is the phase IIb failure of Pfizer&#8217;s SA4Ag vaccine candidate. Composed of recombinant MntC, ClfA and both CP5 and CP8, each conjugated to a detoxified form of diphtheria toxin, this vaccine was tested in four phase I clinical trials (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B139" ref-type="bibr">139</xref>&#8211;<xref rid="B141" ref-type="bibr">141</xref>) before ultimately failing to reach designated protection endpoints in a subsequent efficacy trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02388165">NCT02388165</ext-link>). In phase I trials, a single dose of vaccine was sufficient to elicit high titers of specific and functional antibody responses in recipients from age 18&#8211;80 shown to last for at least a year after vaccination. Functionality was determined through antibody-mediated opsonophagocytic killing of bacteria and through inhibition of ClfA-mediated binding to its ligand, fibrinogen. Although SA4Ag was therefore deemed to be highly immunogenic, it failed to cause any reduction in the incidence of <italic toggle="yes">S. aureus</italic> bloodstream infections, surgical site infections or all-cause mortality within periods of 90 and 180 days after recipients underwent spinal surgery (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02388165">NCT02388165</ext-link>). SA4Ag&#8217;s failure in conferring protection to patients carries with it some critical lessons to be understood for <italic toggle="yes">S. aureus</italic> vaccinology. Firstly, and most crucially, the high immunogenicity of SA4Ag, as determined from assays analyzing the sera of vaccinees, had no bearing on its efficacy. One reason for this may be that the assays employed in order to classify the vaccine as immunogenic were not sufficient to capture the components of the immune system associated with preventing <italic toggle="yes">S. aureus</italic> infection. This issue stems again from the lack of defined correlates of protection to <italic toggle="yes">S. aureus</italic> infection, making the term &#8220;immunogenic&#8221; when applied to such vaccines somewhat misleading. In the case of SA4Ag, vaccine-induced humoral immunity was shown to be antigen specific in nature and capable of inducing bacterial opsonophagocytosis. Opsonophagocytic humoral responses were also demonstrated in both V710 and StaphVax vaccines that similarly failed efficacy testing in late-stage clinical trials (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B69" ref-type="bibr">69</xref>). As such, there is a growing consensus that using opsonophagocytosis as a readout for anti-staphylococcal immunogenicity is not sufficient as a standalone predictor of vaccine efficacy (<xref rid="B143" ref-type="bibr">143</xref>). Aligned with this point, none of the vaccine candidates that entered into late stage efficacy trials, reported on vaccine-induced T cell responses in humans, a potentially crucial aspect of immunogenicity when considering immunity from <italic toggle="yes">S. aureus</italic> infections. It is also possible that the <italic toggle="yes">in vitro</italic> assays used for measuring opsonophagocytosis were not predictive of this effect <italic toggle="yes">in vivo</italic>. For example, opsonophagocytosis assays are often performed using neutrophil-like cell lines as opposed to primary human neutrophils (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B69" ref-type="bibr">69</xref>, <xref rid="B138" ref-type="bibr">138</xref>).</p><table-wrap id="T1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>
<italic toggle="yes">Staphylococcus aureus</italic> vaccines currently enrolled in clinical trials.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Company</th><th valign="top" align="center" rowspan="1" colspan="1">Vaccine</th><th valign="top" align="center" rowspan="1" colspan="1">Phase</th><th valign="top" align="center" rowspan="1" colspan="1">Clinical trial number</th><th valign="top" align="center" rowspan="1" colspan="1"> Study population</th><th valign="top" align="center" rowspan="1" colspan="1">Literature</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">GSK</td><td valign="top" align="left" rowspan="1" colspan="1">SA-5Ag: Adjuvanted</td><td valign="top" align="center" rowspan="1" colspan="1">I: Recruiting</td><td valign="top" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04420221">NCT04420221</ext-link></td><td valign="top" align="left" rowspan="1" colspan="1">18 &#8211; 50 year olds at risk of recurrent skin infections</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Novadigm Therapeutics</td><td valign="top" align="left" rowspan="1" colspan="1">NDV-3A: Als-3 (<italic toggle="yes">C. albicans</italic> cross reactive cell wall protein) + Alum</td><td valign="top" align="center" rowspan="1" colspan="1">II: Ongoing</td><td valign="top" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03455309">NCT03455309</ext-link></td><td valign="top" align="left" rowspan="1" colspan="1">Military Personnel</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B136" ref-type="bibr">136</xref>, <xref rid="B137" ref-type="bibr">137</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Olymvax</td><td valign="top" align="left" rowspan="1" colspan="1">rFSAV: Hla, SpA, SEB, IsdB, MntC + Alum</td><td valign="top" align="center" rowspan="1" colspan="1">II: Ongoing</td><td valign="top" align="center" rowspan="1" colspan="1">CTR20181788, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03966040">NCT03966040</ext-link></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B138" ref-type="bibr">138</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pfizer</td><td valign="top" align="left" rowspan="1" colspan="1">SA4Ag: CP5-dptx, CP8-dptx, ClfA, MntC</td><td valign="top" align="center" rowspan="1" colspan="1">IIb: Failure</td><td valign="top" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02388165">NCT02388165</ext-link></td><td valign="top" align="left" rowspan="1" colspan="1">Patients undergoing spinal surgery</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B20" ref-type="bibr">20</xref>,&#160;<xref rid="B139" ref-type="bibr">139</xref>&#8211;<xref rid="B141" ref-type="bibr">141</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Integrated Biotherapeutics</td><td valign="top" align="left" rowspan="1" colspan="1">i. Stebvax: SEB + alum<break/>ii. IBT-V02: SEB, SEA, TSST-1, LukS, LukF, LukAB, Hla + alum</td><td valign="top" align="center" rowspan="1" colspan="1">I: Completed<break/>I: Scheduled</td><td valign="top" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00974935">NCT00974935</ext-link></td><td valign="top" align="left" rowspan="1" colspan="1">18 &#8211; 40 year olds</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B142" ref-type="bibr">142</xref>)</td></tr></tbody></table></table-wrap><p>Another lesson from SA4Ag&#8217;s failure is that while retrospective analysis of Nabi&#8217;s StaphVax vaccine seemed to indicate that waning antibody titres might lead to a decreased efficacy overtime (<xref rid="B19" ref-type="bibr">19</xref>), here SA4Ag was specifically shown to induce lasting humoral responses for periods of time longer than the efficacy study itself (<xref rid="B141" ref-type="bibr">141</xref>). Considering that SA4Ag was given&#160;as a single, unadjuvanted dose, it is conceivable that administration of the vaccine acted to simply boost pre-existing <italic toggle="yes">S. aureus</italic> immune responses without significantly enhancing the quality and functionality of humoral or cellular immunity.</p><p>There are at least five <italic toggle="yes">S. aureus</italic> vaccines currently engaged in various stages of clinical trials (<xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>). Novadigm&#8217;s NDV3-A vaccine consists of the N-terminal part of the <italic toggle="yes">Candida albicans</italic> cell-wall protein Als3p adjuvanted with alum. Although a fungal protein, this vaccine provides cross-protection against <italic toggle="yes">S. aureus</italic> during murine models of bacteremia and skin infection due to cross-kingdom antigen overlap (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B136" ref-type="bibr">136</xref>, <xref rid="B144" ref-type="bibr">144</xref>). Currently this vaccine is in a phase II trial aimed at preventing nasal colonization with <italic toggle="yes">S. aureus</italic> in military personnel, a population in which the frequency of <italic toggle="yes">S. aureus</italic> skin infections is high (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03455309">NCT03455309</ext-link>). Encouragingly, this vaccine has been associated with strong cellular immune responses in preclinical testing and crucially, was show to elicit antigen-specific production of the T cell cytokines IFN-&#947; and IL-17 in human recipients during a phase I trial (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B137" ref-type="bibr">137</xref>). Furthermore, aside from IgG antibody responses, NDV3 was also found to induce a potent IgA response. Typically, non-IgG antibodies are not examined during the study of <italic toggle="yes">S. aureus</italic> immunity, however bovine research has suggested an anti-staphylococcal role for IgA and considering that in humans, <italic toggle="yes">S. aureus</italic> most commonly occupies mucosal niches, determining whether such antibodies can suppress colonization represents an area worth further study (<xref rid="B145" ref-type="bibr">145</xref>). Suppressing colonization is a novel clinical endpoint to set for an <italic toggle="yes">S. aureus</italic> vaccine and indeed, a crucial step for disease eradication, while also representing a major risk factor for the development of staphylococcal bacteremia (<xref rid="B146" ref-type="bibr">146</xref>, <xref rid="B147" ref-type="bibr">147</xref>). A prior phase I trial by GSK investigating the safety and immunogenicity of a four-component vaccine containing: CP5, CP8, Hla and ClfA was found to have no effect on rates of <italic toggle="yes">S. aureus</italic> carriage over two years (<xref rid="B82" ref-type="bibr">82</xref>). This vaccine induced strong IgG responses and weak cellular immune responses in recipients suggesting that, as concluded when discussing vaccine efficacy, prevention of colonization may require more than robust IgG responses alone.</p><p>Olymvax have developed a <italic toggle="yes">S. aureus</italic> vaccine named rFSAV currently in phase II trials (CTR20181788). This vaccine is composed of five recombinant <italic toggle="yes">S. aureus</italic> antigens: Hla, SEB, MntC, IsdB and SpA and showed promising efficacy in preclinical murine experiments (<xref rid="B138" ref-type="bibr">138</xref>). In addition to promoting opsonophagocytosis, sera from mice immunized with rFSAV were also shown to neutralize the lytic activity of Hla and prevent a slight depletion of splenic B cells observed in mice, mediated by treatment with SpA (<xref rid="B138" ref-type="bibr">138</xref>, <xref rid="B148" ref-type="bibr">148</xref>). Importantly, this vaccine represents an alternate aspect of &#8220;immunogenicity&#8221; against <italic toggle="yes">S. aureus</italic>: inhibition of <italic toggle="yes">S. aureus</italic> immune-evasion strategies. This can be understood through the inclusion of both Hla and SpA in the vaccine formulation. Hla engages in the lytic killing of many leukocyte cell types and further disrupts cellular tight-junctions, facilitating <italic toggle="yes">S. aureus</italic> invasiveness (<xref rid="B149" ref-type="bibr">149</xref>, <xref rid="B150" ref-type="bibr">150</xref>). Moreover, Hla intoxication leads to platelet aggregates that are deposited in the liver causing microvascular dysfunction and thrombosis in infected mice (<xref rid="B151" ref-type="bibr">151</xref>). In addition, Hla was recently shown to prevent the expansion of T cells during primary murine <italic toggle="yes">S. aureus</italic> skin infection, implicating itself as an important immune-evasion toxin (<xref rid="B152" ref-type="bibr">152</xref>). SpA acts both as a B cell superantigen and to sequester antibodies by their Fc portion, therefore functioning to suppress the humoral immune response through two separate mechanisms (<xref rid="B153" ref-type="bibr">153</xref>, <xref rid="B154" ref-type="bibr">154</xref>). Lastly, SEB is known to induce rapid expansion, activation and subsequent anergy in a large proportion of the host T cell compartment (<xref rid="B155" ref-type="bibr">155</xref>). Considering the previously discussed evidence that anti-IsdB antibodies may in fact be pathological, combined with clinical serological data reporting a similar phenomenon, extremely close observation should be kept on individuals receiving this experimental vaccine to prevent vaccine-induced mortality during <italic toggle="yes">S. aureus</italic> infections as seen in the V710 trial (<xref rid="B66" ref-type="bibr">66</xref>, <xref rid="B156" ref-type="bibr">156</xref>).</p><p>Integrated BioTherapeutics have developed a heptavalent <italic toggle="yes">S. aureus</italic> vaccine consisting of seven <italic toggle="yes">S. aureus</italic> toxoids: Hla, Panton-Valentine Leukocidin (PVL) F and S subunits, Leukocidin A/B, SEA, SEB and Toxic shock syndrome toxin 1 (<xref rid="B157" ref-type="bibr">157</xref>). Preclinical data has shown that this vaccine, named IBT-V02, confers protection to both mice and rabbits against <italic toggle="yes">S. aureus</italic> skin infection, with protection being entirely mediated by vaccine-induced antibodies (<xref rid="B142" ref-type="bibr">142</xref>). Interestingly, vaccine efficacy (as measured through the development of infection-induced skin lesions) was unaffected when mice were pre-exposed intradermally to a low dose of <italic toggle="yes">S. aureus</italic> prior to vaccination. As mentioned previously, humans are naturally exposed to <italic toggle="yes">S. aureus</italic> and harbor pre-existing immunity (<xref rid="B81" ref-type="bibr">81</xref>). Pre-exposing mice to <italic toggle="yes">S. aureus</italic> therefore represents an encouraging degree of humanization to the mouse model. After receiving significant funding grants from the National Institute of Allergy and Infectious Disease and CARB-X, IBT-V02 is expected to enter early phase clinical trials soon. Integrated BioTherapeutics are also developing a vaccine aimed specifically at neutralizing systemic toxicity induced by SEB which may find use in preventing potential SEB-related biological warfare attacks. This vaccine, consisting of a mutated, non-MHC-II binding recombinant SEB protein successfully completed a phase I trial in 2016 (<xref rid="B158" ref-type="bibr">158</xref>). GSK are in the recruiting phase of a phase I trial for their SA-5Ag vaccine (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04420221">NCT04420221</ext-link>). The target population in this trial is listed as 18-50 year-olds with a recurrent <italic toggle="yes">S. aureus</italic> skin infection, a novel population for <italic toggle="yes">S. aureus</italic> vaccine trials.</p></sec><sec id="s5"><title>Novel Therapeutic Strategies for the Treatment of <italic toggle="yes">S. aureus</italic> Infections</title><p>In parallel with vaccinology research, the development of therapeutic interventions for <italic toggle="yes">S. aureus</italic>-mediated disease is an area of constant innovation. In recent years, the revamping of older, more established treatment options as well as the development of completely novel strategies has created exciting hope for new treatment options against <italic toggle="yes">S. aureus</italic>. Herein, we discuss some of the most innovative and promising therapeutic interventions for the treatment of <italic toggle="yes">S. aureus</italic> infections.</p><sec id="s5_1"><title>Novel Antibiotic Strategies</title><p>Mortality rates due to <italic toggle="yes">S. aureus</italic> bacteremia are significantly higher in cases of MRSA bacteremia when compared to methicillin susceptible <italic toggle="yes">S. aureus</italic> (MSSA)-mediated disease with one study reporting mortality rates of 49.8% and 22.2% respectively (<xref rid="B159" ref-type="bibr">159</xref>). Such a finding is believed to be a result of the lower efficacy of daptomycin and vancomycin, the two first-line recommended interventions for MRSA infection, in treating <italic toggle="yes">S. aureus</italic> when compared to &#946;-lactam antibiotics which are used to treat MSSA (<xref rid="B160" ref-type="bibr">160</xref>). Improving on this efficacy is therefore a priority for MRSA treatment, a sentiment captured in a recent statement from the World Health Organization following the completion of two reports investigating the global development of antimicrobial drugs, in which they warn that a lack of development will risk our ability to contain the spread of multi-drug resistant bacteria (<xref rid="B161" ref-type="bibr">161</xref>, <xref rid="B162" ref-type="bibr">162</xref>). In early clinical and preclinical studies, novel antibiotics and delivery systems improving the efficacy of established antibiotics are being investigated along with the usage of novel drug combinations. An example of such effects at work can be seen by the recent development of DSTA4637S, an antibody-antibiotic conjugate consisting of a monoclonal antibody targeting <italic toggle="yes">S. aureus</italic> wall teichoic acid, fused to a novel rifamycin-class antibiotic (<xref rid="B163" ref-type="bibr">163</xref>). Mechanistically, DSTA4637S works to promote opsonophagocytosis which, upon entry into the intracellular phagolysosome of human phagocytes, initiates the cleavage of the fused antibiotic, and subsequent bacterial inhibition (<xref rid="B164" ref-type="bibr">164</xref>). Crucially, and unlike currently administered antibiotics, this mechanism is capable of effectively killing intracellular <italic toggle="yes">S. aureus</italic>, thereby reducing the ability of metastatic infections to occur. DSTA4637S recently completed a phase 1 trial (<xref rid="B165" ref-type="bibr">165</xref>).</p><p>The potential power of combination antibiotic therapy was recently exemplified in a small study of 40 participants in which daptomycin treatment was combined with the &#946;-lactam ceftaroline. This study showed that combination treatment significantly reduced mortality when compared to either daptomycin or vancomycin treatment alone in patients with MRSA bacteremia (<xref rid="B166" ref-type="bibr">166</xref>). Though the mechanism for such synergy is not yet understood, it has been proposed that &#946;-lactam antibiotics may directly enhance the bactericidal capacity of the innate immune system, thereby acting as an adjunct to daptomycin treatment (<xref rid="B167" ref-type="bibr">167</xref>).</p><p>Within the last three years, an abundance of novel mechanisms aiming to enhance the delivery of anti-staphylococcal medicines towards site-specific infections such as skin and soft-tissue infections, implant related osteomyelitis or pneumonia have been developed in preclinical settings. For example, following the discovery that mesenchymal stem cells display antibacterial (including anti-<italic toggle="yes">S. aureus</italic>) activity (<xref rid="B168" ref-type="bibr">168</xref>, <xref rid="B169" ref-type="bibr">169</xref>), Yoshitani and colleagues developed a novel therapeutic treatment in rats, consisting of adipose-derived stem cells loaded with the fluoroquinolone antibiotic ciprofloxacin, administered as a local injection to rats with experimentally-induced implant-related <italic toggle="yes">S. aureus</italic> infections. This strategy was shown to decrease bacterial loads at the site of infection while further showing to outperform standard antibiotic treatment in decreasing osteomyelitis and bacterial abscess formation (<xref rid="B170" ref-type="bibr">170</xref>). A relatively more simplistic idea was recently applied for the delivery of hydrogel scaffolds mediating bone repair during a murine model of experimentally induced bone-defects. Here, the hydrogel scaffold was co-delivered with live <italic toggle="yes">S. aureus</italic> in order to model an implant-related infection however, upon the inclusion of the enzyme lysostaphin which displays potent anti-<italic toggle="yes">S. aureus</italic> activity to the scaffold, bacterial presence within implants was negligible at one and six weeks post-introduction of the infected scaffold (<xref rid="B171" ref-type="bibr">171</xref>). Focusing on a separate infection site, Hussain et&#160;al. (<xref rid="B172" ref-type="bibr">172</xref>) developed a <italic toggle="yes">S. aureus</italic>-binding peptide, using a combination of <italic toggle="yes">in vivo</italic> and <italic toggle="yes">in vitro</italic> phage display, and then coated silicon nanoparticles containing vancomycin with this peptide to target antibiotic delivery directly to live bacteria. Importantly, this strategy was shown to completely protect from <italic toggle="yes">S. aureus</italic> pneumonia-induced mortality during a murine model of infection (<xref rid="B172" ref-type="bibr">172</xref>). Positively charged silver nanoparticles are broad spectrum biocides that were used recently to functionalize catheter materials, leading to the effective inhibition of single- as well as dual-species <italic toggle="yes">S. aureus</italic>/<italic toggle="yes">C. albicans</italic> biofilm formation (<xref rid="B173" ref-type="bibr">173</xref>). Catheter-related bloodstream infections due to biofilm formation are a major healthcare problem and mixed bacterial/fungal biofilms formed by these two species represent a relevant clinical complication since &#946;-1-3-glucan secreted by <italic toggle="yes">C. albicans</italic> provides <italic toggle="yes">S. aureus</italic> with enhanced antibiotic tolerance (<xref rid="B174" ref-type="bibr">174</xref>). In summary, an abundance of novel mechanisms involved in pharmacologically increasing the efficacy of antibiotics and in targeting antibiotics directly towards sites of infection are being developed, holding promise for the generation of novel therapeutics to treat <italic toggle="yes">S. aureus</italic>.</p></sec><sec id="s5_2"><title>Bacteriophage Therapy: Phages and Endolysins</title><p>While not a novel strategy for the treatment of bacterial infections, bacteriophage therapies have seen a revitalization in recent years with numerous promising treatments in development for <italic toggle="yes">S. aureus</italic> infections as well as other notable antibiotic resistant bacteria in both preclinical and clinical stages (<xref rid="B161" ref-type="bibr">161</xref>, <xref rid="B175" ref-type="bibr">175</xref>). Two distinct methods by which anti-staphylococcal viruses can be harnessed are through a) the use of virus-derived antibacterial enzymes such as endolysins and b) the injection of full viral particles. An example of a promising phage endolysin is SAL-200, developed by Intron Biotechnology. This <italic toggle="yes">S. aureus-</italic>specific enzyme demonstrated bactericidal activity against over 400 strains of <italic toggle="yes">S. aureus</italic> and was further shown to ameliorate outcomes to murine bacteremia while also synergizing with antibiotic treatment during murine and moth larval systemic infections to deliver greater therapeutic efficacy (<xref rid="B176" ref-type="bibr">176</xref>, <xref rid="B177" ref-type="bibr">177</xref>). SAL-200 has since entered into human clinical trials where it was firstly shown to be well tolerated in healthy volunteers and as such, has now entered into phase II testing (<xref rid="B178" ref-type="bibr">178</xref>) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03089697">NCT03089697</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03446053">NCT03446053</ext-link>). Earlier this year CF-301, another bacteriophage endolysin, completed a proof-of-concept efficacy trial for the treatment of <italic toggle="yes">S. aureus</italic> bacteremia and endocarditis given as an adjunctive therapy with standard of care antibiotic treatment. Interestingly, though the additive efficacy of endolysin treatment during all <italic toggle="yes">S. aureus</italic> infections was 10% fourteen days post-treatment, restricting analysis to cases of MRSA demonstrated that over 42% of patients responded positively to adjunctive treatment (<xref rid="B179" ref-type="bibr">179</xref>). Such a finding is believed to reflect the previously discussed inferiority in anti-bacterial activity associated with antibiotics used during MRSA infections when compared to those used in MSSA infections. The activity of bacteriophage therapy has also been investigated for the treatment of more localized <italic toggle="yes">S. aureus</italic> infections. For example, a phase I trial was recently completed using the AB-SA01 bacteriophage cocktail demonstrating safety and preliminary indications of efficacy in combatting <italic toggle="yes">S. aureus</italic> mediated chronic rhinosinusitis (<xref rid="B180" ref-type="bibr">180</xref>). Consisting of three separate phages, this treatment has also recently been utilized in a small cohort of patients with severe systemic <italic toggle="yes">S. aureus</italic> infections lacking any non-treated controls (<xref rid="B181" ref-type="bibr">181</xref>). While the discussed data is promising, much remains to be seen concerning the use of bacteriophage therapies for <italic toggle="yes">S. aureus</italic> infections, paramount of which is large-scale efficacy. Some further outstanding issues that remain to be consolidated for bacteriophage therapy include: i)&#160;whether pre-existing or treatment-generated antibody responses will inhibit therapeutic efficacy and ii) whether bacteriophages or endolysins will be capable of killing intracellular <italic toggle="yes">S. aureus</italic> (<xref rid="B182" ref-type="bibr">182</xref>).</p></sec><sec id="s5_3"><title>Monoclonal Antibodies</title><p>Passive immunization with monoclonal antibodies is an area of keen interest in the development of <italic toggle="yes">S. aureus</italic> therapeutics. Initially, efficacy trials of both poly and monoclonal antibodies targeting surface antigens of <italic toggle="yes">S. aureus</italic> such as: fibrinogen binding proteins (ClfA and Ser-Asp dipeptide repeat G), lipoteichoic acid and capsular polysaccharides showed largely disappointing results (<xref rid="B183" ref-type="bibr">183</xref>&#8211;<xref rid="B185" ref-type="bibr">185</xref>). More recently however, development has shifted towards monoclonal antibodies targeting staphylococcal toxins and immune evasion proteins as observed by the current antibody therapies engaged in clinical testing (<xref rid="T2" ref-type="table">
<bold>Table&#160;2</bold>
</xref>). The furthest therapeutic along this track is the anti-Hla monoclonal antibody Tosatoxumab developed by Aridis, currently recruiting for a phase 3 trial in patients with <italic toggle="yes">S. aureus</italic> ventilator associated pneumonia (VAP) in addition to standard of care treatment (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03816956">NCT03816956</ext-link>). Tosatoxumab completed a phase 1/2a trial on patients presenting with <italic toggle="yes">S. aureus</italic> pneumonia (including hospital acquired and community acquired pneumonia) showing to be well tolerated in recipients of the antibody. Furthermore, though statistical analysis was restricted to just 25 patients, when specifically looking at patients suffering from VAP, Tosatoxumab was found to significantly reduce the duration of time spent on emergency mechanical ventilation, therefore showing indications of efficacy in reducing <italic toggle="yes">S. aureus</italic>-mediated disease (<xref rid="B188" ref-type="bibr">188</xref>). As such, larger scale data in this patient cohort is expected to reveal a clearer picture as to whether neutralization of alpha-toxin is indeed associated with effective treatment of <italic toggle="yes">S. aureus</italic> VAP. Another monoclonal antibody neutralizing the lytic activity of Hla, Suvratoxumab developed by AstraZeneca, has been developed to have an extended half-life within human blood and again has shown to be well tolerated within recipients (<xref rid="B191" ref-type="bibr">191</xref>, <xref rid="B192" ref-type="bibr">192</xref>). Results of a phase II trial indicate that in patients receiving mechanical ventilation that are pre-colonized with <italic toggle="yes">S. aureus</italic>, Suvratoxumab displays some efficacy in reducing the development of <italic toggle="yes">S. aureus</italic> VAP, however the magnitude of efficacy at 31.9% was not sufficient to meet the efficacy endpoint of the study and furthermore did not reach statistical significance (<xref rid="B189" ref-type="bibr">189</xref>). In summation, though some encouraging results have been observed in the neutralization of Hla as both a prophylactic and therapeutic intervention in <italic toggle="yes">S. aureus</italic> VAP, further studies, particularly with larger sample sizes, are needed to provide a clear result demonstrating efficacy or a lack thereof.</p><table-wrap id="T2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>Therapeutic treatments for <italic toggle="yes">Staphylococcus aureus</italic> infections currently enrolled in clinical trials.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Company</th><th valign="top" align="center" rowspan="1" colspan="1">Medicine</th><th valign="top" align="center" rowspan="1" colspan="1">Phase</th><th valign="top" align="center" rowspan="1" colspan="1">Clinical trial number</th><th valign="top" align="center" rowspan="1" colspan="1">Literature</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Cumberland Pharmaceuticals</td><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Televancin:</bold> Vancomycin derivative</td><td valign="top" align="left" rowspan="1" colspan="1">III failure</td><td valign="top" align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02208063">NCT02208063</ext-link></td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B186" ref-type="bibr">186</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Arsanis</td><td valign="top" align="left" rowspan="1" colspan="1">
<bold>ASN-100:</bold> Two monoclonal antibodies against Hla, PVL, gamma-hemolysin (HlgAB and HlgCB), LukED and LukGH</td><td valign="top" align="left" rowspan="1" colspan="1">II Failure</td><td valign="top" align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02940626">NCT02940626</ext-link></td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B187" ref-type="bibr">187</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Genentech</td><td valign="top" align="left" rowspan="1" colspan="1">
<bold>DSTA4637S:</bold> Monoclonal antibody-antibiotic fusion targeting wall-teichoic acid</td><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02596399">NCT02596399</ext-link></td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B165" ref-type="bibr">165</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">iNtRON Biotechnology</td><td valign="top" align="left" rowspan="1" colspan="1">
<bold>SAL200:</bold> Bacteriophage endolysin</td><td valign="top" align="left" rowspan="1" colspan="1">II Ongoing</td><td valign="top" align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03089697">NCT03089697</ext-link></td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B178" ref-type="bibr">178</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ContraFect</td><td valign="top" align="left" rowspan="1" colspan="1">
<bold>CF-301:</bold> Bacteriophage endolysin</td><td valign="top" align="left" rowspan="1" colspan="1">II Completed</td><td valign="top" align="left" rowspan="1" colspan="1">NCT03163556</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B179" ref-type="bibr">179</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Aridis</td><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Tosatoxumab:</bold> Monoclonal antibody against Hla</td><td valign="top" align="left" rowspan="1" colspan="1">III Recruiting</td><td valign="top" align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03816956">NCT03816956</ext-link></td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B188" ref-type="bibr">188</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AstraZeneca</td><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Suvratoxumab:</bold> Monoclonal antibody against Hla</td><td valign="top" align="left" rowspan="1" colspan="1">II Completed</td><td valign="top" align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02296320">NCT02296320</ext-link></td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B189" ref-type="bibr">189</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">X-Biotech</td><td valign="top" align="left" rowspan="1" colspan="1">
<bold>514G3:</bold> Monoclonal antibody against SpA</td><td valign="top" align="left" rowspan="1" colspan="1">II Completed</td><td valign="top" align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02357966">NCT02357966</ext-link></td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B190" ref-type="bibr">190</xref>)</td></tr></tbody></table></table-wrap><p>Arsanis developed ASN-100, an antibody treatment consisting of two combined monoclonal antibodies that together target six lytic secreted toxins of <italic toggle="yes">S. aureus</italic>: Hla, PVL, gamma-hemolysin (HlgAB and HlgCB), LukED and LukGH (<xref rid="B193" ref-type="bibr">193</xref>, <xref rid="B194" ref-type="bibr">194</xref>). ASN-100 was shown to protect rabbits during an experimental model of pneumonia to a much greater extent than protection offered by a Hla-neutralizing antibody alone (<xref rid="B195" ref-type="bibr">195</xref>). However, phase two clinical testing focusing on preventing the development of <italic toggle="yes">S. aureus</italic> VAP was halted before completion as it was deemed highly unlikely to meet its efficacy endpoints (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02940626">NCT02940626</ext-link>).</p><p>Lastly, X-Biotech has developed 514G3, a monoclonal antibody against SpA, that unlike previously mentioned monoclonal antibody platforms, is focused on treating <italic toggle="yes">S. aureus</italic> bacteremia. In order to counteract SpA&#8217;s ability to sequester antibodies in their reverse orientation, 514G3 is an IgG3 isotype antibody, the sole subclass of IgG antibodies shown not to be bound in such a manner by SpA (<xref rid="B196" ref-type="bibr">196</xref>). Preclinical experiments demonstrated the efficacy of 514G3 in reducing <italic toggle="yes">S. aureus</italic> bacteremia-induced death in mice, while also showing an additive protective effect when mice where treated with vancomycin (<xref rid="B197" ref-type="bibr">197</xref>). 514G3 completed a combined phase I/II clinical trial on bacteremic patients in 2017 (<xref rid="B190" ref-type="bibr">190</xref>). Efficacy results from this trial have been publicly discussed by X-Biotech, who reported a reduction in <italic toggle="yes">S. aureus</italic> related adverse effects in the treated group vs a placebo group (11% <italic toggle="yes">vs.</italic> 26%) however, statistical significance was not reached. Similarly, a non-significant reduction was observed in the duration of hospital stay in bacteremic patients (p=0.092). Considering 36 patients received 514G3 and just 16 received placebo, it may be possible that significance could be achieved in a larger scale trial. It should also be noted that an investigation into whether or not treatment was associated with at least one death during the study was inconclusive, raising the possibility of safety concerns during future trials (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://investors.xbiotech.com/node/6796/pdf">https://investors.xbiotech.com/node/6796/pdf</uri>).</p><p>Overall, the use of monoclonal antibodies as therapeutic and short-term prophylactic treatments for <italic toggle="yes">S. aureus</italic> remains an area with indications of promise but requires further validation in larger controlled clinical studies. Interestingly, it has previously been hypothesized that treatment with monoclonal antibodies may result in an enhanced development of long-term immunity. It is proposed that antibody coating of pathogens or secreted antigens leads to the formation of immune complexes, which are readily phagocytosed by antigen presenting cells thereby driving the development of robust, protective anamnestic immune responses (<xref rid="B198" ref-type="bibr">198</xref>). This effect could be measured through post-treatment observation of patients looking specifically at <italic toggle="yes">S. aureus</italic> infection incidence.</p></sec><sec id="s5_4"><title>Further Experimental Treatments for <italic toggle="yes">S. aureus</italic>
</title><p>Lesser studied but nonetheless highly promising strategies for treating <italic toggle="yes">S. aureus</italic> infections include centyrins, a novel class of therapeutic proteins based on the consensus sequence of the 15 fibronectin type 3 domains of the human protein Tenascin C (<xref rid="B199" ref-type="bibr">199</xref>). Centyrins can be considered as mimetics of monoclonal antibodies due to the fact that specific regions of the protein are highly mutable and may be selected for the ability to bind specifically to antigens with high affinity (<xref rid="B199" ref-type="bibr">199</xref>). Some notable differences when compared to monoclonal antibodies are that firstly, at less than 10% the size of IgG1 antibodies, centyrins are much smaller than monoclonal antibodies (<xref rid="B200" ref-type="bibr">200</xref>). Secondly, centyrins exist as unglycosylated single-chain proteins that lack disulfide bonds and therefore can easily be produced in large quantities in <italic toggle="yes">E. coli</italic>. Thirdly, due to the absence of an antibody Fc region, centyrins will not bind to cellular Fc receptors, thereby restricting their functionality to neutralization, not being able to induce opsonophagocytosis. Centyrins may therefore prove refractory to the sequestering effect of SpA on antibodies. Chan and colleagues recently developed centyrins capable of neutralizing the lytic activity of five bicomponent <italic toggle="yes">S. aureus</italic> toxins against human neutrophils, and further protected mice given otherwise lethal doses of LukED (<xref rid="B201" ref-type="bibr">201</xref>). The authors addressed the fact that centyrins have a short half-life which can be extended within human blood by fusing centyrins with albumin. This modification has previously been shown to extend centyrin half-life to approximately 7.5 days in Macaques, and yet, this is still far behind that of anti-toxin monoclonal antibodies used in previous clinical trials (21 &#8211; 112 days) (<xref rid="B187" ref-type="bibr">187</xref>, <xref rid="B192" ref-type="bibr">192</xref>, <xref rid="B202" ref-type="bibr">202</xref>).</p><p>The previously mentioned effect of trained immunity is an area that may prove interesting for the development of alternative short-term prophylactic strategies for individuals undergoing surgeries and therefore risking the acquisition of an infection. Such an idea is evidenced from older studies demonstrating the protective effect of prior <italic toggle="yes">C. albicans</italic> infection on a subsequent <italic toggle="yes">S. aureus</italic> infection (<xref rid="B203" ref-type="bibr">203</xref>), to more recent publications recapitulating the same effect <italic toggle="yes">via</italic> vaccination with fungal cell wall components (known inducers of trained immunity) (<xref rid="B204" ref-type="bibr">204</xref>). The power of this effect has been observed previously in children vaccinated with the Bacille Calmette-Gu&#233;rin vaccine, another known inducer of trained immunity (<xref rid="B205" ref-type="bibr">205</xref>).</p></sec></sec><sec id="s6"><title>Conclusion</title><p>Making a vaccine that can prevent <italic toggle="yes">S. aureus</italic> infection has proven to be challenging. <italic toggle="yes">S. aureus</italic> is a commensal organism of the human nasal mucosae and the skin that has adapted an array of armaments specifically focused on subverting the human immune system. In spite of this, the scientific community has continued to innovate and develop diverse and complex vaccine designs in order to evoke various arms of the immune system and to tackle many <italic toggle="yes">S. aureus</italic> virulence mechanisms. The bottleneck to licensure is the demonstration of efficacy at the clinical level. To give vaccines entering into clinical trials the best likelihood of success, validation at the preclinical level must be achieved using models that can better recapitulate the human condition during infection. Vaccines currently in clinical trials are using more defined endpoints, enrolling specific populations at risk of infection, targeting virulence and immune-evasion factors of <italic toggle="yes">S. aureus</italic> and have been shown to generate both humoral and cellular facets of the immune system.</p><p>The development of therapeutic and short-term prophylactic treatments for <italic toggle="yes">S. aureus</italic> infections is moving at an encouragingly high speed. Though in many ways the discussed treatments can be imagined as alternatives for vaccination, instead of running parallel to each other, these seemingly distinct fields can generate highly transferrable information and collaborative opportunity. For example, if proven to be efficacious in treating an infection, short-term immunotherapies may outline and inform the antigenic targets of <italic toggle="yes">S. aureus</italic> vaccines. Furthermore, considering that clinical trials will use standard of care therapies as a baseline for the therapeutic efficacy, understanding how immunotherapies, antibiotics and vaccines may synergize could be highly important in future clinical trial design. Our proposed future directions for <italic toggle="yes">S. aureus</italic> vaccinology research are listed in <xref rid="T3" ref-type="table">
<bold>Table&#160;3</bold>
</xref>.</p><table-wrap id="T3" position="float" orientation="portrait"><label>Table&#160;3</label><caption><p>Future directions of <italic toggle="yes">Staphylococcus aureus</italic> vaccinology research.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">1. Developing and utilizing more representative models of infection</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" mimetype="image" mime-subtype="tiff" xlink:href="fimmu-12-705360-g002.jpg"/>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2. Understanding the consequences of pre-exposure</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" mimetype="image" mime-subtype="tiff" xlink:href="fimmu-12-705360-g003.jpg"/>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">3. Determining the correlates of protection</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" mimetype="image" mime-subtype="tiff" xlink:href="fimmu-12-705360-g004.jpg"/>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">4. Designing clinical trials to capture vaccine efficacy</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" mimetype="image" mime-subtype="tiff" xlink:href="fimmu-12-705360-g005.jpg"/>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">5. Disarming immune-evasion tactics employed by <italic toggle="yes">S. aureus</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" mimetype="image" mime-subtype="tiff" xlink:href="fimmu-12-705360-g006.jpg"/>
</td></tr></tbody></table></table-wrap></sec><sec id="s7"><title>Author Contributions</title><p>JC wrote the manuscript. JC, ES, SR, FB, RM, and SP revised and approved the manuscript. All authors contributed to the article and approved the submitted version.</p></sec><sec sec-type="funding-information" id="s8"><title>Funding</title><p>This work was co-sponsored by GlaxoSmithKline Biologicals SA and associated research in Trinity College Dublin was supported by a Science Foundation Ireland Investigator Award (15/IA/3041) to RM. The funders was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.</p></sec><sec sec-type="COI-statement" id="s9"><title>Conflict of Interest</title><p>JC is a PhD fellow who is enrolled in the School of Biochemistry and Immunology at Trinity College Dublin and participates in a postgraduate studentship program at GSK. ES, SR, FB, and SP are employees of the GSK group of companies.</p><p>The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><ack><title>Acknowledgments</title><p>Figures were created with <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com/">BioRender.com</uri> and Servier Medical Art.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kourtis</surname><given-names>AP</given-names></name><name name-style="western"><surname>Hatfield</surname><given-names>K</given-names></name><name name-style="western"><surname>Baggs</surname><given-names>J</given-names></name><name name-style="western"><surname>Mu</surname><given-names>Y</given-names></name><name name-style="western"><surname>See</surname><given-names>I</given-names></name><name name-style="western"><surname>Epson</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Vital Signs: Epidemiology and Recent Trends in Methicillin-Resistant and in Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections &#8212; United States</article-title>. <source>MMWR Morb Mortal Wkly Rep</source> (<year>2019</year>) <volume>68</volume>:<page-range>214&#8211;9</page-range>. &#160;<pub-id pub-id-type="doi">10.15585/mmwr.mm6809e1</pub-id><pub-id pub-id-type="pmcid">PMC6421967</pub-id><pub-id pub-id-type="pmid">30845118</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suaya</surname><given-names>JA</given-names></name><name name-style="western"><surname>Mera</surname><given-names>RM</given-names></name><name name-style="western"><surname>Cassidy</surname><given-names>A</given-names></name><name name-style="western"><surname>O&#8217;Hara</surname><given-names>P</given-names></name><name name-style="western"><surname>Amrine-Madsen</surname><given-names>H</given-names></name><name name-style="western"><surname>Burstin</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Incidence and Cost of Hospitalizations Associated With Staphylococcus aureus Skin and Soft Tissue Infections in the United States From 2001 Through 2009</article-title>. <source>BMC Infect Dis</source> (<year>2014</year>) <volume>14</volume>. &#160;<pub-id pub-id-type="doi">10.1186/1471-2334-14-296</pub-id><pub-id pub-id-type="pmcid">PMC4060579</pub-id><pub-id pub-id-type="pmid">24889406</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hill</surname><given-names>PC</given-names></name><name name-style="western"><surname>Birch</surname><given-names>M</given-names></name><name name-style="western"><surname>Chambers</surname><given-names>S</given-names></name><name name-style="western"><surname>Drinkovic</surname><given-names>D</given-names></name><name name-style="western"><surname>Ellis-Pegler</surname><given-names>RB</given-names></name><name name-style="western"><surname>Everts</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Prospective Study of 424 Cases of Staphylococcus aureus Bacteraemia: Determination of Factors Affecting Incidence and Mortality</article-title>. <source>Intern Med J</source> (<year>2001</year>) <volume>31</volume>:<fpage>97</fpage>&#8211;<lpage>103</lpage>. &#160;<pub-id pub-id-type="doi">10.1046/j.1445-5994.2001.00029.x</pub-id><pub-id pub-id-type="pmid">11480485</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coombs</surname><given-names>GW</given-names></name><name name-style="western"><surname>Daley</surname><given-names>DA</given-names></name><name name-style="western"><surname>Lee</surname><given-names>YT</given-names></name><name name-style="western"><surname>Pang</surname><given-names>S</given-names></name></person-group>. <article-title>Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Sepsis Outcome Programme (ASSOP) Annual Report 2017</article-title>. <source>Commun Dis Intell</source> (<year>2019</year>) <volume>43</volume>. &#160;<pub-id pub-id-type="doi">10.33321/cdi.2019.43.43</pub-id><pub-id pub-id-type="pmid">31522665</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eshwara</surname><given-names>VK</given-names></name><name name-style="western"><surname>Munim</surname><given-names>F</given-names></name><name name-style="western"><surname>Tellapragada</surname><given-names>C</given-names></name><name name-style="western"><surname>Kamath</surname><given-names>A</given-names></name><name name-style="western"><surname>Varma</surname><given-names>M</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>LE</given-names></name><etal/></person-group>. <article-title>Staphylococcus aureus Bacteremia in an Indian Tertiary Care Hospital: Observational Study on Clinical Epidemiology, Resistance Characteristics, and Carriage of the Panton-Valentine Leukocidin Gene</article-title>. <source>Int J Infect Dis</source> (<year>2013</year>) <volume>17</volume>:<page-range>e1051&#8211;5</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.ijid.2013.06.002</pub-id><pub-id pub-id-type="pmid">23891294</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nickerson</surname><given-names>EK</given-names></name><name name-style="western"><surname>Hongsuwan</surname><given-names>M</given-names></name><name name-style="western"><surname>Limmathurotsakul</surname><given-names>D</given-names></name><name name-style="western"><surname>Wuthiekanun</surname><given-names>V</given-names></name><name name-style="western"><surname>Shah</surname><given-names>KR</given-names></name><name name-style="western"><surname>Srisomang</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Staphylococcus aureus Bacteraemia in a Tropical Setting: Patient Outcome and Impact of Antibiotic Resistance</article-title>. <source>PLoS One</source> (<year>2009</year>) <volume>4</volume>(<issue>1</issue>):<fpage>e4308</fpage>. &#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0004308</pub-id><pub-id pub-id-type="pmid">19180198</pub-id><pub-id pub-id-type="pmcid">PMC2628727</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>JW</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JW</given-names></name><name name-style="western"><surname>Kim</surname><given-names>B</given-names></name></person-group>. <article-title>Characterization of Infections With Vancomycin-Intermediate Staphylococcus aureus (VISA) and Staphylococcus aureus With Reduced Vancomycin Susceptibility in South Korea</article-title>. <source>Sci Rep</source> (<year>2019</year>) <volume>9</volume>(<issue>1</issue>):<fpage>6236</fpage>. &#160;<pub-id pub-id-type="doi">10.1038/s41598-019-42307-6</pub-id><pub-id pub-id-type="pmid">30996231</pub-id><pub-id pub-id-type="pmcid">PMC6470132</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albrecht</surname><given-names>VS</given-names></name><name name-style="western"><surname>Limbago</surname><given-names>BM</given-names></name><name name-style="western"><surname>Moran</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Krishnadasan</surname><given-names>A</given-names></name><name name-style="western"><surname>Gorwitz</surname><given-names>RJ</given-names></name><name name-style="western"><surname>McDougal</surname><given-names>LK</given-names></name><etal/></person-group>. <article-title>Staphylococcus aureus Colonization and Strain Type at Various Body Sites Among Patients With a Closed Abscess and Uninfected Controls at U.S. Emergency Departments</article-title>. <source>J Clin Microbiol</source> (<year>2015</year>) <volume>53</volume>:<page-range>3478&#8211;84</page-range>. &#160;<pub-id pub-id-type="doi">10.1128/JCM.01371-15</pub-id><pub-id pub-id-type="pmcid">PMC4609677</pub-id><pub-id pub-id-type="pmid">26292314</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dryla</surname><given-names>A</given-names></name><name name-style="western"><surname>Prustomersky</surname><given-names>S</given-names></name><name name-style="western"><surname>Gelbmann</surname><given-names>D</given-names></name><name name-style="western"><surname>Hanner</surname><given-names>M</given-names></name><name name-style="western"><surname>Bettinger</surname><given-names>E</given-names></name><name name-style="western"><surname>Kocsis</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Comparison of Antibody Repertoires Against Staphylococcus aureus in Healthy Individuals and in Acutely Infected Patients</article-title>. <source>Clin Diagn Lab Immunol</source> (<year>2005</year>) <volume>12</volume>:<page-range>387&#8211;98</page-range>. &#160;<pub-id pub-id-type="doi">10.1128/CDLI.12.3.387-398.2005</pub-id><pub-id pub-id-type="pmcid">PMC1065207</pub-id><pub-id pub-id-type="pmid">15753252</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>JS</given-names></name><name name-style="western"><surname>Pietras</surname><given-names>EM</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>NC</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>RI</given-names></name><name name-style="western"><surname>Farzam</surname><given-names>DM</given-names></name><name name-style="western"><surname>Monroe</surname><given-names>HR</given-names></name><etal/></person-group>. <article-title>IL-17 is Essential for Host Defense Against Cutaneous Staphylococcus aureus Infection in Mice</article-title>. <source>J Clin Invest</source> (<year>2010</year>) <volume>120</volume>:<page-range>1762&#8211;73</page-range>. &#160;<pub-id pub-id-type="doi">10.1172/JCI40891</pub-id><pub-id pub-id-type="pmcid">PMC2860944</pub-id><pub-id pub-id-type="pmid">20364087</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marchitto</surname><given-names>MC</given-names></name><name name-style="western"><surname>Dillen</surname><given-names>CA</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Miller</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Archer</surname><given-names>NK</given-names></name><name name-style="western"><surname>Ortines</surname><given-names>RV</given-names></name><etal/></person-group>. <article-title>Clonal V&#947;6+V&#948;4+ T Cells Promote IL-17&#8211;Mediated Immunity Against Staphylococcus aureus Skin Infection</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2019</year>) <volume>166</volume>:<page-range>10917&#8211;26</page-range>. &#160;<pub-id pub-id-type="doi">10.1073/pnas.1818256116</pub-id><pub-id pub-id-type="pmcid">PMC6561199</pub-id><pub-id pub-id-type="pmid">31088972</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dillen</surname><given-names>CA</given-names></name><name name-style="western"><surname>Pinsker</surname><given-names>BL</given-names></name><name name-style="western"><surname>Marusina</surname><given-names>AI</given-names></name><name name-style="western"><surname>Merleev</surname><given-names>AA</given-names></name><name name-style="western"><surname>Farber</surname><given-names>ON</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Clonally Expanded &#947;&#948; T Cells Protect Against Staphylococcus aureus Skin Reinfection</article-title>. <source>J Clin Invest</source> (<year>2018</year>) <volume>128</volume>:<page-range>1026&#8211;42</page-range>. &#160;<pub-id pub-id-type="doi">10.1172/JCI96481</pub-id><pub-id pub-id-type="pmcid">PMC5824877</pub-id><pub-id pub-id-type="pmid">29400698</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Brien</surname><given-names>EC</given-names></name><name name-style="western"><surname>McLoughlin</surname><given-names>RM</given-names></name></person-group>. <article-title>Considering the &#8216;Alternatives&#8217; for Next-Generation Anti-Staphylococcus aureus Vaccine Development</article-title>. <source>Trends Mol Med</source> (<year>2019</year>) <volume>25</volume>:<page-range>171&#8211;84</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.molmed.2018.12.010</pub-id><pub-id pub-id-type="pmid">30713007</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pollard</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Perrett</surname><given-names>KP</given-names></name><name name-style="western"><surname>Beverley</surname><given-names>PC</given-names></name></person-group>. <article-title>Maintaining Protection Against Invasive Bacteria With Protein- Polysaccharide Conjugate Vaccines</article-title>. <source>Nat Rev Immunol</source> (<year>2009</year>) <volume>9</volume>:<page-range>213&#8211;20</page-range>. &#160;<pub-id pub-id-type="doi">10.1038/nri2494</pub-id><pub-id pub-id-type="pmid">19214194</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ihssen</surname><given-names>J</given-names></name><name name-style="western"><surname>Kowarik</surname><given-names>M</given-names></name><name name-style="western"><surname>Dilettoso</surname><given-names>S</given-names></name><name name-style="western"><surname>Tanner</surname><given-names>C</given-names></name><name name-style="western"><surname>Wacker</surname><given-names>M</given-names></name><name name-style="western"><surname>Th&#246;ny-Meyer</surname><given-names>L</given-names></name></person-group>. <article-title>Production of Glycoprotein Vaccines in Escherichia coli</article-title>. <source>Microb Cell Fact</source> (<year>2010</year>) <volume>9</volume>. &#160;<pub-id pub-id-type="doi">10.1186/1475-2859-9-61</pub-id><pub-id pub-id-type="pmcid">PMC2927510</pub-id><pub-id pub-id-type="pmid">20701771</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohamed</surname><given-names>N</given-names></name><name name-style="western"><surname>Timofeyeva</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jamrozy</surname><given-names>D</given-names></name><name name-style="western"><surname>Rojas</surname><given-names>E</given-names></name><name name-style="western"><surname>Hao</surname><given-names>L</given-names></name><name name-style="western"><surname>Silmon de Monerri</surname><given-names>NC</given-names></name><etal/></person-group>. <article-title>Molecular Epidemiology and Expression of Capsular Polysaccharides in Staphylococcus aureus Clinical Isolates in the United States</article-title>. <source>PLoS One</source> (<year>2019</year>) <volume>14</volume>(<issue>1</issue>):<fpage>e0208356</fpage>. &#160;<pub-id pub-id-type="doi">10.1371/JOURNAL.PONE.0208356</pub-id><pub-id pub-id-type="pmid">30641545</pub-id><pub-id pub-id-type="pmcid">PMC6331205</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verdier</surname><given-names>I</given-names></name><name name-style="western"><surname>Durand</surname><given-names>G</given-names></name><name name-style="western"><surname>Bes</surname><given-names>M</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>KL</given-names></name><name name-style="western"><surname>Lina</surname><given-names>G</given-names></name><name name-style="western"><surname>Vandenesch</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Identification of the Capsular Polysaccharides in Staphylococcus aureus Clinical Isolates by PCR and Agglutination Tests</article-title>. <source>J Clin Microbiol</source> (<year>2007</year>) <volume>45</volume>:<page-range>725&#8211;9</page-range>. &#160;<pub-id pub-id-type="doi">10.1128/JCM.01572-06</pub-id><pub-id pub-id-type="pmcid">PMC1829147</pub-id><pub-id pub-id-type="pmid">17202275</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wacker</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Kowarik</surname><given-names>M</given-names></name><name name-style="western"><surname>Dowd</surname><given-names>M</given-names></name><name name-style="western"><surname>Lipowsky</surname><given-names>G</given-names></name><name name-style="western"><surname>Faridmoayer</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Prevention of Staphylococcus aureus Infections by Glycoprotein Vaccines Synthesized in Escherichia Coli</article-title>. <source>J Infect Dis</source> (<year>2014</year>) <volume>209</volume>:<page-range>1551&#8211;61</page-range>. &#160;<pub-id pub-id-type="doi">10.1093/infdis/jit800</pub-id><pub-id pub-id-type="pmcid">PMC3997581</pub-id><pub-id pub-id-type="pmid">24308931</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shinefield</surname><given-names>H</given-names></name><name name-style="western"><surname>Black</surname><given-names>S</given-names></name><name name-style="western"><surname>Fattom</surname><given-names>A</given-names></name><name name-style="western"><surname>Horwith</surname><given-names>G</given-names></name><name name-style="western"><surname>Rasgon</surname><given-names>S</given-names></name><name name-style="western"><surname>Ordonez</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Use of a Staphylococcus aureus Conjugate Vaccine in Patients Receiving Hemodialysis</article-title>. <source>N Engl J Med</source> (<year>2002</year>) <volume>346</volume>:<page-range>491&#8211;6</page-range>. &#160;<pub-id pub-id-type="doi">10.1056/nejmoa011297</pub-id><pub-id pub-id-type="pmid">11844850</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Begier</surname><given-names>E</given-names></name><name name-style="western"><surname>Seiden</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Patton</surname><given-names>M</given-names></name><name name-style="western"><surname>Zito</surname><given-names>E</given-names></name><name name-style="western"><surname>Severs</surname><given-names>J</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>SA4Ag, a 4-Antigen Staphylococcus aureus Vaccine, Rapidly Induces High Levels of Bacteria-Killing Antibodies</article-title>. <source>Vaccine</source> (<year>2017</year>) <volume>35</volume>:<page-range>1132&#8211;9</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2017.01.024</pub-id><pub-id pub-id-type="pmid">28143674</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boyle-Vavra</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Alam</surname><given-names>MT</given-names></name><name name-style="western"><surname>Read</surname><given-names>TD</given-names></name><name name-style="western"><surname>Sieth</surname><given-names>J</given-names></name><name name-style="western"><surname>Cywes-Bentley</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>USA300 and USA500 Clonal Lineages of Staphylococcus aureus do Not Produce a Capsular Polysaccharide Due to Conserved Mutations in the Cap5 Locus</article-title>. <source>MBio</source> (<year>2015</year>) <volume>6</volume>(<issue>2</issue>):<page-range>e02585&#8211;14</page-range>. &#160;<pub-id pub-id-type="doi">10.1128/mBio.02585-14</pub-id><pub-id pub-id-type="pmcid">PMC4453534</pub-id><pub-id pub-id-type="pmid">25852165</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bottero</surname><given-names>D</given-names></name><name name-style="western"><surname>Gaillard</surname><given-names>ME</given-names></name><name name-style="western"><surname>Zurita</surname><given-names>E</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>G</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>DS</given-names></name><name name-style="western"><surname>Bartel</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Characterization of the Immune Response Induced by Pertussis Omvs-Based Vaccine</article-title>. <source>Vaccine</source> (<year>2016</year>) <volume>34</volume>:<page-range>3303&#8211;9</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2016.04.079</pub-id><pub-id pub-id-type="pmid">27151884</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dowling</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>H</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>WK</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>S</given-names></name><name name-style="western"><surname>Brightman</surname><given-names>S</given-names></name><name name-style="western"><surname>Bergelson</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>A Meningococcal Outer Membrane Vesicle Vaccine Incorporating Genetically Attenuated Endotoxin Dissociates Inflammation From Immunogenicity</article-title>. <source>Front Immunol</source> (<year>2016</year>) <volume>7</volume>:<elocation-id>562</elocation-id>. &#160;<pub-id pub-id-type="doi">10.3389/fimmu.2016.00562</pub-id><pub-id pub-id-type="pmid">28008331</pub-id><pub-id pub-id-type="pmcid">PMC5143884</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kesty</surname><given-names>NC</given-names></name><name name-style="western"><surname>Kuehn</surname><given-names>MJ</given-names></name></person-group>. <article-title>Incorporation of Heterologous Outer Membrane and Periplasmic Proteins Into Escherichia coli Outer Membrane Vesicles</article-title>. <source>J Biol Chem</source> (<year>2004</year>) <volume>279</volume>:<page-range>2069&#8211;76</page-range>. &#160;<pub-id pub-id-type="doi">10.1074/jbc.M307628200</pub-id><pub-id pub-id-type="pmcid">PMC3525464</pub-id><pub-id pub-id-type="pmid">14578354</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Launay</surname><given-names>O</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>DJM</given-names></name><name name-style="western"><surname>Anemona</surname><given-names>A</given-names></name><name name-style="western"><surname>Loulergue</surname><given-names>P</given-names></name><name name-style="western"><surname>Leahy</surname><given-names>J</given-names></name><name name-style="western"><surname>Scir&#233;</surname><given-names>AS</given-names></name><etal/></person-group>. <article-title>Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella Sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe</article-title>. <source>EBioMedicine</source> (<year>2017</year>) <volume>22</volume>:<page-range>164&#8211;72</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.ebiom.2017.07.013</pub-id><pub-id pub-id-type="pmcid">PMC5552227</pub-id><pub-id pub-id-type="pmid">28735965</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gerke</surname><given-names>C</given-names></name><name name-style="western"><surname>Colucci</surname><given-names>AM</given-names></name><name name-style="western"><surname>Giannelli</surname><given-names>C</given-names></name><name name-style="western"><surname>Sanzone</surname><given-names>S</given-names></name><name name-style="western"><surname>Vitali</surname><given-names>CG</given-names></name><name name-style="western"><surname>Sollai</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Production of a Shigella Sonnei Vaccine Based on Generalized Modules for Membrane Antigens (GMMA), 1790GAHB</article-title>. <source>PLoS One</source> (<year>2015</year>) <volume>10</volume>. &#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0134478</pub-id><pub-id pub-id-type="pmcid">PMC4527750</pub-id><pub-id pub-id-type="pmid">26248044</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Irene</surname><given-names>C</given-names></name><name name-style="western"><surname>Fantappi&#232;</surname><given-names>L</given-names></name><name name-style="western"><surname>Caproni</surname><given-names>E</given-names></name><name name-style="western"><surname>Zerbini</surname><given-names>F</given-names></name><name name-style="western"><surname>Anesi</surname><given-names>A</given-names></name><name name-style="western"><surname>Tomasi</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Bacterial Outer Membrane Vesicles Engineered With Lipidated Antigens as a Platform for Staphylococcus aureus Vaccine</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2019</year>) <volume>116</volume>:<page-range>21780&#8211;8</page-range>. &#160;<pub-id pub-id-type="doi">10.1073/pnas.1905112116</pub-id><pub-id pub-id-type="pmcid">PMC6815149</pub-id><pub-id pub-id-type="pmid">31591215</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Netea</surname><given-names>MG</given-names></name><name name-style="western"><surname>Joosten</surname><given-names>LAB</given-names></name><name name-style="western"><surname>Latz</surname><given-names>E</given-names></name><name name-style="western"><surname>Mills</surname><given-names>KHG</given-names></name><name name-style="western"><surname>Natoli</surname><given-names>G</given-names></name><name name-style="western"><surname>Stunnenberg</surname><given-names>HG</given-names></name><etal/></person-group>. <article-title>Trained Immunity: A Program of Innate Immune Memory in Health and Disease</article-title>. <source>Science</source> (<year>2016</year>) <volume>352</volume>:<fpage>427</fpage>. &#160;<pub-id pub-id-type="doi">10.1126/science.aaf1098</pub-id><pub-id pub-id-type="pmcid">PMC5087274</pub-id><pub-id pub-id-type="pmid">27102489</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>LC</given-names></name><name name-style="western"><surname>Chaili</surname><given-names>S</given-names></name><name name-style="western"><surname>Filler</surname><given-names>SG</given-names></name><name name-style="western"><surname>Miller</surname><given-names>LS</given-names></name><name name-style="western"><surname>Solis</surname><given-names>NV</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Innate Immune Memory Contributes to Host Defense Against Recurrent Skin and Skin Structure Infections Caused by Methicillin-Resistant Staphylococcus aureus</article-title>. <source>Infect Immun</source> (<year>2017</year>) <volume>85</volume>(<issue>2</issue>):<page-range>e00876&#8211;16</page-range>. &#160;<pub-id pub-id-type="doi">10.1128/IAI.00876-16</pub-id><pub-id pub-id-type="pmcid">PMC5278165</pub-id><pub-id pub-id-type="pmid">27849182</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>LC</given-names></name><name name-style="western"><surname>Rossetti</surname><given-names>M</given-names></name><name name-style="western"><surname>Miller</surname><given-names>LS</given-names></name><name name-style="western"><surname>Filler</surname><given-names>SG</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>CW</given-names></name><name name-style="western"><surname>Lee</surname><given-names>HK</given-names></name><etal/></person-group>. <article-title>Protective Immunity in Recurrent Staphylococcus aureus Infection Reflects Localized Immune Signatures and Macrophage-Conferred Memory</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2018</year>) <volume>115</volume>:<page-range>E11111&#8211;9</page-range>. &#160;<pub-id pub-id-type="doi">10.1073/pnas.1808353115</pub-id><pub-id pub-id-type="pmcid">PMC6255181</pub-id><pub-id pub-id-type="pmid">30297395</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feuerstein</surname><given-names>R</given-names></name><name name-style="western"><surname>Forde</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Lohrmann</surname><given-names>F</given-names></name><name name-style="western"><surname>Kolter</surname><given-names>J</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Zimmermann</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Resident Macrophages Acquire Innate Immune Memory in Staphylococcal Skin Infection</article-title>. <source>Elife</source> (<year>2020</year>) <volume>9</volume>:<fpage>1</fpage>&#8211;<lpage>21</lpage>. &#160;<pub-id pub-id-type="doi">10.7554/eLife.55602</pub-id><pub-id pub-id-type="pmcid">PMC7343389</pub-id><pub-id pub-id-type="pmid">32639232</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>EY</given-names></name><name name-style="western"><surname>Choi</surname><given-names>DY</given-names></name><name name-style="western"><surname>Kim</surname><given-names>DK</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JW</given-names></name><name name-style="western"><surname>Park</surname><given-names>JO</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Gram-Positive Bacteria Produce Membrane Vesicles: Proteomics-Based Characterization of Staphylococcus aureus-Derived Membrane Vesicles</article-title>. <source>Proteomics</source> (<year>2009</year>) <volume>9</volume>:<page-range>5425&#8211;36</page-range>. &#160;<pub-id pub-id-type="doi">10.1002/pmic.200900338</pub-id><pub-id pub-id-type="pmid">19834908</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bose</surname><given-names>S</given-names></name><name name-style="western"><surname>Aggarwal</surname><given-names>S</given-names></name><name name-style="western"><surname>Singh</surname><given-names>DV</given-names></name><name name-style="western"><surname>Acharya</surname><given-names>N</given-names></name></person-group>. <article-title>Extracellular Vesicles: An Emerging Platform in Gram-Positive Bacteria</article-title>. <source>Microb Cell</source> (<year>2021</year>) <volume>7</volume>:<page-range>312&#8211;22</page-range>. &#160;<pub-id pub-id-type="doi">10.15698/MIC2020.12.737</pub-id><pub-id pub-id-type="pmcid">PMC7713254</pub-id><pub-id pub-id-type="pmid">33335921</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>CD</given-names></name><name name-style="western"><surname>Weidenmaier</surname><given-names>C</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JC</given-names></name></person-group>. <article-title>Release of Staphylococcus aureus Extracellular Vesicles and Their Application as a Vaccine Platform</article-title>. <source>Nat Commun</source> (<year>2018</year>) <volume>9</volume>. &#160;<pub-id pub-id-type="doi">10.1038/s41467-018-03847-z</pub-id><pub-id pub-id-type="pmcid">PMC5895597</pub-id><pub-id pub-id-type="pmid">29643357</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>MH</given-names></name><name name-style="western"><surname>Jeon</surname><given-names>J</given-names></name><name name-style="western"><surname>Kim</surname><given-names>OY</given-names></name><name name-style="western"><surname>Choi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Seo</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Active Immunization With Extracellular Vesicles Derived From Staphylococcus aureus Effectively Protects Against Staphylococcal Lung Infections, Mainly <italic toggle="yes">via</italic> Th1 Cell-Mediated Immunity</article-title>. <source>PLoS One</source> (<year>2015</year>) <volume>10</volume>. &#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0136021</pub-id><pub-id pub-id-type="pmcid">PMC4558092</pub-id><pub-id pub-id-type="pmid">26333035</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>SW</given-names></name><name name-style="western"><surname>Kim</surname><given-names>MR</given-names></name><name name-style="western"><surname>Lee</surname><given-names>EY</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YS</given-names></name><name name-style="western"><surname>Jeon</surname><given-names>SG</given-names></name><etal/></person-group>. <article-title>Extracellular Vesicles Derived From Staphylococcus aureus Induce Atopic Dermatitis-Like Skin Inflammation</article-title>. <source>Allergy Eur J Allergy Clin Immunol</source> (<year>2011</year>) <volume>66</volume>:<page-range>351&#8211;9</page-range>. &#160;<pub-id pub-id-type="doi">10.1111/j.1398-9995.2010.02483.x</pub-id><pub-id pub-id-type="pmcid">PMC3052535</pub-id><pub-id pub-id-type="pmid">20831718</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>AF</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>AG</given-names></name><name name-style="western"><surname>Lalor</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Leech</surname><given-names>JM</given-names></name><name name-style="western"><surname>O&#8217;Keeffe</surname><given-names>KM</given-names></name><name name-style="western"><surname>Mac Aog&#225;in</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Memory Th1 Cells are Protective in Invasive Staphylococcus aureus Infection</article-title>. <source>PLoS Pathog</source> (<year>2015</year>) <volume>11</volume>. &#160;<pub-id pub-id-type="doi">10.1371/journal.ppat.1005226</pub-id><pub-id pub-id-type="pmcid">PMC4634925</pub-id><pub-id pub-id-type="pmid">26539822</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>L</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>AS</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><name name-style="western"><surname>Farber</surname><given-names>JM</given-names></name><name name-style="western"><surname>Avanesian</surname><given-names>V</given-names></name><name name-style="western"><surname>Baquir</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Th1-Th17 Cells Mediate Protective Adaptive Immunity Against Staphylococcus aureus and Candida Albicans Infection in Mice</article-title>. <source>PLoS Pathog</source> (<year>2009</year>) <volume>5</volume>. &#160;<pub-id pub-id-type="doi">10.1371/journal.ppat.1000703</pub-id><pub-id pub-id-type="pmcid">PMC2792038</pub-id><pub-id pub-id-type="pmid">20041174</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keller</surname><given-names>MD</given-names></name><name name-style="western"><surname>Ching</surname><given-names>KL</given-names></name><name name-style="western"><surname>Liang</surname><given-names>FX</given-names></name><name name-style="western"><surname>Dhabaria</surname><given-names>A</given-names></name><name name-style="western"><surname>Tam</surname><given-names>K</given-names></name><name name-style="western"><surname>Ueberheide</surname><given-names>BM</given-names></name><etal/></person-group>. <article-title>Decoy Exosomes Provide Protection Against Bacterial Toxins</article-title>. <source>Nature</source> (<year>2020</year>) <volume>579</volume>:<page-range>260&#8211;4</page-range>. &#160;<pub-id pub-id-type="doi">10.1038/s41586-020-2066-6</pub-id><pub-id pub-id-type="pmcid">PMC7519780</pub-id><pub-id pub-id-type="pmid">32132711</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patterson</surname><given-names>J</given-names></name><name name-style="western"><surname>Kagina</surname><given-names>BM</given-names></name><name name-style="western"><surname>Gold</surname><given-names>M</given-names></name><name name-style="western"><surname>Hussey</surname><given-names>GD</given-names></name><name name-style="western"><surname>Muloiwa</surname><given-names>R</given-names></name></person-group>. <article-title>Comparison of Adverse Events Following Immunisation With Acellular and Whole-Cell Pertussis Vaccines: A Systematic Review</article-title>. <source>Vaccine</source> (<year>2018</year>) <volume>36</volume>:<page-range>6007&#8211;16</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2018.08.022</pub-id><pub-id pub-id-type="pmid">30143272</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alleman</surname><given-names>MM</given-names></name><name name-style="western"><surname>Jorba</surname><given-names>J</given-names></name><name name-style="western"><surname>Greene</surname><given-names>SA</given-names></name><name name-style="western"><surname>Diop</surname><given-names>OM</given-names></name><name name-style="western"><surname>Iber</surname><given-names>J</given-names></name><name name-style="western"><surname>Tallis</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Update on Vaccine-Derived Poliovirus Outbreaks &#8212; Worldwide, July 2019&#8211;February 2020</article-title>. <source>MMWR Morb Mortal Wkly Rep</source> (<year>2020</year>) <volume>69</volume>:<page-range>489&#8211;95</page-range>. &#160;<pub-id pub-id-type="doi">10.15585/mmwr.mm6916a1</pub-id><pub-id pub-id-type="pmcid">PMC7188410</pub-id><pub-id pub-id-type="pmid">32324719</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heaton</surname><given-names>MP</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>RB</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>TL</given-names></name></person-group>. <article-title>Controlled Lysis of Bacterial Cells Utilizing Mutants With Defective Synthesis of D-Alanine</article-title>. <source>Can J Microbiol</source> (<year>1988</year>) <volume>34</volume>:<page-range>256&#8211;61</page-range>. &#160;<pub-id pub-id-type="doi">10.1139/m88-047</pub-id><pub-id pub-id-type="pmid">3138014</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palumbo</surname><given-names>E</given-names></name><name name-style="western"><surname>Favier</surname><given-names>CF</given-names></name><name name-style="western"><surname>Deghorain</surname><given-names>M</given-names></name><name name-style="western"><surname>Cocconcelli</surname><given-names>PS</given-names></name><name name-style="western"><surname>Grangette</surname><given-names>C</given-names></name><name name-style="western"><surname>Mercenier</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Knockout of the Alanine Racemase Gene in Lactobacillus Plantarum Results in Septation Defects and Cell Wall Perforation</article-title>. <source>FEMS Microbiol Lett</source> (<year>2004</year>) <volume>233</volume>:<page-range>131&#8211;8</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.femsle.2004.02.001</pub-id><pub-id pub-id-type="pmid">15043879</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wijsman</surname><given-names>HJW</given-names></name></person-group>. <article-title>The Characterization of an Alanine Racemase Mutant of Escherichia Coli</article-title>. <source>Genet Res</source> (<year>1972</year>) <volume>20</volume>:<page-range>269&#8211;77</page-range>. &#160;<pub-id pub-id-type="doi">10.1017/S001667230001380X</pub-id><pub-id pub-id-type="pmid">4594607</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steen</surname><given-names>A</given-names></name><name name-style="western"><surname>Palumbo</surname><given-names>E</given-names></name><name name-style="western"><surname>Deghorain</surname><given-names>M</given-names></name><name name-style="western"><surname>Cocconcelli</surname><given-names>PS</given-names></name><name name-style="western"><surname>Delcour</surname><given-names>J</given-names></name><name name-style="western"><surname>Kuipers</surname><given-names>OP</given-names></name><etal/></person-group>. <article-title>Autolysis of Lactococcus Lactis is Increased Upon D-Alanine Depletion of Peptidoglycan and Lipoteichoic Acids</article-title>. <source>J Bacteriol</source> (<year>2005</year>) <volume>187</volume>:<page-range>114&#8211;24</page-range>. &#160;<pub-id pub-id-type="doi">10.1128/JB.187.1.114-124.2005</pub-id><pub-id pub-id-type="pmcid">PMC538808</pub-id><pub-id pub-id-type="pmid">15601695</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moscoso</surname><given-names>M</given-names></name><name name-style="western"><surname>Garc&#237;a</surname><given-names>P</given-names></name><name name-style="western"><surname>Cabral</surname><given-names>MP</given-names></name><name name-style="western"><surname>Rumbo</surname><given-names>C</given-names></name><name name-style="western"><surname>Bou</surname><given-names>G</given-names></name></person-group>. <article-title>A D-Alanine Auxotrophic Live Vaccine is Effective Against Lethal Infection Caused by Staphylococcus aureus</article-title>. <source>Virulence</source> (<year>2018</year>) <volume>9</volume>:<page-range>604&#8211;20</page-range>. &#160;<pub-id pub-id-type="doi">10.1080/21505594.2017.1417723</pub-id><pub-id pub-id-type="pmcid">PMC5955480</pub-id><pub-id pub-id-type="pmid">29297750</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name><name name-style="western"><surname>Jun</surname><given-names>M</given-names></name><name name-style="western"><surname>Ledue</surname><given-names>O</given-names></name><name name-style="western"><surname>Herd</surname><given-names>M</given-names></name><name name-style="western"><surname>Malley</surname><given-names>R</given-names></name><name name-style="western"><surname>Lu</surname><given-names>YJ</given-names></name></person-group>. <article-title>Antibody-Mediated Protection Against Staphylococcus aureus Dermonecrosis and Sepsis by a Whole Cell Vaccine</article-title>. <source>Vaccine</source> (<year>2017</year>) <volume>35</volume>:<page-range>3834&#8211;43</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2017.05.085</pub-id><pub-id pub-id-type="pmid">28601365</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tollersrud</surname><given-names>T</given-names></name><name name-style="western"><surname>Zernichow</surname><given-names>L</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>SR</given-names></name><name name-style="western"><surname>Kenny</surname><given-names>K</given-names></name><name name-style="western"><surname>Lund</surname><given-names>A</given-names></name></person-group>. <article-title>Staphylococcus aureus Capsular Polysaccharide Type 5 Conjugate and Whole Cell Vaccines Stimulate Antibody Responses in Cattle</article-title>. <source>Vaccine</source> (<year>2001</year>) <volume>19</volume>:<page-range>3896&#8211;903</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/S0264-410X(01)00124-4</pub-id><pub-id pub-id-type="pmid">11427263</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burnside</surname><given-names>K</given-names></name><name name-style="western"><surname>Lembo</surname><given-names>A</given-names></name><name name-style="western"><surname>Harrell</surname><given-names>MI</given-names></name><name name-style="western"><surname>Klein</surname><given-names>JA</given-names></name><name name-style="western"><surname>Lopez-Guisa</surname><given-names>J</given-names></name><name name-style="western"><surname>Siegesmund</surname><given-names>AM</given-names></name><etal/></person-group>. <article-title>Vaccination With a UV-Irradiated Genetically Attenuated Mutant of Staphylococcus aureus Provides Protection Against Subsequent Systemic Infection</article-title>. <source>J Infect Dis</source> (<year>2012</year>) <volume>206</volume>:<page-range>1734&#8211;44</page-range>. &#160;<pub-id pub-id-type="doi">10.1093/infdis/jis579</pub-id><pub-id pub-id-type="pmcid">PMC3488195</pub-id><pub-id pub-id-type="pmid">22966130</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prenafeta</surname><given-names>A</given-names></name><name name-style="western"><surname>March</surname><given-names>R</given-names></name><name name-style="western"><surname>Foix</surname><given-names>A</given-names></name><name name-style="western"><surname>Casals</surname><given-names>I</given-names></name><name name-style="western"><surname>Costa</surname><given-names>L</given-names></name></person-group>. <article-title>Study of the Humoral Immunological Response After Vaccination With a Staphylococcus aureus Biofilm-Embedded Bacterin in Dairy Cows: Possible Role of the Exopolysaccharide Specific Antibody Production in the Protection From Staphylococcus aureus Induced Mastitis</article-title>. <source>Vet Immunol Immunopathol</source> (<year>2010</year>) <volume>134</volume>:<page-range>208&#8211;17</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vetimm.2009.09.020</pub-id><pub-id pub-id-type="pmid">19836084</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Middleton</surname><given-names>JR</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J</given-names></name><name name-style="western"><surname>Rinehart</surname><given-names>CL</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>VN</given-names></name><name name-style="western"><surname>Luby</surname><given-names>CD</given-names></name><name name-style="western"><surname>Steevens</surname><given-names>BJ</given-names></name></person-group>. <article-title>Efficacy of Different Lysigin&#8482; Formulations in the Prevention of Staphylococcus aureus Intramammary Infection in Dairy Heifers</article-title>. <source>J Dairy Res</source> (<year>2006</year>) <volume>73</volume>:<page-range>10&#8211;9</page-range>. &#160;<pub-id pub-id-type="doi">10.1017/S0022029905001354</pub-id><pub-id pub-id-type="pmid">16433956</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Romo</surname><given-names>GS</given-names></name><name name-style="western"><surname>Gonzalez-Ibarra</surname><given-names>M</given-names></name><name name-style="western"><surname>Donis-Hernandez</surname><given-names>FR</given-names></name><name name-style="western"><surname>Zendejas-Buitron</surname><given-names>VM</given-names></name><name name-style="western"><surname>Pedroza-Gonzalez</surname><given-names>A</given-names></name></person-group>. <article-title>Immunization With Heat-Inactivated Staphylococcus aureus Induced an Antibody Response Mediated by Igg1 and Igg2 in Patients With Recurrent Tonsillitis</article-title>. <source>Microbiol Immunol</source> (<year>2015</year>) <volume>59</volume>:<fpage>193</fpage>&#8211;<lpage>201</lpage>. &#160;<pub-id pub-id-type="doi">10.1111/1348-0421.12241</pub-id><pub-id pub-id-type="pmid">25648612</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mulligan</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Lyke</surname><given-names>KE</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Phase&#160;I/II Study of COVID-19 RNA Vaccine BNT162b1 in Adults</article-title>. <source>Nature</source> (<year>2020</year>) <volume>586</volume>:<page-range>589&#8211;93</page-range>. &#160;<pub-id pub-id-type="doi">10.1038/s41586-020-2639-4</pub-id><pub-id pub-id-type="pmid">32785213</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>LA</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Rouphael</surname><given-names>NG</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>PC</given-names></name><name name-style="western"><surname>Makhene</surname><given-names>M</given-names></name><name name-style="western"><surname>Coler</surname><given-names>RN</given-names></name><etal/></person-group>. <article-title>An mRNA Vaccine Against SARS-Cov-2 &#8212; Preliminary Report</article-title>. <source>N&#160;Engl J Med</source> (<year>2020</year>) <volume>383</volume>:<page-range>1920&#8211;31</page-range>. &#160;<pub-id pub-id-type="doi">10.1056/nejmoa2022483</pub-id><pub-id pub-id-type="pmcid">PMC7377258</pub-id><pub-id pub-id-type="pmid">32663912</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paludan</surname><given-names>C</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>D</given-names></name><name name-style="western"><surname>Landthaler</surname><given-names>M</given-names></name><name name-style="western"><surname>Vockerodt</surname><given-names>M</given-names></name><name name-style="western"><surname>Kube</surname><given-names>D</given-names></name><name name-style="western"><surname>Tuschl</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Endogenous MHC Class II Processing of a Viral Nuclear Antigen After Autophagy</article-title>. <source>Science</source> (<year>2005</year>) <volume>307</volume>:<page-range>593&#8211;6</page-range>. &#160;<pub-id pub-id-type="doi">10.1126/science.1104904</pub-id><pub-id pub-id-type="pmid">15591165</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaraquemada</surname><given-names>D</given-names></name><name name-style="western"><surname>Marti</surname><given-names>M</given-names></name><name name-style="western"><surname>Long</surname><given-names>EO</given-names></name></person-group>. <article-title>An Endogenous Processing Pathway in Vaccinia Virus-Infected Cells for Presentation of Cytoplasmic Antigens to Class II-Restricted T Cells</article-title>. <source>J Exp Med</source> (<year>1990</year>) <volume>172</volume>:<page-range>947&#8211;54</page-range>. &#160;<pub-id pub-id-type="doi">10.1084/jem.172.3.947</pub-id><pub-id pub-id-type="pmcid">PMC2188531</pub-id><pub-id pub-id-type="pmid">2388037</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uebele</surname><given-names>J</given-names></name><name name-style="western"><surname>Stein</surname><given-names>C</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>MT</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>A</given-names></name><name name-style="western"><surname>Kleinert</surname><given-names>F</given-names></name><name name-style="western"><surname>Tich&#225;</surname><given-names>O</given-names></name><etal/></person-group>. <article-title>Antigen Delivery to Dendritic Cells Shapes Human CD4+and CD8+T Cell Memory Responses to Staphylococcus aureus</article-title>. <source>PLoS Pathog</source> (<year>2017</year>) <volume>13</volume>. &#160;<pub-id pub-id-type="doi">10.1371/journal.ppat.1006387</pub-id><pub-id pub-id-type="pmcid">PMC5444865</pub-id><pub-id pub-id-type="pmid">28542586</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zautner</surname><given-names>AE</given-names></name><name name-style="western"><surname>Krause</surname><given-names>M</given-names></name><name name-style="western"><surname>Stropahl</surname><given-names>G</given-names></name><name name-style="western"><surname>Holtfreter</surname><given-names>S</given-names></name><name name-style="western"><surname>Frickmann</surname><given-names>H</given-names></name><name name-style="western"><surname>Maletzki</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Intracellular Persisting Staphylococcus aureus is the Major Pathogen in Recurrent Tonsillitis</article-title>. <source>PLoS One</source> (<year>2010</year>) <volume>5</volume>. &#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0009452</pub-id><pub-id pub-id-type="pmcid">PMC2830486</pub-id><pub-id pub-id-type="pmid">20209109</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sachse</surname><given-names>F</given-names></name><name name-style="western"><surname>Becker</surname><given-names>K</given-names></name><name name-style="western"><surname>Von Eiff</surname><given-names>C</given-names></name><name name-style="western"><surname>Metze</surname><given-names>D</given-names></name><name name-style="western"><surname>Rudack</surname><given-names>C</given-names></name></person-group>. <article-title>Staphylococcus aureus Invades the Epithelium in Nasal Polyposis and Induces IL-6 in Nasal Epithelial Cells <italic toggle="yes">In Vitro</italic>
</article-title>. <source>Allergy Eur J Allergy Clin Immunol</source> (<year>2010</year>) <volume>65</volume>:<page-range>1430&#8211;7</page-range>. &#160;<pub-id pub-id-type="doi">10.1111/j.1398-9995.2010.02381.x</pub-id><pub-id pub-id-type="pmid">20456313</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Keeffe</surname><given-names>KM</given-names></name><name name-style="western"><surname>Wilk</surname><given-names>MM</given-names></name><name name-style="western"><surname>Leech</surname><given-names>JM</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>AG</given-names></name><name name-style="western"><surname>Laabei</surname><given-names>M</given-names></name><name name-style="western"><surname>Monk</surname><given-names>IR</given-names></name><etal/></person-group>. <article-title>Manipulation of Autophagy in Phagocytes Facilitates Staphylococcus aureus Bloodstream Infection</article-title>. <source>Infect Immun</source> (<year>2015</year>) <volume>83</volume>:<page-range>3445&#8211;57</page-range>. &#160;<pub-id pub-id-type="doi">10.1128/IAI.00358-15</pub-id><pub-id pub-id-type="pmcid">PMC4534639</pub-id><pub-id pub-id-type="pmid">26099586</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maruggi</surname><given-names>G</given-names></name><name name-style="western"><surname>Chiarot</surname><given-names>E</given-names></name><name name-style="western"><surname>Giovani</surname><given-names>C</given-names></name><name name-style="western"><surname>Buccato</surname><given-names>S</given-names></name><name name-style="western"><surname>Bonacci</surname><given-names>S</given-names></name><name name-style="western"><surname>Frigimelica</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Immunogenicity and Protective Efficacy Induced by Self-Amplifying mRNA Vaccines Encoding Bacterial Antigens</article-title>. <source>Vaccine</source> (<year>2017</year>) <volume>35</volume>:<page-range>361&#8211;8</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2016.11.040</pub-id><pub-id pub-id-type="pmid">27939014</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaudreau</surname><given-names>MC</given-names></name><name name-style="western"><surname>Lacasse</surname><given-names>P</given-names></name><name name-style="western"><surname>Talbot</surname><given-names>BG</given-names></name></person-group>. <article-title>Protective Immune Responses to a Multi-Gene DNA Vaccine Against Staphylococcus aureus</article-title>. <source>Vaccine</source> (<year>2007</year>) <volume>25</volume>:<page-range>814&#8211;24</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2006.09.043</pub-id><pub-id pub-id-type="pmid">17027124</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Senna</surname><given-names>JPM</given-names></name><name name-style="western"><surname>Roth</surname><given-names>DM</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>JS</given-names></name><name name-style="western"><surname>Machado</surname><given-names>DC</given-names></name><name name-style="western"><surname>Santos</surname><given-names>DS</given-names></name></person-group>. <article-title>Protective Immune Response Against Methicillin Resistant Staphylococcus aureus in a Murine Model Using a DNA Vaccine Approach</article-title>. <source>Vaccine</source> (<year>2003</year>) <volume>21</volume>:<page-range>2661&#8211;6</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/S0264-410X(02)00738-7</pub-id><pub-id pub-id-type="pmid">12744903</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hobernik</surname><given-names>D</given-names></name><name name-style="western"><surname>Bros</surname><given-names>M</given-names></name></person-group>. <article-title>DNA Vaccines&#8212;How Far From Clinical Use</article-title>? <source>Int J Mol Sci</source> (<year>2018</year>) <volume>19</volume>. &#160;<pub-id pub-id-type="doi">10.3390/ijms19113605</pub-id><pub-id pub-id-type="pmcid">PMC6274812</pub-id><pub-id pub-id-type="pmid">30445702</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brito</surname><given-names>LA</given-names></name><name name-style="western"><surname>Chan</surname><given-names>M</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>CA</given-names></name><name name-style="western"><surname>Hekele</surname><given-names>A</given-names></name><name name-style="western"><surname>Carsillo</surname><given-names>T</given-names></name><name name-style="western"><surname>Schaefer</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>A Cationic Nanoemulsion for the Delivery of Next-Generation RNA Vaccines</article-title>. <source>Mol Ther</source> (<year>2014</year>) <volume>22</volume>:<page-range>2118&#8211;29</page-range>. &#160;<pub-id pub-id-type="doi">10.1038/mt.2014.133</pub-id><pub-id pub-id-type="pmcid">PMC4429691</pub-id><pub-id pub-id-type="pmid">25027661</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McNeely</surname><given-names>TB</given-names></name><name name-style="western"><surname>Shah</surname><given-names>NA</given-names></name><name name-style="western"><surname>Fridman</surname><given-names>A</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>A</given-names></name><name name-style="western"><surname>Hartzel</surname><given-names>JS</given-names></name><name name-style="western"><surname>Keshari</surname><given-names>RS</given-names></name><etal/></person-group>. <article-title>Mortality Among Recipients of the Merck V710 Staphylococcus aureus Vaccine After Postoperative s. Aureus Infections: An Analysis of Possible Contributing Host Factors</article-title>. <source>Hum Vaccines Immunother</source> (<year>2014</year>) <volume>10</volume>:<page-range>3513&#8211;6</page-range>. &#160;<pub-id pub-id-type="doi">10.4161/hv.34407</pub-id><pub-id pub-id-type="pmcid">PMC4514053</pub-id><pub-id pub-id-type="pmid">25483690</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fowler</surname><given-names>VG</given-names></name><name name-style="western"><surname>Proctor</surname><given-names>RA</given-names></name></person-group>. <article-title>Where Does a Staphylococcus aureus Vaccine Stand</article-title>? <source>Clin Microbiol Infect</source> (<year>2014</year>) <volume>20</volume>:<fpage>66</fpage>&#8211;<lpage>75</lpage>. &#160;<pub-id pub-id-type="doi">10.1111/1469-0691.12570</pub-id><pub-id pub-id-type="pmid">24476315</pub-id><pub-id pub-id-type="pmcid">PMC4067250</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fattom</surname><given-names>A</given-names></name><name name-style="western"><surname>Fuller</surname><given-names>S</given-names></name><name name-style="western"><surname>Propst</surname><given-names>M</given-names></name><name name-style="western"><surname>Winston</surname><given-names>S</given-names></name><name name-style="western"><surname>Muenz</surname><given-names>L</given-names></name><name name-style="western"><surname>He</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Safety and Immunogenicity of a Booster Dose of Staphylococcus aureus Types 5 and 8 Capsular Polysaccharide Conjugate Vaccine (Staphvax <sup>&#174;</sup>) in Hemodialysis Patients</article-title>. <source>Vaccine</source> (<year>2004</year>) <volume>23</volume>:<page-range>656&#8211;63</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2004.06.043</pub-id><pub-id pub-id-type="pmid">15542186</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fowler</surname><given-names>VG</given-names></name><name name-style="western"><surname>Allen</surname><given-names>KB</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>ED</given-names></name><name name-style="western"><surname>Moustafa</surname><given-names>M</given-names></name><name name-style="western"><surname>Isgro</surname><given-names>F</given-names></name><name name-style="western"><surname>Boucher</surname><given-names>HW</given-names></name><etal/></person-group>. <article-title>Effect of an Investigational Vaccine for Preventing Staphylococcus aureus Infections After Cardiothoracic Surgery: A Randomized Trial</article-title>. <source>JAMA - J Am Med Assoc</source> (<year>2013</year>) <volume>309</volume>:<page-range>1368&#8211;78</page-range>. &#160;<pub-id pub-id-type="doi">10.1001/jama.2013.3010</pub-id><pub-id pub-id-type="pmid">23549582</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torres</surname><given-names>VJ</given-names></name><name name-style="western"><surname>Pishchany</surname><given-names>G</given-names></name><name name-style="western"><surname>Humayun</surname><given-names>M</given-names></name><name name-style="western"><surname>Schneewind</surname><given-names>O</given-names></name><name name-style="western"><surname>Skaar</surname><given-names>EP</given-names></name></person-group>. <article-title>Staphylococcus aureus IsdB is a Hemoglobin Receptor Required for Heme Iron Utilization</article-title>. <source>J Bacteriol</source> (<year>2006</year>) <volume>188</volume>:<page-range>8421&#8211;9</page-range>. &#160;<pub-id pub-id-type="doi">10.1128/JB.01335-06</pub-id><pub-id pub-id-type="pmcid">PMC1698231</pub-id><pub-id pub-id-type="pmid">17041042</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thwaites</surname><given-names>GE</given-names></name><name name-style="western"><surname>Gant</surname><given-names>V</given-names></name></person-group>. <article-title>Are Bloodstream Leukocytes Trojan Horses for the Metastasis of Staphylococcus aureus</article-title>? <source>Nat Rev Microbiol</source> (<year>2011</year>) <volume>9</volume>:<page-range>215&#8211;22</page-range>. &#160;<pub-id pub-id-type="doi">10.1038/nrmicro2508</pub-id><pub-id pub-id-type="pmid">21297670</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nishitani</surname><given-names>K</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>M</given-names></name><name name-style="western"><surname>Morita</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yokogawa</surname><given-names>N</given-names></name><name name-style="western"><surname>Xie</surname><given-names>C</given-names></name><name name-style="western"><surname>De Mesy Bentley</surname><given-names>KL</given-names></name><etal/></person-group>. <article-title>IsdB Antibody-Mediated Sepsis Following S. aureus Surgical Site Infection</article-title>. <source>JCI Insight</source> (<year>2020</year>) <volume>5</volume>. &#160;<pub-id pub-id-type="doi">10.1172/jci.insight.141164</pub-id><pub-id pub-id-type="pmcid">PMC7566716</pub-id><pub-id pub-id-type="pmid">33004694</pub-id></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>LY</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tong</surname><given-names>YN</given-names></name><name name-style="western"><surname>Peng</surname><given-names>LS</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>BH</given-names></name><etal/></person-group>. <article-title>Protective Effects of a Nanoemulsion Adjuvant Vaccine (2C-Staph/NE) Administered Intranasally Against Invasive Staphylococcus aureus Pneumonia</article-title>. <source>RSC Adv</source> (<year>2018</year>) <volume>8</volume>:<fpage>9996</fpage>&#8211;<lpage>10008</lpage>. &#160;<pub-id pub-id-type="doi">10.1039/c7ra13630g</pub-id><pub-id pub-id-type="pmcid">PMC9078739</pub-id><pub-id pub-id-type="pmid">35540845</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monaci</surname><given-names>E</given-names></name><name name-style="western"><surname>Mancini</surname><given-names>F</given-names></name><name name-style="western"><surname>Lofano</surname><given-names>G</given-names></name><name name-style="western"><surname>Bacconi</surname><given-names>M</given-names></name><name name-style="western"><surname>Tavarini</surname><given-names>S</given-names></name><name name-style="western"><surname>Sammicheli</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>MF59- and Al(OH)3-Adjuvanted Staphylococcus aureus (4C-Staph) Vaccines Induce Sustained Protective Humoral and Cellular Immune Responses, With a Critical Role for Effector CD4 T Cells at Low Antibody Titers</article-title>. <source>Front Immunol</source> (<year>2015</year>) <volume>6</volume>:<elocation-id>439</elocation-id>. &#160;<pub-id pub-id-type="doi">10.3389/fimmu.2015.00439</pub-id><pub-id pub-id-type="pmid">26441955</pub-id><pub-id pub-id-type="pmcid">PMC4561515</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bagnoli</surname><given-names>F</given-names></name><name name-style="western"><surname>Fontana</surname><given-names>MR</given-names></name><name name-style="western"><surname>Soldaini</surname><given-names>E</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>RPN</given-names></name><name name-style="western"><surname>Fiaschi</surname><given-names>L</given-names></name><name name-style="western"><surname>Cartocci</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Vaccine Composition Formulated With a Novel TLR7-Dependent Adjuvant Induces High and Broad Protection Against Staphylococcus aureus</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2015</year>) <volume>112</volume>:<page-range>3680&#8211;5</page-range>. &#160;<pub-id pub-id-type="doi">10.1073/pnas.1424924112</pub-id><pub-id pub-id-type="pmcid">PMC4378396</pub-id><pub-id pub-id-type="pmid">25775551</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mancini</surname><given-names>F</given-names></name><name name-style="western"><surname>Monaci</surname><given-names>E</given-names></name><name name-style="western"><surname>Lofano</surname><given-names>G</given-names></name><name name-style="western"><surname>Torre</surname><given-names>A</given-names></name><name name-style="western"><surname>Bacconi</surname><given-names>M</given-names></name><name name-style="western"><surname>Tavarini</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>One Dose of Staphylococcus aureus 4C-Staph Vaccine Formulated With a Novel TLR7-Dependent Adjuvant Rapidly Protects Mice Through Antibodies, Effector CD4+ T Cells, and IL-17A</article-title>. <source>PLoS One</source> (<year>2016</year>) <volume>11</volume>. &#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0147767</pub-id><pub-id pub-id-type="pmcid">PMC4727907</pub-id><pub-id pub-id-type="pmid">26812180</pub-id></mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>HW</given-names></name><name name-style="western"><surname>Wei</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>BS</given-names></name><name name-style="western"><surname>Jing</surname><given-names>HM</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Q</given-names></name><name name-style="western"><surname>Tong</surname><given-names>YN</given-names></name><etal/></person-group>. <article-title>Induction of Systemic and Mucosal Immunity Against Methicillin-Resistant Staphylococcus aureus Infection by a Novel Nanoemulsion Adjuvant Vaccine</article-title>. <source>Int J Nanomed</source> (<year>2015</year>) <volume>10</volume>:<page-range>7275&#8211;90</page-range>. &#160;<pub-id pub-id-type="doi">10.2147/IJN.S91529</pub-id><pub-id pub-id-type="pmcid">PMC4672755</pub-id><pub-id pub-id-type="pmid">26664118</pub-id></mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luna</surname><given-names>BM</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>TB</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>B</given-names></name><name name-style="western"><surname>Pantapalangkoor</surname><given-names>P</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J</given-names></name><name name-style="western"><surname>Boyle-Vavra</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Vaccines Targeting Staphylococcus aureus Skin and Bloodstream Infections Require Different Composition</article-title>. <source>PLoS One</source> (<year>2019</year>) <volume>14</volume>. &#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0217439</pub-id><pub-id pub-id-type="pmcid">PMC6557488</pub-id><pub-id pub-id-type="pmid">31181086</pub-id></mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gar&#231;on</surname><given-names>N</given-names></name><name name-style="western"><surname>Vaughn</surname><given-names>DW</given-names></name><name name-style="western"><surname>Didierlaurent</surname><given-names>AM</given-names></name></person-group>. <article-title>Development and Evaluation of AS03, an Adjuvant System Containing &#945;-Tocopherol and Squalene in an Oil-in-Water Emulsion</article-title>. <source>Expert Rev Vaccines</source> (<year>2012</year>) <volume>11</volume>:<page-range>349&#8211;66</page-range>. &#160;<pub-id pub-id-type="doi">10.1586/erv.11.192</pub-id><pub-id pub-id-type="pmid">22380826</pub-id></mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leroux-Roels</surname><given-names>I</given-names></name><name name-style="western"><surname>Borkowski</surname><given-names>A</given-names></name><name name-style="western"><surname>Vanwolleghem</surname><given-names>T</given-names></name><name name-style="western"><surname>Dram&#233;</surname><given-names>M</given-names></name><name name-style="western"><surname>Clement</surname><given-names>F</given-names></name><name name-style="western"><surname>Hons</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Antigen Sparing and Cross-Reactive Immunity With an Adjuvanted Rh5n1 Prototype Pandemic Influenza Vaccine: A Randomised Controlled Trial</article-title>. <source>Lancet</source> (<year>2007</year>) <volume>370</volume>:<page-range>580&#8211;9</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/S0140-6736(07)61297-5</pub-id><pub-id pub-id-type="pmid">17707753</pub-id></mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rigat</surname><given-names>F</given-names></name><name name-style="western"><surname>Bartolini</surname><given-names>E</given-names></name><name name-style="western"><surname>Dalsass</surname><given-names>M</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>N</given-names></name><name name-style="western"><surname>Marchi</surname><given-names>S</given-names></name><name name-style="western"><surname>Speziale</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Retrospective Identification of a Broad Igg Repertoire Differentiating Patients With S. aureus Skin and Soft Tissue Infections From Controls</article-title>. <source>Front Immunol</source> (<year>2019</year>) <volume>10</volume>:<elocation-id>114</elocation-id>. &#160;<pub-id pub-id-type="doi">10.3389/fimmu.2019.00114</pub-id><pub-id pub-id-type="pmid">30792711</pub-id><pub-id pub-id-type="pmcid">PMC6375365</pub-id></mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levy</surname><given-names>J</given-names></name><name name-style="western"><surname>Licini</surname><given-names>L</given-names></name><name name-style="western"><surname>Haelterman</surname><given-names>E</given-names></name><name name-style="western"><surname>Moris</surname><given-names>P</given-names></name><name name-style="western"><surname>Lestrate</surname><given-names>P</given-names></name><name name-style="western"><surname>Damaso</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Safety and Immunogenicity of an Investigational 4-Component Staphylococcus aureus Vaccine With or Without AS03B Adjuvant: Results of a Randomized Phase I Trial</article-title>. <source>Hum Vaccines Immunother</source> (<year>2015</year>) <volume>11</volume>:<page-range>620&#8211;31</page-range>. &#160;<pub-id pub-id-type="doi">10.1080/21645515.2015.1011021</pub-id><pub-id pub-id-type="pmcid">PMC4514337</pub-id><pub-id pub-id-type="pmid">25715157</pub-id></mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Veer</surname><given-names>M</given-names></name><name name-style="western"><surname>Kemp</surname><given-names>J</given-names></name><name name-style="western"><surname>Chatelier</surname><given-names>J</given-names></name><name name-style="western"><surname>Elhay</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Meeusen</surname><given-names>ENT</given-names></name></person-group>. <article-title>The Kinetics of Soluble and Particulate Antigen Trafficking in the Afferent Lymph, and its Modulation by Aluminum-Based Adjuvant</article-title>. <source>Vaccine</source> (<year>2010</year>) <volume>28</volume>:<page-range>6597&#8211;602</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2010.07.056</pub-id><pub-id pub-id-type="pmid">20678587</pub-id></mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Willingham</surname><given-names>SB</given-names></name><name name-style="western"><surname>Ting</surname><given-names>JP-Y</given-names></name><name name-style="western"><surname>Re</surname><given-names>F</given-names></name></person-group>. <article-title>Cutting Edge: Inflammasome Activation by Alum and Alum&#8217;s Adjuvant Effect are Mediated by NLRP3</article-title>. <source>J Immunol</source> (<year>2008</year>) <volume>181</volume>:<fpage>17</fpage>&#8211;<lpage>21</lpage>. &#160;<pub-id pub-id-type="doi">10.4049/jimmunol.181.1.17</pub-id><pub-id pub-id-type="pmid">18566365</pub-id><pub-id pub-id-type="pmcid">PMC2587213</pub-id></mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Comoy</surname><given-names>EE</given-names></name><name name-style="western"><surname>Capron</surname><given-names>A</given-names></name><name name-style="western"><surname>Thyphronitis</surname><given-names>G</given-names></name></person-group>. <article-title>
<italic toggle="yes">In Vivo</italic> Induction of Type 1 and 2 Immune Responses Against Protein Antigens</article-title>. <source>Int Immunol</source> (<year>1997</year>) <volume>9</volume>:<page-range>523&#8211;31</page-range>. &#160;<pub-id pub-id-type="doi">10.1093/intimm/9.4.523</pub-id><pub-id pub-id-type="pmid">9138012</pub-id></mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brewer</surname><given-names>JM</given-names></name><name name-style="western"><surname>Conacher</surname><given-names>M</given-names></name><name name-style="western"><surname>Hunter</surname><given-names>CA</given-names></name><name name-style="western"><surname>Mohrs</surname><given-names>M</given-names></name><name name-style="western"><surname>Brombacher</surname><given-names>F</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>J</given-names></name></person-group>. <article-title>Aluminium Hydroxide Adjuvant Initiates Strong Antigen-Specific Th2 Responses in the Absence of IL-4- or IL-13-Mediated Signaling</article-title>. <source>J Immunol</source> (<year>1999</year>) <volume>163</volume>:<page-range>6448&#8211;54</page-range>.<pub-id pub-id-type="pmid">10586035</pub-id></mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Serre</surname><given-names>K</given-names></name><name name-style="western"><surname>B&#233;n&#233;zech</surname><given-names>C</given-names></name><name name-style="western"><surname>Desanti</surname><given-names>G</given-names></name><name name-style="western"><surname>Bobat</surname><given-names>S</given-names></name><name name-style="western"><surname>Toellner</surname><given-names>KM</given-names></name><name name-style="western"><surname>Bird</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Helios is Associated With CD4 T Cells Differentiating to T Helper 2 and Follicular Helper T Cells <italic toggle="yes">In Vivo</italic> Independently of Foxp3 Expression</article-title>. <source>PLoS One</source> (<year>2011</year>) <volume>6</volume>. &#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0020731</pub-id><pub-id pub-id-type="pmcid">PMC3108993</pub-id><pub-id pub-id-type="pmid">21677778</pub-id></mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anthony</surname><given-names>RM</given-names></name><name name-style="western"><surname>Rutitzky</surname><given-names>LI</given-names></name><name name-style="western"><surname>Urban</surname><given-names>JF</given-names></name><name name-style="western"><surname>Stadecker</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Gause</surname><given-names>WC</given-names></name></person-group>. <article-title>Protective Immune Mechanisms in Helminth Infection</article-title>. <source>Nat Rev Immunol</source> (<year>2007</year>) <volume>7</volume>:<page-range>975&#8211;87</page-range>. &#160;<pub-id pub-id-type="doi">10.1038/nri2199</pub-id><pub-id pub-id-type="pmcid">PMC2258092</pub-id><pub-id pub-id-type="pmid">18007680</pub-id></mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crum-Cianflone</surname><given-names>NF</given-names></name><name name-style="western"><surname>Burgi</surname><given-names>AA</given-names></name><name name-style="western"><surname>Hale</surname><given-names>BR</given-names></name></person-group>. <article-title>Increasing Rates of Community-Acquired Methicillin-Resistant Staphylococcus aureus Infections Among HIV-Infected Persons</article-title>. <source>Int J STD AIDS</source> (<year>2007</year>) <volume>18</volume>:<page-range>521&#8211;6</page-range>. &#160;<pub-id pub-id-type="doi">10.1258/095646207781439702</pub-id><pub-id pub-id-type="pmid">17686212</pub-id></mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puel</surname><given-names>A</given-names></name><name name-style="western"><surname>Cypowyj</surname><given-names>S</given-names></name><name name-style="western"><surname>Bustamante</surname><given-names>J</given-names></name><name name-style="western"><surname>Wright</surname><given-names>JF</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Lim</surname><given-names>HK</given-names></name><etal/></person-group>. <article-title>Chronic Mucocutaneous Candidiasis in Humans With Inborn Errors of Interleukin-17 Immunity</article-title>. <source>Science</source> (<year>2011</year>) <volume>332</volume>:<page-range>65&#8211;8</page-range>. &#160;<pub-id pub-id-type="doi">10.1126/science.1200439</pub-id><pub-id pub-id-type="pmcid">PMC3070042</pub-id><pub-id pub-id-type="pmid">21350122</pub-id></mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Minegishi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Saito</surname><given-names>M</given-names></name><name name-style="western"><surname>Nagasawa</surname><given-names>M</given-names></name><name name-style="western"><surname>Takada</surname><given-names>H</given-names></name><name name-style="western"><surname>Hara</surname><given-names>T</given-names></name><name name-style="western"><surname>Tsuchiya</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Molecular Explanation for the Contradiction Between Systemic Th17 Defect and Localized Bacterial Infection in Hyper-Ige Syndrome</article-title>. <source>J Exp Med</source> (<year>2009</year>) <volume>206</volume>:<page-range>1291&#8211;301</page-range>. &#160;<pub-id pub-id-type="doi">10.1084/jem.20082767</pub-id><pub-id pub-id-type="pmcid">PMC2715068</pub-id><pub-id pub-id-type="pmid">19487419</pub-id></mixed-citation></ref><ref id="B92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Essink</surname><given-names>B</given-names></name><name name-style="western"><surname>Fierro</surname><given-names>C</given-names></name><name name-style="western"><surname>Rosen</surname><given-names>J</given-names></name><name name-style="western"><surname>Figueroa</surname><given-names>AL</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><name name-style="western"><surname>Verhoeven</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Versus Standard and Alternate B Strain MF59-Adjuvanted Trivalent Influenza Vaccines in Older Adults</article-title>. <source>Vaccine</source> (<year>2020</year>) <volume>38</volume>:<page-range>242&#8211;50</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2019.10.021</pub-id><pub-id pub-id-type="pmid">31635976</pub-id></mixed-citation></ref><ref id="B93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sugai</surname><given-names>T</given-names></name><name name-style="western"><surname>Mori</surname><given-names>M</given-names></name><name name-style="western"><surname>Nakazawa</surname><given-names>M</given-names></name><name name-style="western"><surname>Ichino</surname><given-names>M</given-names></name><name name-style="western"><surname>Naruto</surname><given-names>T</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>A Cpg-Containing Oligodeoxynucleotide as an Efficient Adjuvant Counterbalancing the Th1/Th2 Immune Response in Diphtheria-Tetanus-Pertussis Vaccine</article-title>. <source>Vaccine</source> (<year>2005</year>) <volume>23</volume>:<page-range>5450&#8211;6</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2004.09.041</pub-id><pub-id pub-id-type="pmid">16006019</pub-id></mixed-citation></ref><ref id="B94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cooper</surname><given-names>CL</given-names></name><name name-style="western"><surname>Davis</surname><given-names>HL</given-names></name><name name-style="western"><surname>Morris</surname><given-names>ML</given-names></name><name name-style="western"><surname>Efler</surname><given-names>SM</given-names></name><name name-style="western"><surname>Krieg</surname><given-names>AM</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Safety and Immunogenicity of CPG 7909 Injection as an Adjuvant to Fluarix Influenza Vaccine</article-title>. <source>Vaccine</source> (<year>2004</year>) <volume>22</volume>:<page-range>3136&#8211;43</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2004.01.058</pub-id><pub-id pub-id-type="pmid">15297066</pub-id></mixed-citation></ref><ref id="B95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lacey</surname><given-names>KA</given-names></name><name name-style="western"><surname>Mulcahy</surname><given-names>ME</given-names></name><name name-style="western"><surname>Towell</surname><given-names>AM</given-names></name><name name-style="western"><surname>Geoghegan</surname><given-names>JA</given-names></name><name name-style="western"><surname>McLoughlin</surname><given-names>RM</given-names></name></person-group>. <article-title>Clumping Factor B is an Important Virulence Factor During Staphylococcus aureus Skin Infection and a Promising Vaccine Target</article-title>. <source>PLoS Pathog</source> (<year>2019</year>) <volume>15</volume>. &#160;<pub-id pub-id-type="doi">10.1371/journal.ppat.1007713</pub-id><pub-id pub-id-type="pmcid">PMC6497315</pub-id><pub-id pub-id-type="pmid">31009507</pub-id></mixed-citation></ref><ref id="B96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lacey</surname><given-names>KA</given-names></name><name name-style="western"><surname>Leech</surname><given-names>JM</given-names></name><name name-style="western"><surname>Lalor</surname><given-names>SJ</given-names></name><name name-style="western"><surname>McCormack</surname><given-names>N</given-names></name><name name-style="western"><surname>Geoghegan</surname><given-names>JA</given-names></name><name name-style="western"><surname>McLoughlin</surname><given-names>RM</given-names></name></person-group>. <article-title>The Staphylococcus aureus Cell Wall-Anchored Protein Clumping Factor a is an Important T Cell Antigen</article-title>. <source>Infect Immun</source> (<year>2017</year>) <volume>85</volume>. &#160;<pub-id pub-id-type="doi">10.1128/IAI.00549-17</pub-id><pub-id pub-id-type="pmcid">PMC5695125</pub-id><pub-id pub-id-type="pmid">28947645</pub-id></mixed-citation></ref><ref id="B97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Date</surname><given-names>SV</given-names></name><name name-style="western"><surname>Modrusan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Lawrence</surname><given-names>M</given-names></name><name name-style="western"><surname>Morisaki</surname><given-names>JH</given-names></name><name name-style="western"><surname>Toy</surname><given-names>K</given-names></name><name name-style="western"><surname>Shah</surname><given-names>IM</given-names></name><etal/></person-group>. <article-title>Global Gene Expression of Methicillin-Resistant Staphylococcus aureus USA300 During Human and Mouse Infection</article-title>. <source>J Infect Dis</source> (<year>2014</year>) <volume>209</volume>:<page-range>1542&#8211;50</page-range>. &#160;<pub-id pub-id-type="doi">10.1093/infdis/jit668</pub-id><pub-id pub-id-type="pmid">24286981</pub-id></mixed-citation></ref><ref id="B98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Junhee Seok</surname><given-names>H</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>W</given-names></name><name name-style="western"><surname>Alex</surname><given-names>GC</given-names></name><name name-style="western"><surname>Michael</surname><given-names>NM</given-names></name><name name-style="western"><surname>Henry</surname><given-names>VB</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Genomic Responses in Mouse Models Poorly Mimic Human Inflammatory Diseases</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2013</year>) <volume>110</volume>:<page-range>3507&#8211;12</page-range>. &#160;<pub-id pub-id-type="doi">10.1073/pnas.1222878110</pub-id><pub-id pub-id-type="pmcid">PMC3587220</pub-id><pub-id pub-id-type="pmid">23401516</pub-id></mixed-citation></ref><ref id="B99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beura</surname><given-names>LK</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>SE</given-names></name><name name-style="western"><surname>Bi</surname><given-names>K</given-names></name><name name-style="western"><surname>Schenkel</surname><given-names>JM</given-names></name><name name-style="western"><surname>Odumade</surname><given-names>OA</given-names></name><name name-style="western"><surname>Casey</surname><given-names>KA</given-names></name><etal/></person-group>. <article-title>Normalizing the Environment Recapitulates Adult Human Immune Traits in Laboratory Mice</article-title>. <source>Nature</source> (<year>2016</year>) <volume>532</volume>:<page-range>512&#8211;6</page-range>. &#160;<pub-id pub-id-type="doi">10.1038/nature17655</pub-id><pub-id pub-id-type="pmcid">PMC4871315</pub-id><pub-id pub-id-type="pmid">27096360</pub-id></mixed-citation></ref><ref id="B100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tam</surname><given-names>K</given-names></name><name name-style="western"><surname>Torres</surname><given-names>VJ</given-names></name></person-group>. <article-title>Staphylococcus aureus Secreted Toxins and Extracellular Enzymes</article-title>. <source>Microbiol Spectr</source> (<year>2019</year>) <volume>7</volume>. &#160;<pub-id pub-id-type="doi">10.1128/microbiolspec.gpp3-0039-2018</pub-id><pub-id pub-id-type="pmcid">PMC6422052</pub-id><pub-id pub-id-type="pmid">30873936</pub-id></mixed-citation></ref><ref id="B101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spaan</surname><given-names>AN</given-names></name><name name-style="western"><surname>Van Strijp</surname><given-names>JAG</given-names></name><name name-style="western"><surname>Torres</surname><given-names>VJ</given-names></name></person-group>. <article-title>Leukocidins: Staphylococcal Bi-Component Pore-Forming Toxins Find Their Receptors</article-title>. <source>Nat Rev Microbiol</source> (<year>2017</year>) <volume>15</volume>:<page-range>435&#8211;47</page-range>. &#160;<pub-id pub-id-type="doi">10.1038/nrmicro.2017.27</pub-id><pub-id pub-id-type="pmcid">PMC5621924</pub-id><pub-id pub-id-type="pmid">28420883</pub-id></mixed-citation></ref><ref id="B102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tseng</surname><given-names>CW</given-names></name><name name-style="western"><surname>Biancotti</surname><given-names>JC</given-names></name><name name-style="western"><surname>Berg</surname><given-names>BL</given-names></name><name name-style="western"><surname>Gate</surname><given-names>D</given-names></name><name name-style="western"><surname>Kolar</surname><given-names>SL</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Increased Susceptibility of Humanized NSG Mice to Panton-Valentine Leukocidin and Staphylococcus aureus Skin Infection</article-title>. <source>PLoS Pathog</source> (<year>2015</year>) <volume>11</volume>. &#160;<pub-id pub-id-type="doi">10.1371/journal.ppat.1005292</pub-id><pub-id pub-id-type="pmcid">PMC4664407</pub-id><pub-id pub-id-type="pmid">26618545</pub-id></mixed-citation></ref><ref id="B103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knop</surname><given-names>J</given-names></name><name name-style="western"><surname>Hanses</surname><given-names>F</given-names></name><name name-style="western"><surname>Leist</surname><given-names>T</given-names></name><name name-style="western"><surname>Archin</surname><given-names>NM</given-names></name><name name-style="western"><surname>Buchholz</surname><given-names>S</given-names></name><name name-style="western"><surname>Gl&#228;sner</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Staphylococcus aureus Infection in Humanized Mice: A New Model to Study Pathogenicity Associated With Human Immune Response</article-title>. <source>J Infect Dis</source> (<year>2015</year>) <volume>212</volume>:<page-range>435&#8211;44</page-range>. &#160;<pub-id pub-id-type="doi">10.1093/infdis/jiv073</pub-id><pub-id pub-id-type="pmid">25657257</pub-id></mixed-citation></ref><ref id="B104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prince</surname><given-names>A</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Kitur</surname><given-names>K</given-names></name><name name-style="western"><surname>Parker</surname><given-names>D</given-names></name></person-group>. <article-title>Humanized Mice Exhibit Increased Susceptibility to Staphylococcus aureus Pneumonia</article-title>. <source>J Infect Dis</source> (<year>2017</year>) <volume>215</volume>:<page-range>1386&#8211;95</page-range>. &#160;<pub-id pub-id-type="doi">10.1093/infdis/jiw425</pub-id><pub-id pub-id-type="pmcid">PMC5853420</pub-id><pub-id pub-id-type="pmid">27638942</pub-id></mixed-citation></ref><ref id="B105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parker</surname><given-names>D</given-names></name></person-group>. <article-title>Humanized Mouse Models of Staphylococcus aureus Infection</article-title>. <source>Front Immunol</source> (<year>2017</year>) <volume>8</volume>:<elocation-id>512</elocation-id>. &#160;<pub-id pub-id-type="doi">10.3389/fimmu.2017.00512</pub-id><pub-id pub-id-type="pmid">28523002</pub-id><pub-id pub-id-type="pmcid">PMC5415562</pub-id></mixed-citation></ref><ref id="B106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salgado-Pab&#243;n</surname><given-names>W</given-names></name><name name-style="western"><surname>Schlievert</surname><given-names>PM</given-names></name></person-group>. <article-title>Models Matter: The Search for an Effective Staphylococcus aureus Vaccine</article-title>. <source>Nat Rev Microbiol</source> (<year>2014</year>) <volume>12</volume>:<page-range>585&#8211;91</page-range>. &#160;<pub-id pub-id-type="doi">10.1038/nrmicro3308</pub-id><pub-id pub-id-type="pmid">24998740</pub-id></mixed-citation></ref><ref id="B107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Venkatasubramaniam</surname><given-names>A</given-names></name><name name-style="western"><surname>Liao</surname><given-names>G</given-names></name><name name-style="western"><surname>Cho</surname><given-names>E</given-names></name><name name-style="western"><surname>Adhikari</surname><given-names>RP</given-names></name><name name-style="western"><surname>Kort</surname><given-names>T</given-names></name><name name-style="western"><surname>Holtsberg</surname><given-names>FW</given-names></name><etal/></person-group>. <article-title>Safety and Immunogenicity of a 4-Component Toxoid-Based Staphylococcus aureus Vaccine in Rhesus Macaques</article-title>. <source>Front Immunol</source> (<year>2021</year>) <volume>12</volume>:<elocation-id>621754</elocation-id>. &#160;<pub-id pub-id-type="doi">10.3389/fimmu.2021.621754</pub-id><pub-id pub-id-type="pmid">33717122</pub-id><pub-id pub-id-type="pmcid">PMC7947289</pub-id></mixed-citation></ref><ref id="B108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verreault</surname><given-names>D</given-names></name><name name-style="western"><surname>Ennis</surname><given-names>J</given-names></name><name name-style="western"><surname>Whaley</surname><given-names>K</given-names></name><name name-style="western"><surname>Killeen</surname><given-names>SZ</given-names></name><name name-style="western"><surname>Karauzum</surname><given-names>H</given-names></name><name name-style="western"><surname>Javad Aman</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Effective Treatment of Staphylococcal Enterotoxin B Aerosol Intoxication in Rhesus Macaques by Using Two Parenterally Administered High-Affinity Monoclonal Antibodies</article-title>. <source>Antimicrob Agents Chemother</source> (<year>2019</year>) <volume>63</volume>. &#160;<pub-id pub-id-type="doi">10.1128/AAC.02049-18</pub-id><pub-id pub-id-type="pmcid">PMC6496046</pub-id><pub-id pub-id-type="pmid">30782986</pub-id></mixed-citation></ref><ref id="B109"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schulz</surname><given-names>D</given-names></name><name name-style="western"><surname>Grumann</surname><given-names>D</given-names></name><name name-style="western"><surname>Tr&#252;be</surname><given-names>P</given-names></name><name name-style="western"><surname>Pritchett-Corning</surname><given-names>K</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>S</given-names></name><name name-style="western"><surname>Reppschl&#228;ger</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Laboratory Mice Are Frequently Colonized With Staphylococcus aureus and Mount a Systemic Immune Response-Note of Caution for <italic toggle="yes">In Vivo</italic> Infection Experiments</article-title>. <source>Front Cell Infect Microbiol</source> (<year>2017</year>) <volume>7</volume>:<elocation-id>152</elocation-id>. &#160;<pub-id pub-id-type="doi">10.3389/fcimb.2017.00152</pub-id><pub-id pub-id-type="pmid">28512627</pub-id><pub-id pub-id-type="pmcid">PMC5411432</pub-id></mixed-citation></ref><ref id="B110"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holtfreter</surname><given-names>S</given-names></name><name name-style="western"><surname>Radcliff</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Grumann</surname><given-names>D</given-names></name><name name-style="western"><surname>Read</surname><given-names>H</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>S</given-names></name><name name-style="western"><surname>Monecke</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Characterization of a Mouse-Adapted Staphylococcus aureus Strain</article-title>. <source>PLoS One</source> (<year>2013</year>) <volume>8</volume>. &#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0071142</pub-id><pub-id pub-id-type="pmcid">PMC3759423</pub-id><pub-id pub-id-type="pmid">24023720</pub-id></mixed-citation></ref><ref id="B111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flaxman</surname><given-names>A</given-names></name><name name-style="western"><surname>Van Diemen</surname><given-names>PM</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Allen</surname><given-names>E</given-names></name><name name-style="western"><surname>Lindemann</surname><given-names>C</given-names></name><name name-style="western"><surname>Rollier</surname><given-names>CS</given-names></name><etal/></person-group>. <article-title>Development of Persistent Gastrointestinal S. aureus Carriage in Mice</article-title>. <source>Sci Rep</source> (<year>2017</year>) <volume>7</volume>. &#160;<pub-id pub-id-type="doi">10.1038/s41598-017-12576-0</pub-id><pub-id pub-id-type="pmcid">PMC5622074</pub-id><pub-id pub-id-type="pmid">28963555</pub-id></mixed-citation></ref><ref id="B112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leech</surname><given-names>JM</given-names></name><name name-style="western"><surname>Dhariwala</surname><given-names>MO</given-names></name><name name-style="western"><surname>Lowe</surname><given-names>MM</given-names></name><name name-style="western"><surname>Chu</surname><given-names>K</given-names></name><name name-style="western"><surname>Merana</surname><given-names>GR</given-names></name><name name-style="western"><surname>Cornuot</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Toxin-Triggered Interleukin-1 Receptor Signaling Enables Early-Life Discrimination of Pathogenic Versus Commensal Skin Bacteria</article-title>. <source>Cell Host Microbe</source> (<year>2019</year>) <volume>26</volume>:<fpage>795</fpage>&#8211;<lpage>809.e5</lpage>. &#160;<pub-id pub-id-type="doi">10.1016/j.chom.2019.10.007</pub-id><pub-id pub-id-type="pmid">31784259</pub-id><pub-id pub-id-type="pmcid">PMC6989301</pub-id></mixed-citation></ref><ref id="B113"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>B</given-names></name><name name-style="western"><surname>Olaniyi</surname><given-names>R</given-names></name><name name-style="western"><surname>Kwiecinski</surname><given-names>JM</given-names></name><name name-style="western"><surname>Wardenburg</surname><given-names>JB</given-names></name></person-group>. <article-title>Staphylococcus aureus Toxin Suppresses Antigen-Specific T Cell Responses</article-title>. <source>J Clin Invest</source> (<year>2020</year>) <volume>130</volume>:<page-range>1122&#8211;7</page-range>. &#160;<pub-id pub-id-type="doi">10.1172/JCI130728</pub-id><pub-id pub-id-type="pmcid">PMC7269593</pub-id><pub-id pub-id-type="pmid">31873074</pub-id></mixed-citation></ref><ref id="B114"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>LG</given-names></name><name name-style="western"><surname>Eells</surname><given-names>SJ</given-names></name><name name-style="western"><surname>David</surname><given-names>MZ</given-names></name><name name-style="western"><surname>Ortiz</surname><given-names>N</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>AR</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Staphylococcus aureus Skin Infection Recurrences Among Household Members: An Examination of Host, Behavioral, and Pathogen-Level Predictors</article-title>. <source>Clin Infect Dis</source> (<year>2015</year>) <volume>60</volume>:<page-range>753&#8211;63</page-range>. &#160;<pub-id pub-id-type="doi">10.1093/cid/ciu943</pub-id><pub-id pub-id-type="pmcid">PMC4402346</pub-id><pub-id pub-id-type="pmid">25428411</pub-id></mixed-citation></ref><ref id="B115"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomes</surname><given-names>MC</given-names></name><name name-style="western"><surname>Mostowy</surname><given-names>S</given-names></name></person-group>. <article-title>The Case for Modeling Human Infection in Zebrafish</article-title>. <source>Trends Microbiol</source> (<year>2020</year>) <volume>28</volume>:<page-range>10&#8211;8</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.tim.2019.08.005</pub-id><pub-id pub-id-type="pmid">31604611</pub-id></mixed-citation></ref><ref id="B116"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hepburn</surname><given-names>L</given-names></name><name name-style="western"><surname>Prajsnar</surname><given-names>TK</given-names></name><name name-style="western"><surname>Klapholz</surname><given-names>C</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>P</given-names></name><name name-style="western"><surname>Loynes</surname><given-names>CA</given-names></name><name name-style="western"><surname>Ogryzko</surname><given-names>NV</given-names></name><etal/></person-group>. <article-title>A Spaetzle-Like Role for Nerve Growth Factor &#946; in Vertebrate Immunity to Staphylococcus aureus</article-title>. <source>Science</source> (<year>2014</year>) <volume>346</volume>:<page-range>641&#8211;6</page-range>. &#160;<pub-id pub-id-type="doi">10.1126/science.1258705</pub-id><pub-id pub-id-type="pmcid">PMC4255479</pub-id><pub-id pub-id-type="pmid">25359976</pub-id></mixed-citation></ref><ref id="B117"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mei</surname><given-names>F</given-names></name><name name-style="western"><surname>Rolain</surname><given-names>M</given-names></name><name name-style="western"><surname>Yi Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Kumar Singh</surname><given-names>P</given-names></name><name name-style="western"><surname>Thummel</surname><given-names>R</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name></person-group>. <article-title>Zebrafish Are Resistant to Staphylococcus aureus Endophthalmitis</article-title>. <source>Pathogens</source> (<year>2019</year>) <volume>8</volume>. &#160;<pub-id pub-id-type="doi">10.3390/pathogens8040207</pub-id><pub-id pub-id-type="pmcid">PMC6963345</pub-id><pub-id pub-id-type="pmid">31717750</pub-id></mixed-citation></ref><ref id="B118"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><name name-style="western"><surname>Koo</surname><given-names>BK</given-names></name><name name-style="western"><surname>Knoblich</surname><given-names>JA</given-names></name></person-group>. <article-title>Human Organoids: Model Systems for Human Biology and Medicine</article-title>. <source>Nat Rev Mol Cell Biol</source> (<year>2020</year>) <volume>21</volume>:<page-range>571&#8211;84</page-range>. &#160;<pub-id pub-id-type="doi">10.1038/s41580-020-0259-3</pub-id><pub-id pub-id-type="pmcid">PMC7339799</pub-id><pub-id pub-id-type="pmid">32636524</pub-id></mixed-citation></ref><ref id="B119"><label>119</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><name name-style="western"><surname>Rabbani</surname><given-names>CC</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H</given-names></name><name name-style="western"><surname>Steinhart</surname><given-names>MR</given-names></name><name name-style="western"><surname>Woodruff</surname><given-names>BM</given-names></name><name name-style="western"><surname>Pflum</surname><given-names>ZE</given-names></name><etal/></person-group>. <article-title>Hair-Bearing Human Skin Generated Entirely From Pluripotent Stem Cells</article-title>. <source>Nature</source> (<year>2020</year>) <volume>582</volume>:<fpage>399</fpage>&#8211;<lpage>404</lpage>. &#160;<pub-id pub-id-type="doi">10.1038/s41586-020-2352-3</pub-id><pub-id pub-id-type="pmid">32494013</pub-id><pub-id pub-id-type="pmcid">PMC7593871</pub-id></mixed-citation></ref><ref id="B120"><label>120</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nilsson Hall</surname><given-names>G</given-names></name><name name-style="western"><surname>Mendes</surname><given-names>LF</given-names></name><name name-style="western"><surname>Gklava</surname><given-names>C</given-names></name><name name-style="western"><surname>Geris</surname><given-names>L</given-names></name><name name-style="western"><surname>Luyten</surname><given-names>FP</given-names></name><name name-style="western"><surname>Papantoniou</surname><given-names>I</given-names></name></person-group>. <article-title>Developmentally Engineered Callus Organoid Bioassemblies Exhibit Predictive <italic toggle="yes">In Vivo</italic> Long Bone Healing</article-title>. <source>Adv Sci</source> (<year>2020</year>) <volume>7</volume>. &#160;<pub-id pub-id-type="doi">10.1002/advs.201902295</pub-id><pub-id pub-id-type="pmcid">PMC6974953</pub-id><pub-id pub-id-type="pmid">31993293</pub-id></mixed-citation></ref><ref id="B121"><label>121</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leeman</surname><given-names>KT</given-names></name><name name-style="western"><surname>Pessina</surname><given-names>P</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>CF</given-names></name></person-group>. <article-title>Mesenchymal Stem Cells Increase Alveolar Differentiation in Lung Progenitor Organoid Cultures</article-title>. <source>Sci Rep</source> (<year>2019</year>) <volume>9</volume>. &#160;<pub-id pub-id-type="doi">10.1038/s41598-019-42819-1</pub-id><pub-id pub-id-type="pmcid">PMC6478947</pub-id><pub-id pub-id-type="pmid">31015509</pub-id></mixed-citation></ref><ref id="B122"><label>122</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dye</surname><given-names>BR</given-names></name><name name-style="western"><surname>Hill</surname><given-names>DR</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>MA</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>YH</given-names></name><name name-style="western"><surname>Nagy</surname><given-names>MS</given-names></name><name name-style="western"><surname>Dyal</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>
<italic toggle="yes">In Vitro</italic> Generation of Human Pluripotent Stem Cell Derived Lung Organoids</article-title>. <source>Elife</source> (<year>2015</year>) <volume>2015</volume>:<fpage>1</fpage>&#8211;<lpage>25</lpage>. &#160;<pub-id pub-id-type="doi">10.7554/eLife.05098</pub-id><pub-id pub-id-type="pmcid">PMC4370217</pub-id><pub-id pub-id-type="pmid">25803487</pub-id></mixed-citation></ref><ref id="B123"><label>123</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>RA</given-names></name><name name-style="western"><surname>Chong</surname><given-names>B</given-names></name><name name-style="western"><surname>Mirchandani</surname><given-names>N</given-names></name><name name-style="western"><surname>Brinster</surname><given-names>NK</given-names></name><name name-style="western"><surname>Yamanaka</surname><given-names>K</given-names></name><name name-style="western"><surname>Dowgiert</surname><given-names>RK</given-names></name><etal/></person-group>. <article-title>The Vast Majority of CLA + T Cells are Resident in Normal Skin</article-title>. <source>J Immunol</source> (<year>2006</year>) <volume>176</volume>:<page-range>4431&#8211;9</page-range>. &#160;<pub-id pub-id-type="doi">10.4049/jimmunol.176.7.4431</pub-id><pub-id pub-id-type="pmid">16547281</pub-id></mixed-citation></ref><ref id="B124"><label>124</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schoettler</surname><given-names>N</given-names></name><name name-style="western"><surname>Hrusch</surname><given-names>CL</given-names></name><name name-style="western"><surname>Blaine</surname><given-names>KM</given-names></name><name name-style="western"><surname>Sperling</surname><given-names>AI</given-names></name><name name-style="western"><surname>Ober</surname><given-names>C</given-names></name></person-group>. <article-title>Transcriptional Programming and T Cell Receptor Repertoires Distinguish Human Lung and Lymph Node Memory T Cells</article-title>. <source>Commun Biol</source> (<year>2019</year>) <volume>2</volume>. &#160;<pub-id pub-id-type="doi">10.1038/s42003-019-0657-2</pub-id><pub-id pub-id-type="pmcid">PMC6853923</pub-id><pub-id pub-id-type="pmid">31754641</pub-id></mixed-citation></ref><ref id="B125"><label>125</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>W</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Z</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Lee</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Tebon</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Organ-on-a-Chip for Cancer and Immune Organs Modeling</article-title>. <source>Adv Healthc Mater</source> (<year>2019</year>) <volume>8</volume>. &#160;<pub-id pub-id-type="doi">10.1002/adhm.201801363</pub-id><pub-id pub-id-type="pmcid">PMC6424124</pub-id><pub-id pub-id-type="pmid">30605261</pub-id></mixed-citation></ref><ref id="B126"><label>126</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Ellett</surname><given-names>F</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>CN</given-names></name><name name-style="western"><surname>Jalali</surname><given-names>F</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>RR</given-names></name><name name-style="western"><surname>Irimia</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>A Microscale, Full-Thickness, Human Skin on a Chip Assay Simulating Neutrophil Responses to Skin Infection and Antibiotic Treatments</article-title>. <source>Lab Chip</source> (<year>2019</year>) <volume>19</volume>:<page-range>3094&#8211;103</page-range>. &#160;<pub-id pub-id-type="doi">10.1039/c9lc00399a</pub-id><pub-id pub-id-type="pmcid">PMC6776466</pub-id><pub-id pub-id-type="pmid">31423506</pub-id></mixed-citation></ref><ref id="B127"><label>127</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deinhardt-Emmer</surname><given-names>S</given-names></name><name name-style="western"><surname>Rennert</surname><given-names>K</given-names></name><name name-style="western"><surname>Schicke</surname><given-names>E</given-names></name><name name-style="western"><surname>Cseresny&#233;s</surname><given-names>Z</given-names></name><name name-style="western"><surname>Windolph</surname><given-names>M</given-names></name><name name-style="western"><surname>Nietzsche</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Co-Infection With Staphylococcus aureus After Primary Influenza Virus Infection Leads to Damage of the Endothelium in a Human Alveolus-on-a-Chip Model</article-title>. <source>Biofabrication</source> (<year>2020</year>) <volume>12</volume>. &#160;<pub-id pub-id-type="doi">10.1088/1758-5090/ab7073</pub-id><pub-id pub-id-type="pmid">31994489</pub-id></mixed-citation></ref><ref id="B128"><label>128</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santiago-Rodriguez</surname><given-names>TM</given-names></name><name name-style="western"><surname>Naidu</surname><given-names>M</given-names></name><name name-style="western"><surname>Jones</surname><given-names>MB</given-names></name><name name-style="western"><surname>Ly</surname><given-names>M</given-names></name><name name-style="western"><surname>Pride</surname><given-names>DT</given-names></name></person-group>. <article-title>Identification of Staphylococcal Phage With Reduced Transcription in Human Blood Through Transcriptome Sequencing</article-title>. <source>Front Microbiol</source> (<year>2015</year>) <volume>6</volume>:<elocation-id>216</elocation-id>. &#160;<pub-id pub-id-type="doi">10.3389/fmicb.2015.00216</pub-id><pub-id pub-id-type="pmid">26074882</pub-id><pub-id pub-id-type="pmcid">PMC4447126</pub-id></mixed-citation></ref><ref id="B129"><label>129</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ibberson</surname><given-names>CB</given-names></name><name name-style="western"><surname>Whiteley</surname><given-names>M</given-names></name></person-group>. <article-title>The Staphylococcus aureus Transcriptome During Cystic Fibrosis Lung Infection</article-title>. <source>MBio</source> (<year>2019</year>) <volume>10</volume>. &#160;<pub-id pub-id-type="doi">10.1128/mBio.02774-19</pub-id><pub-id pub-id-type="pmcid">PMC6867902</pub-id><pub-id pub-id-type="pmid">31744924</pub-id></mixed-citation></ref><ref id="B130"><label>130</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boero</surname><given-names>E</given-names></name><name name-style="western"><surname>Mnich</surname><given-names>ME</given-names></name><name name-style="western"><surname>Manetti</surname><given-names>AGO</given-names></name><name name-style="western"><surname>Soldaini</surname><given-names>E</given-names></name><name name-style="western"><surname>Grimaldi</surname><given-names>L</given-names></name><name name-style="western"><surname>Bagnoli</surname><given-names>F</given-names></name></person-group>. <article-title>Human Three-Dimensional Models for Studying Skin Pathogens</article-title>. <source>Curr Topics Microbiol Immunol</source> (<year>2020</year>) <volume>430</volume>:<fpage>3</fpage>&#8211;<lpage>27</lpage>. &#160;<pub-id pub-id-type="doi">10.1007/82_2020_219</pub-id><pub-id pub-id-type="pmid">32601967</pub-id></mixed-citation></ref><ref id="B131"><label>131</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mandal</surname><given-names>A</given-names></name><name name-style="western"><surname>Boopathy</surname><given-names>AV</given-names></name><name name-style="western"><surname>Lam</surname><given-names>LKW</given-names></name><name name-style="western"><surname>Moynihan</surname><given-names>KD</given-names></name><name name-style="western"><surname>Welch</surname><given-names>ME</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>NR</given-names></name><etal/></person-group>. <article-title>Cell and Fluid Sampling Microneedle Patches for Monitoring Skin-Resident Immunity</article-title>. <source>Sci Transl Med</source> (<year>2018</year>) <volume>10</volume>. &#160;<pub-id pub-id-type="doi">10.1126/scitranslmed.aar2227</pub-id><pub-id pub-id-type="pmcid">PMC11972007</pub-id><pub-id pub-id-type="pmid">30429353</pub-id></mixed-citation></ref><ref id="B132"><label>132</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olaniyi</surname><given-names>RO</given-names></name><name name-style="western"><surname>Pancotto</surname><given-names>L</given-names></name><name name-style="western"><surname>Grimaldi</surname><given-names>L</given-names></name><name name-style="western"><surname>Bagnoli</surname><given-names>F</given-names></name></person-group>. <article-title>Deciphering the Pathological Role of Staphylococcal &#945;-Toxin and Panton-Valentine Leukocidin Using a Novel Ex Vivo Human Skin Model</article-title>. <source>Front Immunol</source> (<year>2018</year>) <volume>9</volume>:<elocation-id>951</elocation-id>. &#160;<pub-id pub-id-type="doi">10.3389/fimmu.2018.00951</pub-id><pub-id pub-id-type="pmid">29867940</pub-id><pub-id pub-id-type="pmcid">PMC5953321</pub-id></mixed-citation></ref><ref id="B133"><label>133</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steinstraesser</surname><given-names>L</given-names></name><name name-style="western"><surname>Sorkin</surname><given-names>M</given-names></name><name name-style="western"><surname>Niederbichler</surname><given-names>AD</given-names></name><name name-style="western"><surname>Becerikli</surname><given-names>M</given-names></name><name name-style="western"><surname>Stupka</surname><given-names>J</given-names></name><name name-style="western"><surname>Daigeler</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>A Novel Human Skin Chamber Model to Study Wound Infection Ex Vivo</article-title>. <source>Arch Dermatol Res</source> (<year>2010</year>) <volume>302</volume>:<page-range>357&#8211;65</page-range>. &#160;<pub-id pub-id-type="doi">10.1007/s00403-009-1009-8</pub-id><pub-id pub-id-type="pmcid">PMC2876270</pub-id><pub-id pub-id-type="pmid">19956960</pub-id></mixed-citation></ref><ref id="B134"><label>134</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hendriks</surname><given-names>A</given-names></name><name name-style="western"><surname>Mnich</surname><given-names>ME</given-names></name><name name-style="western"><surname>Clemente</surname><given-names>B</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>AR</given-names></name><name name-style="western"><surname>Tavarini</surname><given-names>S</given-names></name><name name-style="western"><surname>Bagnoli</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Staphylococcus aureus-Specific Tissue-Resident Memory CD4+ T Cells are Abundant in Healthy Human Skin</article-title>. <source>Front Immunol</source> (<year>2021</year>) <volume>12</volume>:<elocation-id>642711</elocation-id>. &#160;<pub-id pub-id-type="doi">10.3389/fimmu.2021.642711</pub-id><pub-id pub-id-type="pmid">33796109</pub-id><pub-id pub-id-type="pmcid">PMC8008074</pub-id></mixed-citation></ref><ref id="B135"><label>135</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clegg</surname><given-names>J</given-names></name><name name-style="western"><surname>Soldaini</surname><given-names>E</given-names></name><name name-style="western"><surname>Bagnoli</surname><given-names>F</given-names></name><name name-style="western"><surname>McLoughlin</surname><given-names>RM</given-names></name></person-group>. <article-title>Targeting Skin-Resident Memory T Cells <italic toggle="yes">via</italic> Vaccination to Combat Staphylococcus aureus Infections</article-title>. <source>Trends Immunol</source> (<year>2021</year>) <volume>42</volume>:<fpage>6</fpage>&#8211;<lpage>17</lpage>. &#160;<pub-id pub-id-type="doi">10.1016/j.it.2020.11.005</pub-id><pub-id pub-id-type="pmid">33309137</pub-id></mixed-citation></ref><ref id="B136"><label>136</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeaman</surname><given-names>MR</given-names></name><name name-style="western"><surname>Filler</surname><given-names>SG</given-names></name><name name-style="western"><surname>Chaili</surname><given-names>S</given-names></name><name name-style="western"><surname>Barr</surname><given-names>K</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Kupferwasser</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Mechanisms of NDV-3 Vaccine Efficacy in MRSA Skin Versus Invasive Infection</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2014</year>) <volume>111</volume>:<page-range>E5555&#8211;63</page-range>. &#160;<pub-id pub-id-type="doi">10.1073/pnas.1415610111</pub-id><pub-id pub-id-type="pmcid">PMC4280579</pub-id><pub-id pub-id-type="pmid">25489065</pub-id></mixed-citation></ref><ref id="B137"><label>137</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmidt</surname><given-names>CS</given-names></name><name name-style="western"><surname>White</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>AS</given-names></name><name name-style="western"><surname>Filler</surname><given-names>SG</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yeaman</surname><given-names>MR</given-names></name><etal/></person-group>. <article-title>NDV-3, a Recombinant Alum-Adjuvanted Vaccine for Candida and Staphylococcus aureus, Is Safe and Immunogenic in Healthy Adults</article-title>. <source>Vaccine</source> (<year>2012</year>) <volume>30</volume>:<page-range>7594&#8211;600</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2012.10.038</pub-id><pub-id pub-id-type="pmcid">PMC3513491</pub-id><pub-id pub-id-type="pmid">23099329</pub-id></mixed-citation></ref><ref id="B138"><label>138</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>H</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Gu</surname><given-names>J</given-names></name><name name-style="western"><surname>Jing</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Rapid and Broad Immune Efficacy of a Recombinant Five-Antigen Vaccine Against Staphylococcus aureus Infection in Animal Models</article-title>. <source>Vaccines</source> (<year>2020</year>) <volume>8</volume>. &#160;<pub-id pub-id-type="doi">10.3390/vaccines8010134</pub-id><pub-id pub-id-type="pmcid">PMC7157245</pub-id><pub-id pub-id-type="pmid">32197534</pub-id></mixed-citation></ref><ref id="B139"><label>139</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inoue</surname><given-names>M</given-names></name><name name-style="western"><surname>Yonemura</surname><given-names>T</given-names></name><name name-style="western"><surname>Baber</surname><given-names>J</given-names></name><name name-style="western"><surname>Shoji</surname><given-names>Y</given-names></name><name name-style="western"><surname>Aizawa</surname><given-names>M</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Safety, Tolerability, and Immunogenicity of a Novel 4-Antigen Staphylococcus aureus Vaccine (SA4Ag) in Healthy Japanese Adults</article-title>. <source>Hum Vaccines Immunother</source> (<year>2018</year>) <volume>14</volume>:<page-range>2682&#8211;91</page-range>. &#160;<pub-id pub-id-type="doi">10.1080/21645515.2018.1496764</pub-id><pub-id pub-id-type="pmcid">PMC6314418</pub-id><pub-id pub-id-type="pmid">30084709</pub-id></mixed-citation></ref><ref id="B140"><label>140</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Creech</surname><given-names>CB</given-names></name><name name-style="western"><surname>Frenck</surname><given-names>RW</given-names></name><name name-style="western"><surname>Sheldon</surname><given-names>EA</given-names></name><name name-style="western"><surname>Seiden</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Kankam</surname><given-names>MK</given-names></name><name name-style="western"><surname>Zito</surname><given-names>ET</given-names></name><etal/></person-group>. <article-title>Safety, Tolerability, and Immunogenicity of a Single Dose 4-Antigen or 3-Antigen Staphylococcus aureus Vaccine in Healthy Older Adults: Results of a Randomised Trial</article-title>. <source>Vaccine</source> (<year>2017</year>) <volume>35</volume>:<page-range>385&#8211;94</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2016.11.032</pub-id><pub-id pub-id-type="pmid">27866765</pub-id></mixed-citation></ref><ref id="B141"><label>141</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frenck</surname><given-names>RW</given-names></name><name name-style="western"><surname>Buddy Creech</surname><given-names>C</given-names></name><name name-style="western"><surname>Sheldon</surname><given-names>EA</given-names></name><name name-style="western"><surname>Seiden</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Kankam</surname><given-names>MK</given-names></name><name name-style="western"><surname>Baber</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Safety, Tolerability, and Immunogenicity of a 4-Antigen Staphylococcus aureus Vaccine (SA4Ag): Results From a First-in-Human Randomised, Placebo-Controlled Phase 1/2 Study</article-title>. <source>Vaccine</source> (<year>2017</year>) <volume>35</volume>:<page-range>375&#8211;84</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2016.11.010</pub-id><pub-id pub-id-type="pmid">27916408</pub-id></mixed-citation></ref><ref id="B142"><label>142</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karauzum</surname><given-names>H</given-names></name><name name-style="western"><surname>Venkatasubramaniam</surname><given-names>A</given-names></name><name name-style="western"><surname>Adhikari</surname><given-names>RP</given-names></name><name name-style="western"><surname>Kort</surname><given-names>T</given-names></name><name name-style="western"><surname>Holtsberg</surname><given-names>FW</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>IBT-V02: A Multicomponent Toxoid Vaccine Protects Against Primary and Secondary Skin Infections Caused by Staphylococcus aureus</article-title>. <source>Front Immunol</source> (<year>2021</year>) <volume>12</volume>. &#160;<pub-id pub-id-type="doi">10.3389/fimmu.2021.624310</pub-id><pub-id pub-id-type="pmcid">PMC7987673</pub-id><pub-id pub-id-type="pmid">33777005</pub-id></mixed-citation></ref><ref id="B143"><label>143</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>LS</given-names></name><name name-style="western"><surname>Fowler</surname><given-names>VG</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>SK</given-names></name><name name-style="western"><surname>Rose</surname><given-names>WE</given-names></name><name name-style="western"><surname>Proctor</surname><given-names>RA</given-names></name></person-group>. <article-title>Development of a Vaccine Against Staphylococcus aureus Invasive Infections: Evidence Based on Human Immunity, Genetics and Bacterial Evasion Mechanisms</article-title>. <source>FEMS Microbiol Rev</source> (<year>2019</year>) <volume>44</volume>:<page-range>123&#8211;53</page-range>. &#160;<pub-id pub-id-type="doi">10.1093/femsre/fuz030</pub-id><pub-id pub-id-type="pmcid">PMC7053580</pub-id><pub-id pub-id-type="pmid">31841134</pub-id></mixed-citation></ref><ref id="B144"><label>144</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spellberg</surname><given-names>B</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>AS</given-names></name><name name-style="western"><surname>Yeaman</surname><given-names>MR</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Avanesian</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>The Antifungal Vaccine Derived From the Recombinant N Terminus of Als3p Protects Mice Against the Bacterium Staphylococcus aureus</article-title>. <source>Infect Immun</source> (<year>2008</year>) <volume>76</volume>:<page-range>4574&#8211;80</page-range>. &#160;<pub-id pub-id-type="doi">10.1128/IAI.00700-08</pub-id><pub-id pub-id-type="pmcid">PMC2546811</pub-id><pub-id pub-id-type="pmid">18644876</pub-id></mixed-citation></ref><ref id="B145"><label>145</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagasawa</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kiku</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sugawara</surname><given-names>K</given-names></name><name name-style="western"><surname>Hirose</surname><given-names>A</given-names></name><name name-style="western"><surname>Kai</surname><given-names>C</given-names></name><name name-style="western"><surname>Kitano</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Staphylococcus aureus-Specific Iga Antibody in Milk Suppresses the Multiplication of S. aureus in Infected Bovine Udder</article-title>. <source>BMC Vet Res</source> (<year>2019</year>) <volume>15</volume>. &#160;<pub-id pub-id-type="doi">10.1186/s12917-019-2025-3</pub-id><pub-id pub-id-type="pmcid">PMC6688226</pub-id><pub-id pub-id-type="pmid">31399125</pub-id></mixed-citation></ref><ref id="B146"><label>146</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>MW</given-names></name><name name-style="western"><surname>Greenfield</surname><given-names>BK</given-names></name><name name-style="western"><surname>Snyder</surname><given-names>RE</given-names></name><name name-style="western"><surname>Steinmaus</surname><given-names>CM</given-names></name><name name-style="western"><surname>Riley</surname><given-names>LW</given-names></name></person-group>. <article-title>The Association Between Community-Associated Staphylococcus aureus Colonization and Disease: A Meta-Analysis</article-title>. <source>BMC Infect Dis</source> (<year>2018</year>) <volume>18</volume>. &#160;<pub-id pub-id-type="doi">10.1186/s12879-018-2990-3</pub-id><pub-id pub-id-type="pmcid">PMC5822478</pub-id><pub-id pub-id-type="pmid">29466953</pub-id></mixed-citation></ref><ref id="B147"><label>147</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wertheim</surname><given-names>HFL</given-names></name><name name-style="western"><surname>Vos</surname><given-names>MC</given-names></name><name name-style="western"><surname>Ott</surname><given-names>A</given-names></name><name name-style="western"><surname>Van Belkum</surname><given-names>A</given-names></name><name name-style="western"><surname>Voss</surname><given-names>A</given-names></name><name name-style="western"><surname>Kluytmans</surname><given-names>JAJW</given-names></name><etal/></person-group>. <article-title>Risk and Outcome of Nosocomial Staphylococcus aureus Bacteraemia in Nasal Carriers Versus Non-Carriers</article-title>. <source>Lancet</source> (<year>2004</year>) <volume>364</volume>:<page-range>703&#8211;5</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/S0140-6736(04)16897-9</pub-id><pub-id pub-id-type="pmid">15325835</pub-id></mixed-citation></ref><ref id="B148"><label>148</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goodyear</surname><given-names>CS</given-names></name><name name-style="western"><surname>Sugiyama</surname><given-names>F</given-names></name><name name-style="western"><surname>Silverman</surname><given-names>GJ</given-names></name></person-group>. <article-title>Temporal and Dose-Dependent Relationships Between In Vivo B Cell Receptor-Targeted Proliferation and Deletion-Induced by a Microbial B Cell Toxin</article-title>. <source>J Immunol</source> (<year>2006</year>) <volume>176</volume>:<page-range>2262&#8211;71</page-range>. &#160;<pub-id pub-id-type="doi">10.4049/jimmunol.176.4.2262</pub-id><pub-id pub-id-type="pmid">16455982</pub-id></mixed-citation></ref><ref id="B149"><label>149</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nygaard</surname><given-names>TK</given-names></name><name name-style="western"><surname>Pallister</surname><given-names>KB</given-names></name><name name-style="western"><surname>DuMont</surname><given-names>AL</given-names></name><name name-style="western"><surname>DeWald</surname><given-names>M</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>RL</given-names></name><name name-style="western"><surname>Pallister</surname><given-names>EQ</given-names></name><etal/></person-group>. <article-title>Alpha-Toxin Induces Programmed Cell Death of Human T Cells, B Cells, and Monocytes During USA300 Infection</article-title>. <source>PLoS One</source> (<year>2012</year>) <volume>7</volume>. &#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0036532</pub-id><pub-id pub-id-type="pmcid">PMC3344897</pub-id><pub-id pub-id-type="pmid">22574180</pub-id></mixed-citation></ref><ref id="B150"><label>150</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Becker</surname><given-names>KA</given-names></name><name name-style="western"><surname>Fahsel</surname><given-names>B</given-names></name><name name-style="western"><surname>Kemper</surname><given-names>H</given-names></name><name name-style="western"><surname>Mayeres</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Wilker</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Staphylococcus aureus Alpha-Toxin Disrupts Endothelial-Cell Tight Junctions <italic toggle="yes">via</italic> Acid Sphingomyelinase and Ceramide</article-title>. <source>Infect Immun</source> (<year>2018</year>) <volume>86</volume>. &#160;<pub-id pub-id-type="doi">10.1128/IAI.00606-17</pub-id><pub-id pub-id-type="pmcid">PMC5736828</pub-id><pub-id pub-id-type="pmid">29084896</pub-id></mixed-citation></ref><ref id="B151"><label>151</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Surewaard</surname><given-names>BGJ</given-names></name><name name-style="western"><surname>Thanabalasuriar</surname><given-names>A</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tkaczyk</surname><given-names>C</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>TS</given-names></name><name name-style="western"><surname>Bardoel</surname><given-names>BW</given-names></name><etal/></person-group>. <article-title>&#945;-Toxin Induces Platelet Aggregation and Liver Injury During Staphylococcus aureus Sepsis</article-title>. <source>Cell Host Microbe</source> (<year>2018</year>) <volume>24</volume>:<fpage>271</fpage>&#8211;<lpage>284.e3</lpage>. &#160;<pub-id pub-id-type="doi">10.1016/j.chom.2018.06.017</pub-id><pub-id pub-id-type="pmid">30033122</pub-id><pub-id pub-id-type="pmcid">PMC6295203</pub-id></mixed-citation></ref><ref id="B152"><label>152</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shenoy</surname><given-names>AT</given-names></name><name name-style="western"><surname>Wasserman</surname><given-names>GA</given-names></name><name name-style="western"><surname>Arafa</surname><given-names>EI</given-names></name><name name-style="western"><surname>Wooten</surname><given-names>AK</given-names></name><name name-style="western"><surname>Smith</surname><given-names>NMS</given-names></name><name name-style="western"><surname>Martin</surname><given-names>IMC</given-names></name><etal/></person-group>. <article-title>Lung CD4+ Resident Memory T Cells Remodel Epithelial Responses to Accelerate Neutrophil Recruitment During Pneumonia</article-title>. <source>Mucosal Immunol</source> (<year>2020</year>) <volume>13</volume>:<page-range>334&#8211;43</page-range>. &#160;<pub-id pub-id-type="doi">10.1038/s41385-019-0229-2</pub-id><pub-id pub-id-type="pmcid">PMC7044037</pub-id><pub-id pub-id-type="pmid">31748706</pub-id></mixed-citation></ref><ref id="B153"><label>153</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jansson</surname><given-names>B</given-names></name><name name-style="western"><surname>Uhl&#233;n</surname><given-names>M</given-names></name><name name-style="western"><surname>Nygren</surname><given-names>P&#197;</given-names></name></person-group>. <article-title>All Individual Domains of Staphylococcal Protein a Show Fab Binding</article-title>. <source>FEMS Immunol Med Microbiol</source> (<year>1998</year>) <volume>20</volume>:<fpage>69</fpage>&#8211;<lpage>78</lpage>. &#160;<pub-id pub-id-type="doi">10.1016/S0928-8244(97)00108-9</pub-id><pub-id pub-id-type="pmid">9514577</pub-id></mixed-citation></ref><ref id="B154"><label>154</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graille</surname><given-names>M</given-names></name><name name-style="western"><surname>Stura</surname><given-names>EA</given-names></name><name name-style="western"><surname>Corper</surname><given-names>AL</given-names></name><name name-style="western"><surname>Sutton</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Taussig</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Charbonnier</surname><given-names>JB</given-names></name><etal/></person-group>. <article-title>Crystal Structure of a Staphylococcus aureus Protein a Domain Complexed With the Fab Fragment of a Human Igm Antibody: Structural Basis for Recognition of B-Cell Receptors and Superantigen Activity</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2000</year>) <volume>97</volume>:<page-range>5399&#8211;404</page-range>. &#160;<pub-id pub-id-type="doi">10.1073/pnas.97.10.5399</pub-id><pub-id pub-id-type="pmcid">PMC25840</pub-id><pub-id pub-id-type="pmid">10805799</pub-id></mixed-citation></ref><ref id="B155"><label>155</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>William T Lee</surname><given-names>DKJ</given-names></name></person-group>. <article-title>Staphylococcal Enterotoxin B (SEB) Induces Memory CD4 T Cell Anergy <italic toggle="yes">In Vivo</italic> and Impairs Recall Immunity to Unrelated Antigens</article-title>. <source>J Clin Cell Immunol</source> (<year>2015</year>) <volume>06</volume>:<fpage>1</fpage>&#8211;<lpage>8</lpage>. &#160;<pub-id pub-id-type="doi">10.4172/2155-9899.1000346</pub-id><pub-id pub-id-type="pmcid">PMC4720977</pub-id><pub-id pub-id-type="pmid">26807307</pub-id></mixed-citation></ref><ref id="B156"><label>156</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nishitani</surname><given-names>K</given-names></name><name name-style="western"><surname>Beck</surname><given-names>CA</given-names></name><name name-style="western"><surname>Rosenberg</surname><given-names>AF</given-names></name><name name-style="western"><surname>Kates</surname><given-names>SL</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>EM</given-names></name><name name-style="western"><surname>Daiss</surname><given-names>JL</given-names></name></person-group>. <article-title>A Diagnostic Serum Antibody Test for Patients With Staphylococcus aureus Osteomyelitis</article-title>. <source>Clin Orthop Relat Res</source> (<year>2015</year>) <volume>473</volume>:<page-range>2735&#8211;49</page-range>. &#160;<pub-id pub-id-type="doi">10.1007/s11999-015-4354-2</pub-id><pub-id pub-id-type="pmcid">PMC4523516</pub-id><pub-id pub-id-type="pmid">26013151</pub-id></mixed-citation></ref><ref id="B157"><label>157</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aman</surname><given-names>MJ</given-names></name></person-group>. <article-title>Integrated Biotherapeutics</article-title>. <source>Hum Vaccines Immunother</source> (<year>2018</year>) <volume>14</volume>:<page-range>1308&#8211;10</page-range>. &#160;<pub-id pub-id-type="doi">10.1080/21645515.2018.1440105</pub-id><pub-id pub-id-type="pmcid">PMC6037449</pub-id><pub-id pub-id-type="pmid">29641293</pub-id></mixed-citation></ref><ref id="B158"><label>158</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>WH</given-names></name><name name-style="western"><surname>Pasetti</surname><given-names>MF</given-names></name><name name-style="western"><surname>Adhikari</surname><given-names>RP</given-names></name><name name-style="western"><surname>Baughman</surname><given-names>H</given-names></name><name name-style="western"><surname>Douglas</surname><given-names>R</given-names></name><name name-style="western"><surname>El-Khorazaty</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Safety and Immunogenicity of a Parenterally Administered, Structure-Based Rationally Modified Recombinant Staphylococcal Enterotoxin B Protein Vaccine, Stebvax</article-title>. <source>Clin Vaccine Immunol</source> (<year>2016</year>) <volume>23</volume>:<page-range>918&#8211;25</page-range>. &#160;<pub-id pub-id-type="doi">10.1128/CVI.00399-16</pub-id><pub-id pub-id-type="pmcid">PMC5139602</pub-id><pub-id pub-id-type="pmid">27707765</pub-id></mixed-citation></ref><ref id="B159"><label>159</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>FD</given-names></name><name name-style="western"><surname>Chen</surname><given-names>YY</given-names></name><name name-style="western"><surname>Chen</surname><given-names>TL</given-names></name><name name-style="western"><surname>Liu</surname><given-names>CY</given-names></name></person-group>. <article-title>Risk Factors and Mortality in Patients With Nosocomial Staphylococcus aureus Bacteremia</article-title>. <source>Am J Infect Control</source> (<year>2008</year>) <volume>36</volume>:<page-range>118&#8211;22</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.ajic.2007.02.005</pub-id><pub-id pub-id-type="pmid">18313513</pub-id></mixed-citation></ref><ref id="B160"><label>160</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Bayer</surname><given-names>A</given-names></name><name name-style="western"><surname>Cosgrove</surname><given-names>SE</given-names></name><name name-style="western"><surname>Daum</surname><given-names>RS</given-names></name><name name-style="western"><surname>Fridkin</surname><given-names>SK</given-names></name><name name-style="western"><surname>Gorwitz</surname><given-names>RJ</given-names></name><etal/></person-group>. <article-title>Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children</article-title>. <source>Clin Infect Dis</source> (<year>2011</year>) <volume>52</volume>. &#160;<pub-id pub-id-type="doi">10.1093/cid/ciq146</pub-id><pub-id pub-id-type="pmid">21208910</pub-id></mixed-citation></ref><ref id="B161"><label>161</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group>. <article-title>2019 Antibacterial Agents in Clinical Development: An Analysis of the Antibacterial Clinical Development Pipeline</article-title>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name> (<year>2019</year>).</mixed-citation></ref><ref id="B162"><label>162</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Organization</surname><given-names>WH</given-names></name></person-group>. <article-title>Antibacterial Agents in Preclinical Development: An Open Access Database</article-title>. <publisher-name>World Health Organization</publisher-name> (<year>2019</year>) p. <fpage>20</fpage>.</mixed-citation></ref><ref id="B163"><label>163</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>C</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H</given-names></name><name name-style="western"><surname>Baruch</surname><given-names>A</given-names></name><name name-style="western"><surname>Lewin-Koh</surname><given-names>N</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M</given-names></name><name name-style="western"><surname>Guo</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Sustained Activity of Novel THIOMAB Antibody-Antibiotic Conjugate Against Staphylococcus aureus in a Mouse Model: Longitudinal Pharmacodynamic Assessment by Bioluminescence Imaging</article-title>. <source>PLoS One</source> (<year>2019</year>) <volume>14</volume>. &#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0224096</pub-id><pub-id pub-id-type="pmcid">PMC6818770</pub-id><pub-id pub-id-type="pmid">31661493</pub-id></mixed-citation></ref><ref id="B164"><label>164</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lehar</surname><given-names>SM</given-names></name><name name-style="western"><surname>Pillow</surname><given-names>T</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M</given-names></name><name name-style="western"><surname>Staben</surname><given-names>L</given-names></name><name name-style="western"><surname>Kajihara</surname><given-names>KK</given-names></name><name name-style="western"><surname>Vandlen</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Novel Antibody-Antibiotic Conjugate Eliminates Intracellular S. aureus</article-title>. <source>Nature</source> (<year>2015</year>) <volume>527</volume>:<page-range>323&#8211;8</page-range>. &#160;<pub-id pub-id-type="doi">10.1038/nature16057</pub-id><pub-id pub-id-type="pmid">26536114</pub-id></mixed-citation></ref><ref id="B165"><label>165</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peck</surname><given-names>M</given-names></name><name name-style="western"><surname>Rothenberg</surname><given-names>ME</given-names></name><name name-style="western"><surname>Deng</surname><given-names>R</given-names></name><name name-style="western"><surname>Lewin-Koh</surname><given-names>N</given-names></name><name name-style="western"><surname>She</surname><given-names>G</given-names></name><name name-style="western"><surname>Kamath</surname><given-names>AV</given-names></name><etal/></person-group>. <article-title>A Phase 1, Randomized, Single-Ascending-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S, an Anti-Staphylococcus aureus Thiomab Antibody-Antibiotic Conjugate, in Healthy Volunteers</article-title>. <source>Antimicrob Agents Chemother</source> (<year>2019</year>) <volume>63</volume>. &#160;<pub-id pub-id-type="doi">10.1128/AAC.02588-18</pub-id><pub-id pub-id-type="pmcid">PMC6535527</pub-id><pub-id pub-id-type="pmid">30910894</pub-id></mixed-citation></ref><ref id="B166"><label>166</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geriak</surname><given-names>M</given-names></name><name name-style="western"><surname>Haddad</surname><given-names>F</given-names></name><name name-style="western"><surname>Rizvi</surname><given-names>K</given-names></name><name name-style="western"><surname>Rose</surname><given-names>W</given-names></name><name name-style="western"><surname>Kullar</surname><given-names>R</given-names></name><name name-style="western"><surname>LaPlante</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Clinical Data on Daptomycin Plus Ceftaroline Versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia</article-title>. <source>Antimicrob Agents Chemother</source> (<year>2019</year>) <volume>63</volume>. &#160;<pub-id pub-id-type="doi">10.1128/AAC.02483-18</pub-id><pub-id pub-id-type="pmcid">PMC6496065</pub-id><pub-id pub-id-type="pmid">30858203</pub-id></mixed-citation></ref><ref id="B167"><label>167</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakoulas</surname><given-names>G</given-names></name><name name-style="western"><surname>Okumura</surname><given-names>CY</given-names></name><name name-style="western"><surname>Thienphrapa</surname><given-names>W</given-names></name><name name-style="western"><surname>Olson</surname><given-names>J</given-names></name><name name-style="western"><surname>Nonejuie</surname><given-names>P</given-names></name><name name-style="western"><surname>Dam</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>Nafcillin Enhances Innate Immune-Mediated Killing of Methicillin-Resistant Staphylococcus aureus</article-title>. <source>J Mol Med</source> (<year>2014</year>) <volume>92</volume>:<page-range>139&#8211;49</page-range>. &#160;<pub-id pub-id-type="doi">10.1007/s00109-013-1100-7</pub-id><pub-id pub-id-type="pmcid">PMC3926703</pub-id><pub-id pub-id-type="pmid">24297496</pub-id></mixed-citation></ref><ref id="B168"><label>168</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mezey</surname><given-names>&#201;</given-names></name><name name-style="western"><surname>Nemeth</surname><given-names>K</given-names></name></person-group>. <article-title>Mesenchymal Stem Cells and Infectious Diseases: Smarter Than Drugs</article-title>. <source>Immunol Lett</source> (<year>2015</year>) <volume>168</volume>:<page-range>208&#8211;14</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.imlet.2015.05.020</pub-id><pub-id pub-id-type="pmid">26051681</pub-id></mixed-citation></ref><ref id="B169"><label>169</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>Y</given-names></name><name name-style="western"><surname>lin</surname><given-names>S</given-names></name><name name-style="western"><surname>Guo</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>C</given-names></name><name name-style="western"><surname>Shen</surname><given-names>S</given-names></name><name name-style="western"><surname>Bu</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Marrow Mesenchymal Stromal Cells Reduce Methicillin-Resistant Staphylococcus aureus Infection in Rat Models</article-title>. <source>Cytotherapy</source> (<year>2014</year>) <volume>16</volume>:<fpage>56</fpage>&#8211;<lpage>63</lpage>. &#160;<pub-id pub-id-type="doi">10.1016/j.jcyt.2013.06.002</pub-id><pub-id pub-id-type="pmid">23993644</pub-id></mixed-citation></ref><ref id="B170"><label>170</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoshitani</surname><given-names>J</given-names></name><name name-style="western"><surname>Kabata</surname><given-names>T</given-names></name><name name-style="western"><surname>Arakawa</surname><given-names>H</given-names></name><name name-style="western"><surname>Kato</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nojima</surname><given-names>T</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Combinational Therapy With Antibiotics and Antibiotic-Loaded Adipose-Derived Stem Cells Reduce Abscess Formation in Implant-Related Infection in Rats</article-title>. <source>Sci Rep</source> (<year>2020</year>) <volume>10</volume>. &#160;<pub-id pub-id-type="doi">10.1038/s41598-020-68184-y</pub-id><pub-id pub-id-type="pmcid">PMC7341734</pub-id><pub-id pub-id-type="pmid">32636453</pub-id></mixed-citation></ref><ref id="B171"><label>171</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>CT</given-names></name><name name-style="western"><surname>Sok</surname><given-names>MCP</given-names></name><name name-style="western"><surname>Martin</surname><given-names>KE</given-names></name><name name-style="western"><surname>Kalelkar</surname><given-names>PP</given-names></name><name name-style="western"><surname>Caplin</surname><given-names>JD</given-names></name><name name-style="western"><surname>Botchwey</surname><given-names>EA</given-names></name><etal/></person-group>. <article-title>Lysostaphin and BMP-2 Co-Delivery Reduces S. aureus Infection and Regenerates Critical-Sized Segmental Bone Defects</article-title>. <source>Sci Adv</source> (<year>2019</year>) <volume>5</volume>. &#160;<pub-id pub-id-type="doi">10.1126/sciadv.aaw1228</pub-id><pub-id pub-id-type="pmcid">PMC6524983</pub-id><pub-id pub-id-type="pmid">31114804</pub-id></mixed-citation></ref><ref id="B172"><label>172</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hussain</surname><given-names>S</given-names></name><name name-style="western"><surname>Joo</surname><given-names>J</given-names></name><name name-style="western"><surname>Kang</surname><given-names>J</given-names></name><name name-style="western"><surname>Kim</surname><given-names>B</given-names></name><name name-style="western"><surname>Braun</surname><given-names>GB</given-names></name><name name-style="western"><surname>She</surname><given-names>ZG</given-names></name><etal/></person-group>. <article-title>Antibiotic-Loaded Nanoparticles Targeted to the Site of Infection Enhance Antibacterial Efficacy</article-title>. <source>Nat BioMed Eng</source> (<year>2018</year>) <volume>2</volume>:<fpage>95</fpage>&#8211;<lpage>103</lpage>. &#160;<pub-id pub-id-type="doi">10.1038/s41551-017-0187-5</pub-id><pub-id pub-id-type="pmid">29955439</pub-id><pub-id pub-id-type="pmcid">PMC6015743</pub-id></mixed-citation></ref><ref id="B173"><label>173</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lara</surname><given-names>HH</given-names></name><name name-style="western"><surname>Lopez-Ribot</surname><given-names>JL</given-names></name></person-group>. <article-title>Inhibition of Mixed Biofilms of Candida Albicans and Methicillin-Resistant Staphylococcus aureus by Positively Charged Silver Nanoparticles and Functionalized Silicone Elastomers</article-title>. <source>Pathogens</source> (<year>2020</year>) <volume>9</volume>:<fpage>1</fpage>&#8211;<lpage>14</lpage>. &#160;<pub-id pub-id-type="doi">10.3390/pathogens9100784</pub-id><pub-id pub-id-type="pmcid">PMC7600790</pub-id><pub-id pub-id-type="pmid">32992727</pub-id></mixed-citation></ref><ref id="B174"><label>174</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kong</surname><given-names>EF</given-names></name><name name-style="western"><surname>Tsui</surname><given-names>C</given-names></name><name name-style="western"><surname>Kuchar&#237;kov&#225;</surname><given-names>S</given-names></name><name name-style="western"><surname>Andes</surname><given-names>D</given-names></name><name name-style="western"><surname>Van Dijck</surname><given-names>P</given-names></name><name name-style="western"><surname>Jabra-Rizk</surname><given-names>MA</given-names></name></person-group>. <article-title>Commensal Protection of Staphylococcus aureus Against Antimicrobials by Candida Albicans Biofilm Matrix</article-title>. <source>MBio</source> (<year>2016</year>) <volume>7</volume>. &#160;<pub-id pub-id-type="doi">10.1128/mBio.01365-16</pub-id><pub-id pub-id-type="pmcid">PMC5061872</pub-id><pub-id pub-id-type="pmid">27729510</pub-id></mixed-citation></ref><ref id="B175"><label>175</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watts</surname><given-names>G</given-names></name></person-group>. <article-title>Phage Therapy: Revival of the Bygone Antimicrobial</article-title>. <source>Lancet (Lond Engl)</source> (<year>2017</year>) <volume>390</volume>:<page-range>2539&#8211;40</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/S0140-6736(17)33249-X</pub-id><pub-id pub-id-type="pmid">29231827</pub-id></mixed-citation></ref><ref id="B176"><label>176</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jun</surname><given-names>SY</given-names></name><name name-style="western"><surname>Jung</surname><given-names>GM</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Oh</surname><given-names>MD</given-names></name><name name-style="western"><surname>Choi</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Lee</surname><given-names>WJ</given-names></name><etal/></person-group>. <article-title>Antibacterial Properties of a Pre-Formulated Recombinant Phage Endolysin, SAL-1</article-title>. <source>Int J Antimicrob Agents</source> (<year>2013</year>) <volume>41</volume>:<page-range>156&#8211;61</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.ijantimicag.2012.10.011</pub-id><pub-id pub-id-type="pmid">23276502</pub-id></mixed-citation></ref><ref id="B177"><label>177</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>NH</given-names></name><name name-style="western"><surname>Park</surname><given-names>WB</given-names></name><name name-style="western"><surname>Cho</surname><given-names>JE</given-names></name><name name-style="western"><surname>Choi</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Choi</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Jun</surname><given-names>SY</given-names></name><etal/></person-group>. <article-title>Effects of Phage Endolysin SAL200 Combined With Antibiotics on Staphylococcus aureus Infection</article-title>. <source>Antimicrob Agents Chemother</source> (<year>2018</year>) <volume>62</volume>. &#160;<pub-id pub-id-type="doi">10.1128/AAC.00731-18</pub-id><pub-id pub-id-type="pmcid">PMC6153796</pub-id><pub-id pub-id-type="pmid">30038042</pub-id></mixed-citation></ref><ref id="B178"><label>178</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jun</surname><given-names>SY</given-names></name><name name-style="western"><surname>Jang</surname><given-names>IJ</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>S</given-names></name><name name-style="western"><surname>Jang</surname><given-names>K</given-names></name><name name-style="western"><surname>Yu</surname><given-names>KS</given-names></name><name name-style="western"><surname>Cho</surname><given-names>JY</given-names></name><etal/></person-group>. <article-title>Pharmacokinetics and Tolerance of the Phage Endolysin-Based Candidate Drug SAL200 After a Single Intravenous Administration Among Healthy Volunteers</article-title>. <source>Antimicrob Agents Chemother</source> (<year>2017</year>) <volume>61</volume>. &#160;<pub-id pub-id-type="doi">10.1128/AAC.02629-16</pub-id><pub-id pub-id-type="pmcid">PMC5444177</pub-id><pub-id pub-id-type="pmid">28348152</pub-id></mixed-citation></ref><ref id="B179"><label>179</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fowler</surname><given-names>VG</given-names></name><name name-style="western"><surname>Das</surname><given-names>AF</given-names></name><name name-style="western"><surname>Lipka-Diamond</surname><given-names>J</given-names></name><name name-style="western"><surname>Schuch</surname><given-names>R</given-names></name><name name-style="western"><surname>Pomerantz</surname><given-names>R</given-names></name><name name-style="western"><surname>J&#225;uregui-Peredo</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Exebacase for Patients With Staphylococcus aureus Bloodstream Infection and Endocarditis</article-title>. <source>J Clin Invest</source> (<year>2020</year>) <volume>130</volume>:<page-range>3750&#8211;60</page-range>. &#160;<pub-id pub-id-type="doi">10.1172/JCI136577</pub-id><pub-id pub-id-type="pmcid">PMC7324170</pub-id><pub-id pub-id-type="pmid">32271718</pub-id></mixed-citation></ref><ref id="B180"><label>180</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ooi</surname><given-names>ML</given-names></name><name name-style="western"><surname>Drilling</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Morales</surname><given-names>S</given-names></name><name name-style="western"><surname>Fong</surname><given-names>S</given-names></name><name name-style="western"><surname>Moraitis</surname><given-names>S</given-names></name><name name-style="western"><surname>MacIas-Valle</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Safety and Tolerability of Bacteriophage Therapy for Chronic Rhinosinusitis Due to Staphylococcus aureus</article-title>. <source>JAMA Otolaryngol - Head Neck Surg</source> (<year>2019</year>) <volume>145</volume>:<page-range>723&#8211;9</page-range>. &#160;<pub-id pub-id-type="doi">10.1001/jamaoto.2019.1191</pub-id><pub-id pub-id-type="pmcid">PMC6587246</pub-id><pub-id pub-id-type="pmid">31219531</pub-id></mixed-citation></ref><ref id="B181"><label>181</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petrovic Fabijan</surname><given-names>A</given-names></name><name name-style="western"><surname>Lin</surname><given-names>RCY</given-names></name><name name-style="western"><surname>Ho</surname><given-names>J</given-names></name><name name-style="western"><surname>Maddocks</surname><given-names>S</given-names></name><name name-style="western"><surname>Ben Zakour</surname><given-names>NL</given-names></name><name name-style="western"><surname>Iredell</surname><given-names>JR</given-names></name><etal/></person-group>. <article-title>Safety of Bacteriophage Therapy in Severe Staphylococcus aureus Infection</article-title>. <source>Nat Microbiol</source> (<year>2020</year>) <volume>5</volume>:<page-range>465&#8211;72</page-range>. &#160;<pub-id pub-id-type="doi">10.1038/s41564-019-0634-z</pub-id><pub-id pub-id-type="pmid">32066959</pub-id></mixed-citation></ref><ref id="B182"><label>182</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kolenda</surname><given-names>C</given-names></name><name name-style="western"><surname>Josse</surname><given-names>J</given-names></name><name name-style="western"><surname>Medina</surname><given-names>M</given-names></name><name name-style="western"><surname>Fevre</surname><given-names>C</given-names></name><name name-style="western"><surname>Lustig</surname><given-names>S</given-names></name><name name-style="western"><surname>Ferry</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Evaluation of the Activity of a Combination of Three Bacteriophages Alone or in Association With Antibiotics on Staphylococcus aureus Embedded in Biofilm or Internalized in Osteoblasts</article-title>. <source>Antimicrob Agents Chemother</source> (<year>2020</year>) <volume>64</volume>. &#160;<pub-id pub-id-type="doi">10.1128/AAC.02231-19</pub-id><pub-id pub-id-type="pmcid">PMC7038305</pub-id><pub-id pub-id-type="pmid">31871084</pub-id></mixed-citation></ref><ref id="B183"><label>183</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeJonge</surname><given-names>M</given-names></name><name name-style="western"><surname>Burchfield</surname><given-names>D</given-names></name><name name-style="western"><surname>Bloom</surname><given-names>B</given-names></name><name name-style="western"><surname>Duenas</surname><given-names>M</given-names></name><name name-style="western"><surname>Walker</surname><given-names>W</given-names></name><name name-style="western"><surname>Polak</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Clinical Trial of Safety and Efficacy of IHN-A21 for the Prevention of Nosocomial Staphylococcal Bloodstream Infection in Premature Infants</article-title>. <source>J Pediatr</source> (<year>2007</year>) <volume>151</volume>:<fpage>260</fpage>&#8211;<lpage>265</lpage>. &#160;<pub-id pub-id-type="doi">10.1016/j.jpeds.2007.04.060</pub-id><pub-id pub-id-type="pmid">17719934</pub-id></mixed-citation></ref><ref id="B184"><label>184</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>M</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>DA</given-names></name></person-group>. <article-title>Anti-Lipoteichoic Acid Monoclonal Antibody (Pagibaximab) Studies for the Prevention of Staphylococcal Bloodstream Infections in Preterm Infants</article-title>. <source>Expert Opin Biol Ther</source> (<year>2015</year>) <volume>15</volume>:<fpage>595</fpage>&#8211;<lpage>600</lpage>. &#160;<pub-id pub-id-type="doi">10.1517/14712598.2015.1019857</pub-id><pub-id pub-id-type="pmid">25736524</pub-id></mixed-citation></ref><ref id="B185"><label>185</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rupp</surname><given-names>ME</given-names></name><name name-style="western"><surname>Holley</surname><given-names>HP</given-names></name><name name-style="western"><surname>Lutz</surname><given-names>J</given-names></name><name name-style="western"><surname>Dicpinigaitis</surname><given-names>PV</given-names></name><name name-style="western"><surname>Woods</surname><given-names>CW</given-names></name><name name-style="western"><surname>Levine</surname><given-names>DP</given-names></name><etal/></person-group>. <article-title>Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial of a Polyclonal Anti-Staphylococcus aureus Capsular Polysaccharide Immune Globulin in Treatment of Staphylococcus aureus Bacteremia</article-title>. <source>Antimicrob Agents Chemother</source> (<year>2007</year>) <volume>51</volume>:<page-range>4249&#8211;54</page-range>. &#160;<pub-id pub-id-type="doi">10.1128/AAC.00570-07</pub-id><pub-id pub-id-type="pmcid">PMC2168017</pub-id><pub-id pub-id-type="pmid">17893153</pub-id></mixed-citation></ref><ref id="B186"><label>186</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stryjewski</surname><given-names>ME</given-names></name><name name-style="western"><surname>Lentnek</surname><given-names>A</given-names></name><name name-style="western"><surname>O&#8217;Riordan</surname><given-names>W</given-names></name><name name-style="western"><surname>Pullman</surname><given-names>J</given-names></name><name name-style="western"><surname>Tambyah</surname><given-names>PA</given-names></name><name name-style="western"><surname>Mir&#243;</surname><given-names>JM</given-names></name><etal/></person-group>. <article-title>A Randomized Phase 2 Trial of Telavancin Versus Standard Therapy in Patients With Uncomplicated Staphylococcus aureus Bacteremia: The ASSURE Study</article-title>. <source>BMC Infect Dis</source> (<year>2014</year>) <volume>14</volume>. &#160;<pub-id pub-id-type="doi">10.1186/1471-2334-14-289</pub-id><pub-id pub-id-type="pmcid">PMC4048626</pub-id><pub-id pub-id-type="pmid">24884578</pub-id></mixed-citation></ref><ref id="B187"><label>187</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magyarics</surname><given-names>Z</given-names></name><name name-style="western"><surname>Leslie</surname><given-names>F</given-names></name><name name-style="western"><surname>Bartko</surname><given-names>J</given-names></name><name name-style="western"><surname>Rouha</surname><given-names>H</given-names></name><name name-style="western"><surname>Luperchio</surname><given-names>S</given-names></name><name name-style="western"><surname>Sch&#246;rgenhofer</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study of the Penetration of a Monoclonal Antibody Combination (ASN100) Targeting Staphylococcus aureus Cytotoxins in the Lung Epithelial Lining Fluid of Healthy Volunteers</article-title>. <source>Antimicrob Agents Chemother</source> (<year>2019</year>) <volume>63</volume>. &#160;<pub-id pub-id-type="doi">10.1128/AAC.00350-19</pub-id><pub-id pub-id-type="pmcid">PMC6658777</pub-id><pub-id pub-id-type="pmid">31138568</pub-id></mixed-citation></ref><ref id="B188"><label>188</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fran&#231;ois</surname><given-names>B</given-names></name><name name-style="western"><surname>Mercier</surname><given-names>E</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>C</given-names></name><name name-style="western"><surname>Asehnoune</surname><given-names>K</given-names></name><name name-style="western"><surname>Nseir</surname><given-names>S</given-names></name><name name-style="western"><surname>Fiancette</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Safety and Tolerability of a Single Administration of AR-301, a Human Monoclonal Antibody, in ICU Patients With Severe Pneumonia Caused by Staphylococcus aureus: First-in-Human Trial</article-title>. <source>Intensive Care Med</source> (<year>2018</year>) <volume>44</volume>:<page-range>1787&#8211;96</page-range>. &#160;<pub-id pub-id-type="doi">10.1007/s00134-018-5229-2</pub-id><pub-id pub-id-type="pmid">30343314</pub-id></mixed-citation></ref><ref id="B189"><label>189</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fran&#231;ois</surname><given-names>B</given-names></name><name name-style="western"><surname>Garcia Sanchez</surname><given-names>M</given-names></name><name name-style="western"><surname>Eggimann</surname><given-names>P</given-names></name><name name-style="western"><surname>Dequin</surname><given-names>P-F</given-names></name><name name-style="western"><surname>Laterre</surname><given-names>P-F</given-names></name><name name-style="western"><surname>Huberlant</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Efficacy and Safety Profile of Suvratoxumab, a Novel Anti-Staphylococcus aureus Monoclonal Antibody: Results of the SAATELLITE Study in Mechanically Ventilated Intensive Care Unit Patients</article-title>. <source>29th Eur Congr Clin Microbiol Infect Dis Amsterdam</source> (<year>2019</year>).</mixed-citation></ref><ref id="B190"><label>190</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huynh</surname><given-names>T</given-names></name><name name-style="western"><surname>Stecher</surname><given-names>M</given-names></name><name name-style="western"><surname>Mckinnon</surname><given-names>J</given-names></name><name name-style="western"><surname>Jung</surname><given-names>N</given-names></name><name name-style="western"><surname>Rupp</surname><given-names>ME</given-names></name></person-group>. <article-title>Safety and Tolerability of 514G3, a True Human Anti-Protein a Monoclonal Antibody for the Treatment of S. aureus Bacteremia</article-title>. <source>Open Forum Infect Dis</source> (<year>2016</year>) <volume>3</volume>. &#160;<pub-id pub-id-type="doi">10.1093/ofid/ofw172.1057</pub-id></mixed-citation></ref><ref id="B191"><label>191</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tkaczyk</surname><given-names>C</given-names></name><name name-style="western"><surname>Semenova</surname><given-names>E</given-names></name><name name-style="western"><surname>Shi</surname><given-names>YY</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>K</given-names></name><name name-style="western"><surname>Oganesyan</surname><given-names>V</given-names></name><name name-style="western"><surname>Warrener</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Alanine Scanning Mutagenesis of the MEDI4893 (Suvratoxumab) Epitope Reduces Alpha Toxin Lytic Activity <italic toggle="yes">In Vitro</italic> and Staphylococcus aureus Fitness in Infection Models</article-title>. <source>Antimicrob Agents Chemother</source> (<year>2018</year>) <volume>62</volume>. &#160;<pub-id pub-id-type="doi">10.1128/AAC.01033-18</pub-id><pub-id pub-id-type="pmcid">PMC6201083</pub-id><pub-id pub-id-type="pmid">30150481</pub-id></mixed-citation></ref><ref id="B192"><label>192</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>XQ</given-names></name><name name-style="western"><surname>Robbie</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Esser</surname><given-names>MT</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>K</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>HI</given-names></name><etal/></person-group>. <article-title>Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults</article-title>. <source>Antimicrob Agents Chemother</source> (<year>2017</year>) <volume>61</volume>. &#160;<pub-id pub-id-type="doi">10.1128/AAC.01020-16</pub-id><pub-id pub-id-type="pmcid">PMC5192133</pub-id><pub-id pub-id-type="pmid">27795368</pub-id></mixed-citation></ref><ref id="B193"><label>193</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rouha</surname><given-names>H</given-names></name><name name-style="western"><surname>Badarau</surname><given-names>A</given-names></name><name name-style="western"><surname>Visram</surname><given-names>ZC</given-names></name><name name-style="western"><surname>Battles</surname><given-names>MB</given-names></name><name name-style="western"><surname>Prinz</surname><given-names>B</given-names></name><name name-style="western"><surname>Magyarics</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Five Birds, One Stone: Neutralization of &#945;-Hemolysin and 4 Bi-Component Leukocidins of Staphylococcus aureus With a Single Human Monoclonal Antibody</article-title>. <source>MAbs</source> (<year>2015</year>) <volume>7</volume>:<page-range>243&#8211;54</page-range>. &#160;<pub-id pub-id-type="doi">10.4161/19420862.2014.985132</pub-id><pub-id pub-id-type="pmcid">PMC5045134</pub-id><pub-id pub-id-type="pmid">25523282</pub-id></mixed-citation></ref><ref id="B194"><label>194</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rouha</surname><given-names>H</given-names></name><name name-style="western"><surname>Weber</surname><given-names>S</given-names></name><name name-style="western"><surname>Janesch</surname><given-names>P</given-names></name><name name-style="western"><surname>Maierhofer</surname><given-names>B</given-names></name><name name-style="western"><surname>Gross</surname><given-names>K</given-names></name><name name-style="western"><surname>Dolezilkova</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Disarming Staphylococcus aureus From Destroying Human Cells by Simultaneously Neutralizing Six Cytotoxins With Two Human Monoclonal Antibodies</article-title>. <source>Virulence</source> (<year>2018</year>) <volume>9</volume>:<page-range>231&#8211;47</page-range>. &#160;<pub-id pub-id-type="doi">10.1080/21505594.2017.1391447</pub-id><pub-id pub-id-type="pmcid">PMC5955178</pub-id><pub-id pub-id-type="pmid">29099326</pub-id></mixed-citation></ref><ref id="B195"><label>195</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diep</surname><given-names>BA</given-names></name><name name-style="western"><surname>Le</surname><given-names>VTM</given-names></name><name name-style="western"><surname>Visram</surname><given-names>ZC</given-names></name><name name-style="western"><surname>Rouha</surname><given-names>H</given-names></name><name name-style="western"><surname>Stulik</surname><given-names>L</given-names></name><name name-style="western"><surname>Dip</surname><given-names>EC</given-names></name><etal/></person-group>. <article-title>Improved Protection in a Rabbit Model of Community-Associated Methicillin-Resistant Staphylococcus aureus Necrotizing Pneumonia Upon Neutralization of Leukocidins in Addition to Alpha-Hemolysin</article-title>. <source>Antimicrob Agents Chemother</source> (<year>2016</year>) <volume>60</volume>:<page-range>6333&#8211;40</page-range>. &#160;<pub-id pub-id-type="doi">10.1128/AAC.01213-16</pub-id><pub-id pub-id-type="pmcid">PMC5038318</pub-id><pub-id pub-id-type="pmid">27527081</pub-id></mixed-citation></ref><ref id="B196"><label>196</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Loghem</surname><given-names>E</given-names></name><name name-style="western"><surname>Frangione</surname><given-names>B</given-names></name><name name-style="western"><surname>Recht</surname><given-names>B</given-names></name><name name-style="western"><surname>Franklin</surname><given-names>EC</given-names></name></person-group>. <article-title>Staphylococcal Protein a and Human Igg Subclasses and Allotypes</article-title>. <source>Scand J Immunol</source> (<year>1982</year>) <volume>15</volume>:<page-range>275&#8211;8</page-range>. &#160;<pub-id pub-id-type="doi">10.1111/j.1365-3083.1982.tb00649.x</pub-id><pub-id pub-id-type="pmid">7089488</pub-id></mixed-citation></ref><ref id="B197"><label>197</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varshney</surname><given-names>AK</given-names></name><name name-style="western"><surname>Kuzmicheva</surname><given-names>GA</given-names></name><name name-style="western"><surname>Lin</surname><given-names>JB</given-names></name><name name-style="western"><surname>Sunley</surname><given-names>KM</given-names></name><name name-style="western"><surname>Bowling</surname><given-names>RA</given-names></name><name name-style="western"><surname>Kwan</surname><given-names>TY</given-names></name><etal/></person-group>. <article-title>A Natural Human Monoclonal Antibody Targeting Staphylococcus Protein a Protects Against Staphylococcus aureus Bacteremia</article-title>. <source>PLoS One</source> (<year>2018</year>) <volume>13</volume>. &#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0190537</pub-id><pub-id pub-id-type="pmcid">PMC5783355</pub-id><pub-id pub-id-type="pmid">29364906</pub-id></mixed-citation></ref><ref id="B198"><label>198</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pelegrin</surname><given-names>M</given-names></name><name name-style="western"><surname>Naranjo-Gomez</surname><given-names>M</given-names></name><name name-style="western"><surname>Piechaczyk</surname><given-names>M</given-names></name></person-group>. <article-title>Antiviral Monoclonal Antibodies: Can They be More Than Simple Neutralizing Agents</article-title>? <source>Trends Microbiol</source> (<year>2015</year>) <volume>23</volume>:<page-range>653&#8211;65</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.tim.2015.07.005</pub-id><pub-id pub-id-type="pmcid">PMC7127033</pub-id><pub-id pub-id-type="pmid">26433697</pub-id></mixed-citation></ref><ref id="B199"><label>199</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diem</surname><given-names>MD</given-names></name><name name-style="western"><surname>Hyun</surname><given-names>L</given-names></name><name name-style="western"><surname>Yi</surname><given-names>F</given-names></name><name name-style="western"><surname>Hippensteel</surname><given-names>R</given-names></name><name name-style="western"><surname>Kuhar</surname><given-names>E</given-names></name><name name-style="western"><surname>Lowenstein</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Selection of High-Affinity Centyrin FN3 Domains From a Simple Library Diversified at a Combination of Strand and Loop Positions</article-title>. <source>Protein Eng Des Sel</source> (<year>2014</year>) <volume>27</volume>:<page-range>419&#8211;29</page-range>. &#160;<pub-id pub-id-type="doi">10.1093/protein/gzu016</pub-id><pub-id pub-id-type="pmid">24786107</pub-id></mixed-citation></ref><ref id="B200"><label>200</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacobs</surname><given-names>SA</given-names></name><name name-style="western"><surname>Diem</surname><given-names>MD</given-names></name><name name-style="western"><surname>Luo</surname><given-names>J</given-names></name><name name-style="western"><surname>Teplyakov</surname><given-names>A</given-names></name><name name-style="western"><surname>Obmolova</surname><given-names>G</given-names></name><name name-style="western"><surname>Malia</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Design of Novel FN3 Domains With High Stability by a Consensus Sequence Approach</article-title>. <source>Protein Eng Des Sel</source> (<year>2012</year>) <volume>25</volume>:<page-range>107&#8211;17</page-range>. &#160;<pub-id pub-id-type="doi">10.1093/protein/gzr064</pub-id><pub-id pub-id-type="pmid">22240293</pub-id></mixed-citation></ref><ref id="B201"><label>201</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>R</given-names></name><name name-style="western"><surname>Buckley</surname><given-names>PT</given-names></name><name name-style="western"><surname>O&#8217;Malley</surname><given-names>A</given-names></name><name name-style="western"><surname>Sause</surname><given-names>WE</given-names></name><name name-style="western"><surname>Alonzo</surname><given-names>F</given-names></name><name name-style="western"><surname>Lubkin</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Identification of Biologic Agents to Neutralize the Bicomponent Leukocidins of Staphylococcus aureus</article-title>. <source>Sci Transl Med</source> (<year>2019</year>) <volume>11</volume>. &#160;<pub-id pub-id-type="doi">10.1126/scitranslmed.aat0882</pub-id><pub-id pub-id-type="pmid">30651319</pub-id></mixed-citation></ref><ref id="B202"><label>202</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacobs</surname><given-names>SA</given-names></name><name name-style="western"><surname>Gibbs</surname><given-names>AC</given-names></name><name name-style="western"><surname>Conk</surname><given-names>M</given-names></name><name name-style="western"><surname>Yi</surname><given-names>F</given-names></name><name name-style="western"><surname>Maguire</surname><given-names>D</given-names></name><name name-style="western"><surname>Kane</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Fusion to a Highly Stable Consensus Albumin Binding Domain Allows for Tunable Pharmacokinetics</article-title>. <source>Protein Eng Des Sel</source> (<year>2015</year>) <volume>28</volume>:<page-range>385&#8211;93</page-range>. &#160;<pub-id pub-id-type="doi">10.1093/protein/gzv040</pub-id><pub-id pub-id-type="pmid">26275855</pub-id></mixed-citation></ref><ref id="B203"><label>203</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bistoni</surname><given-names>F</given-names></name><name name-style="western"><surname>Vecchiarelli</surname><given-names>A</given-names></name><name name-style="western"><surname>Cenci</surname><given-names>E</given-names></name><name name-style="western"><surname>Puccetti</surname><given-names>P</given-names></name><name name-style="western"><surname>Marconi</surname><given-names>P</given-names></name><name name-style="western"><surname>Cassone</surname><given-names>A</given-names></name></person-group>. <article-title>Evidence for Macrophage-Mediated Protection Against Lethal Candida Albicans Infection</article-title>. <source>Infect Immun</source> (<year>1986</year>) <volume>51</volume>:<page-range>668&#8211;74</page-range>. &#160;<pub-id pub-id-type="doi">10.1128/iai.51.2.668-674.1986</pub-id><pub-id pub-id-type="pmcid">PMC262402</pub-id><pub-id pub-id-type="pmid">3943907</pub-id></mixed-citation></ref><ref id="B204"><label>204</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ciarlo</surname><given-names>E</given-names></name><name name-style="western"><surname>Heinonen</surname><given-names>T</given-names></name><name name-style="western"><surname>Th&#233;roude</surname><given-names>C</given-names></name><name name-style="western"><surname>Asgari</surname><given-names>F</given-names></name><name name-style="western"><surname>Le Roy</surname><given-names>D</given-names></name><name name-style="western"><surname>Netea</surname><given-names>MG</given-names></name><etal/></person-group>. <article-title>Trained Immunity Confers Broad-Spectrum Protection Against Bacterial Infections</article-title>. <source>J Infect Dis</source> (<year>2020</year>) <volume>222</volume>:<page-range>1869&#8211;81</page-range>. &#160;<pub-id pub-id-type="doi">10.1093/infdis/jiz692</pub-id><pub-id pub-id-type="pmcid">PMC7653089</pub-id><pub-id pub-id-type="pmid">31889191</pub-id></mixed-citation></ref><ref id="B205"><label>205</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garly</surname><given-names>ML</given-names></name><name name-style="western"><surname>Martins</surname><given-names>CL</given-names></name><name name-style="western"><surname>Bal&#233;</surname><given-names>C</given-names></name><name name-style="western"><surname>Bald&#233;</surname><given-names>MA</given-names></name><name name-style="western"><surname>Hedegaard</surname><given-names>KL</given-names></name><name name-style="western"><surname>Gustafson</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>BCG Scar and Positive Tuberculin Reaction Associated With Reduced Child Mortality in West Africa: A non-Specific Beneficial Effect of BCG</article-title>? <source>Vaccine</source> (<year>2003</year>) <volume>21</volume>:<page-range>2782&#8211;90</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/S0264-410X(03)00181-6</pub-id><pub-id pub-id-type="pmid">12798618</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>